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ABSTRACT  
SYNTHETIC APPROACHES TO CARDIOLIPIN ANALOGS 
Michael A. Frasso, PhD 
University of Pittsburgh, 2020 
The first portion of this document describes the synthesis of three examples of the mitochondrial 
phospholipid cardiolipin with different fatty acid chain lengths and degrees of unsaturation. 
These compounds enabled the assessment of the phospholipase Cld1’s hydrolysis specificity for 
different fatty acid esters in cardiolipin.  
During the final deprotection reaction of the synthesis, trace hydrolysis of the cardiolipin 
acyl groups occurred. To ameliorate this issue, a new protecting group scheme was devised, 
along with conditions for the selective cleavage of a primary triethylsilyl ether in the presence of 
a vicinal, secondary triethylsilyl ether, of which there are a surprisingly limited number of 
examples.  
Finally, a new method for cardiolipin synthesis was developed. The method was inspired 
by the biosynthetic remodeling of cardiolipin and allows for one of the fatty acids to be 
incorporated later in the synthetic, making it ideal for precious or sensitive fatty acids. 
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1.0  INTRODUCTION 
1.1 OVERVIEW OF LIPIDS 
Lipids are essential for life. Their amphiphilic nature and tendency to form micelles allows for 
cell membrane and organelle formation. In addition to their vital structural role, many lipids and 
their metabolites serve as signaling agents in critical cellular processes such as apoptosis1 and 
mitophagy.2 In particular, the mitochondrial glycerophospholipid cardiolipin (CL) plays an 
integral role in mitochondrial structure and in efficient operation of the electron transport chain. 
Additionally, it is intimately involved in the apoptotic program. 
There are two broad classes of fatty acid containing lipids, namely sphingolipids (Figure 
1) and glycerolipids (Figure 2), which contain the aminoalcohol sphingosine and triol glycerol as 
the backbone units, respectively. Sphingolipids are classified by the substitution at the amine and 
primary alcohol. Acylation of the amine with a fatty acid gives the ceramides. The fatty acids 
found in this class of lipids are generally longer (the most abundant lipids containing 24 carbons) 
and contain fewer polyunsaturated residues than glycerolipids. Additionally, α-hydroxyl fatty 
acids are often found in the ceramides, as well as other sphingolipids.3  
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Figure 1: Major classes of sphingolipids. 
Two different functionalizations of ceramide’s primary alcohol lead to two additional 
classes of lipids. Glycosylation with a mono- or polysaccharide yields the glycosphingolipids. 4 
Inclusion of a phosphate headgroup on the ceramides yields the sphingomyelins, and thus they 
can also be considered as phospholipids. These lipids share the same headgroup with the 
glycerophospholipid phosphatidylcholine (vide infra), and for some time, it was suspected that 
the former served primarily as a substitute for latter in membranes. However, the packing 
properties of the two classes are quite different, owing to the differing fatty acid composition of 
each (generally more unsaturated residues for phosphatidylcholine vs. more saturated for 
sphingomyelins) and the hydrogen bond donating capabilities that the amide provides. 
Glycerolipids are the most abundant class of lipids and contain a three-carbon glycerol 
backbone (Figure 2). These can be further divided into two subclasses, namely the neutral 
mon/di/triacylglycerols and the charged (zwitterionic or anionic) glycerophospholipids. 
Glycerophospholipids (GPLs) can be categorized by two primary criteria: the substituents on the 
Sphingolipids
H3C(H2C)12
OH
NH
OR2
R1
OH
NH2
OH
sphingosine
OH
NH
OH
O
R3
ceramides
R3 = fatty alkyl
OH
NH
O
O
R3
sphingomyelins
R3 = fatty alkyl
R4  = (CH2)2NMe3+
P
O
O
OR4
OH
NH
OR2
O
R3
glycosphingolipids
R3 = fatty alkyl
R2  = mono- or
polysaccharide
 3 
glycerol backbone (–acyl, –alkyl, or –H, Figure 2) and the headgroup on the phosphate moiety 
(Table 1). Substitution on the backbone is derived from either fatty acids or fatty alcohols and 
gives rise to diacyl-GPLs or plasmalogens respectively. If no acyl or alkyl chain is present at one 
of the glycerol positions, the prefix lyso- is added to the parent name.  
 
Figure 2: Major classes of glycerolipids. Only one of –R4, –R5 may be H in lyso-GPLs. See Table 1 below for 
phosphate headgroups (–R6). 
Diacyl-GPLs are the most abundant class of GPLs. The phosphate headgroup is 
commonly used when referring to a subclass of diacyl-GPLs, as this often determines a 
significant portion of the biological function (Table 1). Phosphatidic acid (PA) is structurally the 
simplest, with no additionally substitution on the phosphate (dianionic at physiological pH). 
There are three nitrogen-containing GPL headgroups, namely phosphatidylcholine (PC), 
OR2
R1O OR3
mono-, di-, triacylglycerols
R1 = R2 = R3 = acyl, H
Glycerolipids
OR2
R1O OR3
OR5
R4O O P OR
6
O
O
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O
O O
P OR
4
O
O
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O
R9O O P OR
6
O
O
R8
O
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Z-alkenyl
OR11
R10O O P OR
6
O
O
Lyso-GPLs
R10 = alkyl, acyl, H
Z-alkenyl
R11 = alkyl, acyl, H
 4 
phosphatidylethanolamine (PE), and phosphatidylserine (PS), with PC and PE being the major 
membrane components in most cell types (Section 1.2).5, 6 Phosphatidylglycerol (PG) and 
phosphatidylinositol (PI) both have alcohol-containing headgroups.  
Table 1: Major phosphate headgroup structure of GPLs. –R1, –R2, –R4, and –R5 are alkyl, monounsaturated 
or polyunsaturated chains. 
 
CL is unique among GPLs in that is contains three glycerol units, each containing a 
stereocenter. Two of these are 1,2-diacylglycerols (1,2-DAGs), giving CL the possibility of 
carrying up to four unique fatty acids. The two 1,2-DAG units are linked to the central glycerol 
by two phosphate groups that each carry a negative charge at physiological pH (pKa1  ~ 2.15, 
O
O
P
OOR1
O
R2
O
O
O
R3
NH3+
R3Name
HPhosphatidic acid (PA)
Phosphatidylethanolamine (PE)
NMe3+Phosphatidylcholine (PC)
NH3+
CO2-
Phosphatidylserine (PS)
OH
OH
OH
OH
HO
Phosphatidylinositol (PI)
OH
Phosphatidylglycerol (PG) OH
O
P
O
OH
O
O
O O
R4
O R5
O
Cardiolipin (CL)
R1, R2, R4, R5
alkyl or alkenyl
alkyl or alkenyl
alkyl or alkenyl
alkyl or alkenyl
alkyl or alkenyl
alkyl or alkenyl
alkyl or alkenyl
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pKa2 ~3.15).7 These characteristic structural features are responsible for the distinctive effects of 
CL on membrane structure and protein binding. 
1.2 STRUCURE OF LIPID MEMBRANES IN MITOCHONDRIA 
The structure of biological membranes is governed by the complex interplay between lipid 
subclass abundance, fatty chain composition, and the effect of different lipid headgroups. The 
relative abundance of various classes of lipids can vary widely depending on cell type, organelle, 
and even between inner and outer layers (leaflets) of a particular membrane in some cases. Table 
2 shows the percentage of total lipid content for various common classes of lipids. 
Table 2: Percentage of total lipid composition by lipid subclass in mammalian cells.8 
  
 The fatty acids in lipids have a significant effect on membrane packing. Saturated chains 
tend to allow the formation of more densely packed gel phases that rigidify membranes and form 
a thicker bilayer. The Z-alkenes in mono- and polyunsaturated chains lead to varying degrees of 
increased membrane fluidity.9 Polyunsaturated chains in particular lead to significantly 
decreased membrane thickness due to the conformational alterations that the multiple Z-alkenes 
Name
Phosphatidic acid
Phosphatidylethanolamine
Phosphatidylcholine
Phosphatidylserine
Phosphatidylinositol
Sphingomyelin
Cardiolipin
% Total Lipids
1-2
45-55
2-10
10-15
2-5
15-25
5-10
Glycosphingolipids 2-5
Cholesterol 10-20
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produce. These effectively introduce “packing defects” in the hydrophobic portion of the 
membrane relative to more ordered membranes composed of saturated chains. Monounsaturated 
chains introduce the defects closer to the center of membranes, whereas polyunsaturated chains 
provide shallower perturbations (Figure 3).10 These defects allow for some proteins to recognize 
specific patterns in the lipid membrane.11 Additionally, polyunsaturated lipids have been shown 
to aggregate preferentially in regions of high membrane curvature where the increased space 
between headgroups can be filled by the unsaturated chain’s unique architecture.10  
 
Figure 3: Illustration of the difference between deep defects (left, blue) and shallow defects (right, orange) 
induced in lipid membranes by mono- and polyunsaturated chains, respectively. Reproduced in part from 
Phys. Chem. Chem. Phys. 2015, 17, 15589-15597 with permission from the Royal Society of Chemistry; 
permission conveyed through Copyright Clearance Center.  
GPL headgroups also impart their own unique effects on membrane structure. Different 
headgroups prefer different aggregation states and thus help determine the overall shape of 
biological membranes. GPLs like PC and PS have headgroups and hydrophobic tail regions that 
trace out a circle of similar radius and are thus referred to as “cylindrical” GPLs. These cylinders 
can pack together in an orderly fashion and tend to form flat bilayer structures (Figure 4). GPLs 
like PE have a headgroup that can be outlined by a circle with a smaller radius than the 
hydrophobic tails, which leads to a conically shaped lipid. These impart a negative curvature 
upon membranes, with the tendency to form inverted hexagonal phase (see Figure 5).12 
Lyso-GPLs and PIs show the opposite effect and lead to a positive curvature in membranes. 
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Figure 4: Effect of various phospholipids on membrane curvature. Reprinted with permission from Nat. Rev. 
Mol. Cell Bio. 2018, 19, 281-296. Copyright 2018 Springer Nature; permission conveyed through Copyright 
Clearance Center. 
 
Figure 5: A: Inverted hexagonal phase in which the phosphate headgroups (blue) are oriented inwards and 
the hydrophobic tails (black) are outwards. B: Hexagonal phase with headgroups outwards and hydrophobic 
tails inwards.  Reproduced in part from Soft Matter 2014, 10, 3978-3983 with permission from the Royal 
Society of Chemistry; permission conveyed through Copyright Clearance Center. 
 CL’s unique dianionic structure and its tetra-acylated glycerol backbone impart a small 
headgroup and a large hydrophobic region. This correspondingly favors aggregation in an 
inverted hexagonal phase, though lamellar structures are possible.13, 14 Additionally, CL’s acyl 
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chains are commonly polyunsaturated and thus make it even more prone to forming a curved 
membrane environment (~70% of CL is tetralinoleoyl CL in humans).15 CL’s inherent bias for 
curved membranes is likely to contribute to its localization in the poles of bacterial membranes, 
as determined both computationally and experimentally.16-18 
CL plays an important part in the structure of mitochondria. Mitochondria contain two 
membranes, of which CL is primarily confined to the inner mitochondrial membrane (See Figure 
6 for mitochondrial membrane structure). The inner membrane contains an extensive network of 
inward folded tubules known as cristae. CL is found in the matrix-facing layer of the cristae with 
high concentrations at the most curved regions. Studies have shown that CL is essential for the 
proper formation of the mitochondrial cristae.  
 
Figure 6: A: Three-dimensional cryo-electron tomography image of a mouse heart mitochondrion. Outer 
membrane = grey, inner membrane = cyan. B: A two-dimensional tomographic slice of the three-dimensional 
picture. Reproduced with permission from the Creative Commons Attribution 4.0 International License  
(http://creativecommons.org/licenses/by/4.0/); Originally by Werner Kühlbrandt from BMC Biology 2015, 13, 
89, doi 10.1186/s12915-015-201-x. 
Imbedded in the cristae is the electron transport chain, the assembly that gives 
mitochondria the often-used nickname “the powerhouse of the cell” (Figure 7). This series of 
protein complexes transfers electrons from NADPH and succinate to oxygen as the terminal 
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acceptor. During these transformations, a proton gradient is generated across the inner 
mitochondrial membrane, which ultimately drives oxidative phosphorylation and provides the 
cell with the majority of its ATP. CL plays an important role both in the function of individual 
complexes and in the higher order organization of multi-complex units known as 
supercomplexes. For example, it has been shown that there are 10 CLs that support normal 
activity of complex I, and that it promotes the association of complex III and complex IV by 
inserting into a hydrophobic cleft between the two complexes.19, 20 
 
Figure 7: The electron transport chain. Reproduced with permission from the Creative Commons Attribution 
4.0 International License  (http://creativecommons.org/licenses/by/4.0/); Originally by Werner Kühlbrandt 
from BMC Biology 2015, 13, 89, doi 10.1186/s12915-015-201-x. 
CL also plays a role in the degree of oligomerization of complex V dimers, which are 
primarily located at the cristae apex.21 This is important not only for electron transport chain 
function, but also for the highly curved structure of the inner membrane, as complex V oligomers 
are thought to support normal cristae shape.  Though CL has a preference for membrane regions 
of high curvature, individual cardiolipin molecules are not capable of supporting the membrane 
curvature alone, and larger aggregates of lipids and/or proteins are likely required.22 In this 
respect, CL and complex V cooperatively enforce the native cristae structure. 
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1.3 OXIDATION CHEMISTRY OF LIPIDS 
Cells must maintain a delicate balance to survive: they exist in an oxygen-rich environment and 
require oxidation chemistry for energy production, yet most major classes of biomolecules are 
susceptible to oxidative damage. Cells posses defenses against oxidative damage, such as the 
abundant antioxidant glutathione, but these can be overwhelmed for a variety of reasons. 
Notably, lipid oxidation is a key component of two types of cell death, namely apoptosis and 
ferroptosis. There is also significant evidence for oxidative damage to lipids in many diseases 
including cancer,23 Alzheimer’s,24 Parkinson’s,25 diabetes,26 and atherosclerosis.27   
Free radical mediated oxidation of lipids, or lipid peroxidation, takes place via a typical 
radical chain mechanism (Scheme 1).28 Initiators of the process in mitochondria often trace their 
source to electron leakage from the electron transport chain.29 These leaked electrons form the 
superoxide radical anion (O2•-), which is rapidly reduced to H2O2 by superoxide dismutases. 
H2O2 can subsequently act as a source of hydroxyl radicals that can initiate lipid peroxidation. 
The bis-allylic positions of polyunsaturated fatty acid-containing lipids are the most susceptible 
to oxidation due to the highly stabilized radicals that are generated and their comparatively weak 
C–H bond strength (~80 kcal/mol for bis-allylic C–H vs ~90 kcal/mol for allylic C–H).30 The 
resulting allylic radicals react with oxygen nearly at the diffusion limit,31 leading to peroxyl 
radicals in the first propagation step. These radicals are the chain carriers of the process and 
undergo rate limiting hydrogen atom abstraction to form hydroperoxides and an additional 
stabilized carbon-centered radical. The lipid peroxidation radical chain can be broken through 
the action of cellular antioxidants, such as glutathione. The precise fate of the resulting radical 
depends on the nature of the antioxidant.29, 32 
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Scheme 1: Radical chain mechanism for lipid oxidation. In = initiator, kp= rate constant for the rate-limiting 
step of propagation, A = cellular antioxidant. 
There is a wide array of compounds that can be isolated from the nonspecific 
peroxidation of lipids, with the number of possible products increasing as the number of 
unsaturations increases in a given chain. There are two categories of products: primary 
peroxidation products, which consist of hydroperoxides, and secondary products that have 
undergone further transformations. The primary oxidation products of methyl linoleate 1 are 
shown in Scheme 2.33 Hydrogen atom abstraction leads to a pentadienyl radical 2, which can 
undergo a reversible reaction with oxygen at C13, C11, or C9 resulting in peroxyl radicals 3, 4, 
and 5 respectively. Hydrogen atom abstraction by the peroxyl radicals leads to the kinetic 
products 9Z,11E-13-hydroperoxyoctadienoic (HpODE) methyl ester 6, 11-HpODE methyl ester 
7, and 10E,12Z-13-HpODE 8. 4 is highly prone to reforming the pentadienyl radical 2 and can 
only be converted to 7 in the presence of high concentrations of α-tocopherol.34 The 
corresponding thermodynamic products 11 and 14 (containing all E-alkenes) are also obtained 
and result from a similar pathway in which the reversible addition of oxygen to 2 allows for 
double bond isomerization. Two possible secondary products are shown in Scheme 3, resulting 
from either the reduction of hydroperoxide 11 by glutathione/glutathione peroxidase  (10E, 
12Z-9-hydroxyoctadecadienoic acid; HODE) or dehydration (10E, 12Z-9-ketooctadecadienoic 
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acid; KODE). While these reactions are shown with methyl linoleate, related reaction pathways 
can occur in more biologically relevant esters, such as those found in GPLs. 
 
Scheme 2: Primary oxidation products of methyl linoleate. 
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Scheme 3: Two secondary oxidation products of linoleic acid. GPx = glutathione peroxidase. 
In lipids with greater degrees of unsaturation than linoleic acid esters, such as those 
containing arachidonic acid esters, an even larger array of peroxidation products are possible.28 
Hydrogen atom abstraction can occur at C13, C10, or C7, resulting in pentadienyl radicals 18-20 
(Scheme 4). Each of these can undergo a reaction with oxygen analogous to that shown in Figure 
10 with methyl linoleate, as well as more complicated pathways.  
 
Scheme 4: The three pentadienyl radicals derived from arachidonic acid and its esters.35 R* is most 
commonly a glycerol unit. 
1.4 OXIDATIVE DAMAGE OF CARDIOLIPIN AND APOPTOSIS 
CL’s location in the mitochondrial inner membrane predisposes it to oxidative damage even 
during normal cellular function, where an estimated 1-4% of the electrons in the electron 
transport chain result in the superoxide radical.36 Additionally, it is also directly associated with 
C5H11MeO2C
7
HOO
10E,12Z-9-HpODE (8)
C5H11MeO2C
7
O
10E,12Z-9-KODE (16)
C5H11MeO2C
7
HO
10E,12Z-9-HODE (15)
Glutathione
GPx
-H2O
R2
R1
R1 = (CH2)3CO2R*
R2 = (CH2)4CH3
R2
R1
17
18
R2
R1
19
R2
R1
20
+ +
5
7 9
111315
 14 
several of the complexes, which places it in close proximity to significant sources of oxidizing 
equivalents. CL’s high polyunsaturated fatty acid content further exacerbates its susceptibility to 
oxidative damage.  
Despite its close proximity to the electron transport chain, ~80% of the inner 
mitochondrial membrane is other GPLs and yet, under pro-apoptotic conditions, CL is 
preferentially oxidized over these more abundant lipids. For example, in model traumatic brain 
injury conditions (controlled cortical impact), CL was found to be the major phospholipid class 
that had undergone oxidation 3h following injury (Figure 8).37 This is suggestive of an enzymatic 
pathway, and indeed, a CL-cytochrome c peroxidase complex has been found to preferentially 
oxidize CL under these and other pro-apoptotic conditions.38, 39 The complex utilizes H2O2 as the 
oxidant, but can also use lipid hydroperoxides as well.40, 41 
 
Figure 8: Phospholipid oxidation in control, 3h, and 24h following controlled cortical impact (determined by 
HPLC). “100%” is 110 ± 20 pmol phospholipid hydroperoxide per nmol of phospholipid. Approximate 
percentage of total phospholipids for each class are as follows: CL ~ 2%, Sph (sphingomyelin) ~ 1.5%, PI ~ 
3%, PS  ~ 12.5%, PE ~ 37%, PC ~ 43%. Reproduced in part from Ann Neurol. 2007, 62, 154-169 with 
permission from the Wiley Online Library; permission conveyed through Copyright Clearance Center. 
Following oxidation of CL, oxygenated fatty acids are released by the action of 
calcium-independent phospholipase A2 (iPLA2γ).39 The released oxygenated fatty acids are well 
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known lipid mediators in some cases, such as 9-HODE, 13-HODE, and their corresponding 
ketone derivatives. This has led to the suggestion that CL may function as a mitochondrial 
reservoir for lipid signaling agents and would explain the greater diversity of CL species found 
in tissues with important roles in signaling, such as the brain.  
Given the integral role that oxidative damage to CL plays in the apoptotic program and 
its implication in a wide variety of diseases,42-45 there has been significant interest in developing 
methods to prevent CL oxidation. Inhibitors of this process must be able to penetrate into the 
mitochondria and thus must possess unique properties. Many strategies for targeting 
mitochondria have been developed, only two of which will be presented here.46, 47 The first 
involves the use of lipophilic cations.48 Due to the pumping of protons into the intermembrane 
space by the electron transport chain, there is an electrical gradient across the inner membrane of 
about 140-180 mV. Lipophilic cations can pass through membranes, and as such, tend to localize 
in the matrix. The most prominent examples are based on triphenylphosphonium tagged 
antioxidants. High doses lead to mitochondrial membrane depolarization, which can alter ATP 
production and interfere with the transport of other cations across the membrane. Thus, all 
triphenylphosphonium-based anitoxidants suffer from dose-limiting toxicity.49 The antioxidants 
themselves can act on a variety of reactive oxygen species, including superoxide, hydrogen 
peroxide, hydroxyl radicals, and lipid hydroperoxyl radicals (Figure 9).  
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Figure 9: Mitochondria-targeted antioxidants based on triphenylphosphonium salts. The primary reactive 
oxygen species targeted by each is in parentheses. 
 MitoE2 and MitoQ10 are radical chain-breaking hydrogen atom donors and are particularly 
effective for lipid hydroperoxyl radicals (MitoQ10 requires reduction to the active ubiquinol form 
by complex II of the electron transport chain).48 Their lipophilic nature allows for them to remain 
embedded in the mitochondrial inner membrane in close proximity to where lipid 
hydroperoxides are formed. MitoPeroxidase is thought to operate through a more complicated 
mechanism based on information from the parent compound ebselen (21; originally designed as 
a glutathione peroxidase mimetic; see Scheme 5).50 21 readily reacts with cellular thiols to give 
adduct 22. This species disproportionates providing diselenide 23, which acts as the active 
reducing agent for cellular peroxides. The resulting selenic acid 24 can reform 21 with the loss of 
water.  
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Scheme 5: Proposed mechanism of action for ebselen. R1SH = cellular thiols such as glutathione or cysteine 
residues of proteins. R2 = H, alkyl. 
 A second method for targeting antioxidants to the mitochondria is based on naturally 
occurring peptides.  The SS peptides developed by Szeto and Schiller are one example of this.51, 
52 These compounds were developed from dermorphin, a µ opioid receptor agonist (Figure 10).53 
Subsequently, these compounds were found to preferentially localize in the mitochondrial inner 
membrane, though they do not cause membrane depolarization.52, 54 Development ultimately led 
to SS-31, which uses a dimethyltyrosine as the active antioxidant for prevention of CL oxidation. 
Like MitoE2, this compound functions as a chain-breaking hydrogen atom donor. 
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Figure 10: Structures of Dermorphin and SS-31. 
A second class of peptide-based targeting agents is based on the antibiotic Gramicidin S 
and the stable radical 4-amino-TEMPO (4-AT) developed by Wipf and coworkers (Figure 11). 
Gramicidin S is a cyclic peptide whose rigid secondary structure is stabilized by four 
intramolecular hydrogen bonds. Its antibiotic effect stems from the disruption of bacterial cell 
membranes and it also possesses the ability to perturb mitochondrial membrane potential.55, 56 
These properties suggested that Gramicidin S or a fragment that retained the type-II’ β turn 
(D-Phe-Pro) could be an effective mitochondria targeting agent for an antioxidant payload. 4-AT 
was selected as the antioxidant due to its ability to undergo recycling and superoxide dismutase 
mimetic activity.57, 58 Analogs that did not contain the type-II’ β turn  (D-Phe-Pro) showed 
markedly lower mitochondrial localization.59 Additionally, an (E)-alkene was used as an 
effective isostere for one of the peptide bonds and can presumably lead to better bioavailability 
through reduced sensitivity to proteases.46, 60, 61 This compound has found applications in several 
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conditions in which preventing CL oxidation reduces apoptotic cell death, including hemorrhagic 
shock, traumatic brain injury, and Huntington’s disease.62-64 A truncated analog (JP4-039) that 
maintains significant mitochondrial targeting ability was also developed and has been used as a 
radioprotective and radiomitigative agent (Figure 12).65-67  
 
 
Figure 11:  Structures of Gramicidin S and XJB-5-131. Reproduced with permission from Acc. Chem. Res. 
2008, 41, 87-97. Copyright 2008 American Chemical Society. 
 
Figure 12: Structure of JP4-039. 
1.5 SYNTHESIS OF GLYCEROPHOPHOLIPIDS  
1.5.1 Cardiolipin Biosynthesis 
GPL biosynthesis in mammals is centered on two key intermediates, namely cytidine 
diphosphate diacylglycerol (CDP-DAG) and 1,2-DAG, both of which are utilized in CL 
NHBoc
O
HN N O
JP4-039
 20 
biosynthesis (Scheme 6).68 The first step in CDP-DAG synthesis is the acyl-CoA dependent 
acylation of glycerol-3-phosphate (G3P) at the sn-1 (stereospecific numbering nomenclature is 
based on Fischer projection of glycerol with central hydroxyl group to the left; see Figure 13) 
position by G3P acyltransferase and yields lyso-phosphatidic acid (lyso-PA). Lyso-PA can 
subsequently be acylated by lyso-PA acyltransferase and generates PA. Phosphorylation or 
dephosphorylation of PA by CDP-DAG synthase (CDP-DGS) or PA phosphatase-1 (PAP-1) 
gives CDP-DAG and 1,2-DAG, respectively. The synthetic logic of the dephosphorylative route 
to 1,2-DAG has been reflected in a number of chemical syntheses (vide infra). 
An alternative reductive pathway to lyso-PA utilizes dihydroxyacetone phosphate 
(DHAP) as the starting point, and to which no analogous synthetic route has been developed.69 
DHAP is acylated in an acyl-CoA dependent reaction catalyzed by DHAP acyltransferase. 
NADPH-dependent reduction by 1-acyl-DHAP reductase (ADR) completes the second pathway 
to lyso-PA.  
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Scheme 6: Biosynthetic route to key intermediates of GPL synthesis in mammals. 
 
Figure 13: Stereospecific numbering nomenclature using G3P as an example. 
CL biosynthesis takes place exclusively in the mitochondrial inner membrane where CL 
primarily resides (Scheme 7).70 The first step towards CL involves the reaction of CDP-DAG 
with G3P catalyzed by PG glycerol phosphate synthase (PGP synthase). Subsequent 
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dephosphorylation by phosphatidylglycerolphosphatase (PGP-ase) results in PG. The final step 
in the assembly of the parent CL architecture is the incorporation of a second PA residue via the 
reaction of PG with a second equivalent of CDP-DAG.  
 
Scheme 7: Biosynthesis of CL in mammals. 
The CL that results from CL synthase undergoes further modifications, termed 
“remodeling” of the fatty acid composition (Scheme 8). The first step is hydrolysis of one of the 
acyl chains, resulting in a monolyso-CL. Subsequently, a fatty acid is transferred from a donor 
GPL (PC, PE, etc.) and yields a tetra-acylated-CL and lyso-GPL. This reaction is catalyzed by 
the acyltransferase tafazzin in both yeast and higher eukaryotes. The selectivity of this process is 
of interest because nascent CL and remodeled CL have markedly different fatty acid 
composition.71 Additionally, there is a vast difference in the CL species composition in different 
tissue types and it is unknown how this diversity is regulated. For example, tetra-linoleoyl-CL 
predominates in heart muscle,72 whereas there is a much greater occurrence of higher order 
polyunsaturated fatty acids in the brain.73  
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Scheme 8: CL remodeling in yeast. The donor GPL can is most commonly PC or PE. 
S. cerevisiae (yeast) is a useful organism for studying CL remodeling, as it only utilizes a 
single enzyme for each of the remodeling steps, whereas there are multiple enzymes capable of 
acylating CL in mammalian cells.44 There is strong evidence that Cld1, a cardiolipin-specific 
phospholipase, is responsible for the first step in CL remodeling.71, 74 Originally, this was 
described by Leber and coworkers and they found that Cld1 shows a preference for the cleavage 
of palmitic acid residues, though no direct evidence was provided.71 This may provided a partial 
explanation for the transition from more saturated CLs prior to remodeling to a higher content of 
unsaturated fatty acids afterwards. 
Further interest in CL remodeling is generated by Barth syndrome, in which patients 
show significantly altered CL composition. Defects in the tafazzin gene lead to impaired 
reacylation, and thus accumulation of monolyso-CL. This results in a collapse of the heavily 
folded nature of the inner mitochondrial membrane due to CL’s pivotal role in supporting this 
architecture.75, 76 Impaired electron transport chain function has also been observed, likely due to 
CL’s role in proper electron transport chain organization.43, 77 An improperly functioning 
electron transport chain does not effectively consume NADH and FADH2, which further 
exacerbates poor energy production by feedback inhibition of other mitochondrial pathways.78 
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The collective result of these abnormalities is that patients experience an enlarged heart that 
inefficiently circulates blood (dilated cardiomyopathy), exercise intolerance, low white blood 
cell counts (neutropenia), and in rare severe cases, death.43, 44  
1.5.2 General Retrosynthesis for Glycerophospholipids 
Given the great significance and large structural diversity of GPLs, they have attracted the 
attention of the synthetic community for many years. Though variations exist, most GPL 
syntheses follow a similar retrosynthetic outline (Scheme 9). GPLs are most commonly 
manipulated with a protected phosphate (26) to facilitate isolation and purification. If a lyso-GPL 
(R1 or R2 = H) is desired, there will be an additional protecting group involved at the requisite 
position. Intermediate 26 can be prepared from the appropriate glycerol precursor and a 
phosphorus (III) or phosphorus (V) coupling reagent that contains the desired phosphate 
protecting group (vide infra). The most laborious facet of phospholipid synthesis is the assembly 
of the requisite glycerol fragment(s), which is usually derived from L-glyceric acid (28), 
(S)-glycidol ((S)-29), or (S)- solketal ((S)-30). 
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Scheme 9: Overview of GPL retrosynthesis. 
1.5.3 Phosphate Assembly in GPLs 
The protecting group scheme governs much of the chemistry at phosphorus during GPL 
synthesis. Figure 14 shows the most commonly used protecting groups. The methyl, benzyl, and 
cyanoethyl groups (31, 33, 34) have found wide application in a variety of GPLs,79-82 whereas 
the others are more limited. 
 
Figure 14: The most common phosphate protecting groups used in phospholipid synthesis. 
Scheme 10 shows common conditions used for the removal of the most broadly utilized 
phosphate protecting groups. Methyl phosphates such as 31 are most often cleaved with sodium 
iodide in refluxing 2-butanone.82 This method is convenient in that it directly prepares the GPL 
sodium salt without the need for cation exchange. Trimethylsilyl bromide has also been used 
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occasionally. The conditions were originally developed for the cleavage of 
dialkylphosphonates83 and subsequently first applied to phospholipid synthesis for the 
demethylation of fluorinated 2-acyl-lysophosphatidic acid derivatives.84  
 
Scheme 10: Common cleavage conditions for the most widely applied phosphate protecting groups. 
Benzyl phosphates 33 can be cleaved using standard hydrogenolysis conditions.85 This is 
a facile method, but its use precludes the preparation of unsaturated GPLs due to competing 
olefin reduction. While they are stable to a wide variety of conditions, benzyl phosphates can be 
cleaved under prolonged nucleophilic reaction conditions.86  
Arguably, the most universal phosphate protecting group is the cyanoethyl, which has 
found extensive use in oligonucleotide synthesis.87, 88 However, its application to phospholipids 
has been less widespread. Cleavage occurs under mildly basic conditions, most often using 
trialkylamines or ammonia (Scheme 10, 34 to 37).89 These conditions tolerate a wide variety of 
functionality, most notably the skipped dienes in polyunsaturated fatty acid chains. Cyanoethyl 
protecting groups have been successfully applied to the synthesis of some of the more complex 
GPLs including lysobisphosphatidic acid,79, 90 cardiolipin,91, 92 and phosphoinositides.93.  
The first protocols that were developed for GPL synthesis were based on P(V) reagents. 
There has been a large body of work amassed on the topic,94 but these methods have largely been 
supplanted by the use of P(III) reagents. A versatile method that continues to find applications is 
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the dioxaphospholane 38 developed by Hadju (Scheme 11).95 First, substitution with the desired 
glycerol fragment leads to a protected phosphate. This intermediate dioxaphospholane can then 
undergo a nucleophilic ring opening with anhydrous trimethylamine leading to PCs (39) or with 
various nitrogen, oxygen, and sulfur nucleophiles to access other analogs. 
 
Scheme 11: Use of dioxaphospholane 38 in PC synthesis. 
The original impetus for the development of P(III) reagents for phospholipid synthesis 
was their great success in nucleotide synthesis.96 In 1986, Stec and co-workers developed the 
first method broadly applicable to prepare phospholipids using P(III) reagents (Scheme 12).97 
Alcohols undergo monosubstitution under basic conditions with chlorophosphoramidite reagent 
40. The intermediate phosphoramidite can then be coupled to the desired alcohol using tetrazole 
as the promoter. Oxidation using tert-butyl hydroperoxide (t-BuOOH) led to the synthesis of 
protected PCs, PEs, and PGs. This method could also be used to prepare phosphorothioyl 
analogs, which had previously been used in mechanistic studies of phospholipases,98, 99 by 
replacing t-BuOOH with elemental sulfur.  
 
Scheme 12: The original chlorophosphoramidite coupling developed by Stec. 
The closely related phosphordiamidite (replace -Cl with -N(iPr)2 in 40) reagents were 
applied to a triphosphoinositide two years later.100 Both phosphoramidite methods have become 
the preferred P-O bond formation strategies in the more complex phospholipids. 
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1.5.4 Functionalized Glycerol Precursors 
The most common functionalized glycerol precursors are derived from the chiral pool. Hadju and 
coworkers developed a synthesis of 1,2-diacylglycerols beginning with commercially available 
protected L-glyceric acid derivative 42 (Scheme 13).101 Cleavage of the isopropylidene using 
dilute HCl in methanol followed by selective trityl (Tr) protection of the primary alcohol gave 43 
in 79% yield over two steps. Subsequent reduction using LiBH4 gave diol 44 in 85% yield. 
Sequential, selective acylations could be performed to install the desired fatty acid chains in 45. 
While this method provides good yields, it requires two equivalents of the fatty acid for the 
selective acylation of the primary alcohol and thus is not ideal for precious fatty acids. Finally, 
the trityl group could be cleaved without acyl migration using HCl in a chloroform:methanol 
mixture at 0 °C.  
 
Scheme 13: 1,2-DAG synthesis derived from L-glyceric acid developed by Hadju. 
Glycidol derivatives are the second category that has commonly served as functionalized 
glycerol precursors. Originally, the desired enantiomer could be accessed from the asymmetric 
epoxidation of allyl alcohol,102 but both are now commercially available. (R)-Glycidyl tosylate 
47 has been used in the preparation of ether phospholipids (Scheme 14).103 Selective opening of 
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the epoxide with alcohols promoted by BF3.Et2O proceeded in good to excellent yields. BF3.Et2O 
was found to be advantageous over TiCl4 or Ti(OiPr)4, as competitive substitution of the tosylate 
can occur with chloride or isopropoxide ions.104 THP protection of 48 gave protected glycerol 
49. The tosylate could be displaced using tetraethylammonium acetate (Et4NOAc) in acetonitrile, 
though rigorous exclusion of moisture was essential for good yields. Subsequent acetate 
hydrolysis using potassium carbonate in methanol resulted in alcohol 50. The THP was cleaved 
following the incorporation of the phosphate leading to ether GPLs 51.  
 
Scheme 14: Preparation of functionalized glycerol 31 used in ether phospholipid synthesis. 
 
Scheme 15: Use of phosphorylated glycerol 52 in GLP synthesis. 
Konradsson demonstrated that epoxide 52 could be opened regioselectively using a 
mixture of palmitic acid and its cesium salt in DMF at 80 °C (Scheme 15).86 A minor 
(undisclosed) amount of the undesired isomer was also obtained. This could be obtained from 
either a 1,2-acyl shift (path A, Scheme 16) or epoxide opening at the secondary carbon of the 
epoxide (path B, Scheme 16). The undesired isomer 55b was presumed to be from path A due to 
the facility with which epoxide opening occurs at the primary carbon. This hypothesis was 
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confirmed using a Mosher’s ester analysis to show retention of stereochemistry at the secondary 
carbon. 
 
Scheme 16: Possible isomerization pathway investigated by Konradsson. 
The second fatty acid was then installed using a DCC coupling under standard conditions. 
While this method allows for expedient access to differentially acylated phosphatidic acid and 
phosphatidylcholines, it requires a four-fold excess of the fatty acid, which is again undesirable 
for precious acids.   
Minnaard has developed a related method for opening TBS-protected glycidol 56 using a 
cobalt-salen catalyst (Scheme 17).105 The conditions utilize equimolar amounts of 57 and the 
desired fatty acid and avoid the acyl migration issue observed in Konradsson’s work.  
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Scheme 17: Co(salen) catalyzed glycidol opening using an equimolar amount of the fatty acid. 
The most widely used glycerol precursor is solketal, which is commercially available as 
both enantiomers. Hadju and coworkers developed a method to access various lysophospholipids 
from (S)-solketal (Scheme 18)106 that is related to the method presented in Scheme 14 above. The 
isopropylidene of 58 can be selectively cleaved under acidic conditions. Subsequent selective 
acylation of the primary alcohol of 59 can be accomplished using either a DCC coupling or the 
appropriate p-nitrophenyl ester and DMAP in 58-72% yield followed by THP protection. 
Notably, good selectivity could only be achieved in the acylation if a two-fold excess of the diol 
was used. Previously, displacement of the tosylate with Et4NOAc followed by methanolysis was 
used for the two-step conversion to the desired alcohol (49 to 50 in Scheme 14). However, when 
the same sequence was attempted using 61, poor selectivity was observed (there was no second 
ester in 49). The use of the methoxyacetate, as well as the modified methanolysis conditions 
allowed for significantly improved selectivity over the related sequence in Scheme 14. 
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Scheme 18: Preparation of functionalized glycerol 62 used in lysophospholipid synthesis. 
(S)-Solketal (S)-30 has often been protected as a benzyl ether and subjected to acidic 
isopropylidene cleavage (Scheme 19).107 Benzyl protected diol 63 can be subjected to sequential, 
selective acylation reactions and subsequently has the advantage of only requiring a single step 
to deprotect, unlike the Ts group in Scheme 18. A significant disadvantage is that unsaturated 
fatty acids cannot be incorporated with this method, due to alkene reduction under the reaction 
conditions. However, an analogous sequence can be performed with a p-methoxybenzyl (PMB) 
ether that circumvents this issue.85 
 PMB-protected diol 65 has also been used to prepare analogs of both natural 
lysobisphosphatidic acid and its ether analogs.79, 90 Selective TBS protection of the primary 
alcohol followed by alkylation or acylation leads to lysobisphosphatidic acid precursors 67 and 
68. Notably, the PMB cleavage leading to alcohol 68 proceeds without any 1,2-acyl shift.  
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Scheme 19: Routes to functionalized glycerols from solketal. 
The desymmetrization of glycerol is an attractive synthetic alternative to more traditional 
chiral pool derived solketal methods (Scheme 20).108 Tan and coworkers found that a chiral 
imidazole efficiently acts as a scaffolding catalyst for the enantioselective silylation of glycerol 
69 in both good yield and enantioselectivity.109 Notably, decreasing the catalyst loading to 5 
mol% still allows for the product to be isolated in greater than 90% ee, though yields do suffer 
slightly (65% vs 78%). While other methods to desymmetrize glycerol have been 
developed,110-112 this is the most direct and highly selective method to date. 
OH
O
O
(S)-30
1. BnBr, NaH
2. HCl
OBn
OH
HO
63
1. PMBCl, NaH
    DMF
2. PTSA, MeOH
OPMB
OH
HO
65
TBSCl
Imidazole
DMF, 73%
OPMB
OH
TBSO
66
1. R1OTf, proton sponge
CH2Cl2, reflux
2. DDQ, wet CH2Cl2
43%, 2 steps
OH
OR1
TBSO
67
1. R2CO2H, DCC 
CH2Cl2
2. DDQ, wet CH2Cl2
88%, 2 steps
OH
O
TBSO
68
O
R2
1. R1CO2H, DCC
DMAP, CH2Cl2 0oC
2.R2CO2H, DCC,
DMAP, CH2Cl2 
66-71%
OBn
O
OR1
O
R2
O H2, Pd/C
EtOH:AcOH
87-99%
OH
O
OR1
O
R2
O
64 (S)-46
 34 
 
Scheme 20: Tan's enantioselective silylation of glycerol. 
1.5.5 Chemical Synthesis of Cardiolipins 
The essential role of CL in mitochondrial structure,13 bioenergetics,113 and signaling114 has 
attracted the attention of the synthetic chemistry community so that a better understanding of its 
multifaceted biological roles can be obtained. Additionally, CL’s unique structure among GPLs 
adds to its synthetic appeal. Indeed, it was curiosity about CL’s structure that motivated its 
original synthesis by van Deenen in 1965 (Scheme 12).115 The key step in the synthesis was the 
alkylation of silver phosphate salt 71 with diiodide 72 to assemble the CL scaffold.  While this 
method was successful, the silver salts used were photosensitive. 
 
Scheme 21: First synthesis of the cardiolipin scaffold by van Deenen. 
Since the original synthesis, Umpolung approaches for phosphate assembly in which 
glycerol alcohols act as the nucleophiles on activated phosphorus electrophiles have become the 
dominate method by which CLs are synthesized (Figure 24). Previous methods were based on 
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using an activated P(V) reagent (76) and generally formed both PA-glycerol linkages in a single 
operation (Schem 22, right). More recent developments have adapted phosphoramidite chemistry 
to constructing the CL scaffold. If identical DAG segments are desired, a one-pot reaction, in 
which two equivalents of DAG 46 can be coupled to diol 76 using the appropriate 
phosphoramidite coupling reagent 77 (Scheme 22 top). If non-identical acyl chain composition 
on the two DAG fragments is required, sequential phosphate formations can be conducted 
through the intermediacy of an appropriately protected monophosphate like 78 (Scheme 22, 
bottom). 
 
Scheme 22: The three general synthetic strategies to access CLs. 
Ramirez and coworkers utilized protected phosphoanhydride 80 for this purpose along 
with 1,2-DAGs using triethylamine as the base (Scheme 23).116 Cyclic phosphate 81 is activated 
enough to undergo further substitution with protected glycerol 82 in a one-pot fashion, yielding 
protected CL 83 in 30-37% yield. The phosphate protecting group undergoes E2 elimination with 
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trientylamine as the base, releasing the free phosphates and methyl vinyl ketone. Subsequent 
acidic cleavage of the TBS ether and formation of the diammonium salt gave the desired CLs 84 
in 68-78% yield. 
 
Scheme 23: Ramirez and coworkers synthesis of CL using phosphoanhydride 80. 
Watts and coworkers performed a related synthesis of deuterated CLs that were of 
interest for studying CL biophysics by deuterium NMR spectroscopy. They utilized 
phosphorylating reagent 85 prepared in-situ from the triazole and the phosphoryldichloride 
(Scheme 24).117 Hydrolysis of the intermediate gave the triethylammonium salt 86. This 
compound can be activated for further substitution using 2,4,6-triisopropylbenzenesulfonyl 
chloride (TIBSO2Cl) and N-methylimidazole, leading to protected CLs 88. Selective cleavage of 
the 2-chlorophenol protecting group with the aldoximate anion followed by hydrolysis and 
diammonium salt formation gave the desired CLs 89. A closely related synthesis by Ahmad and 
coworkers later found that the parent dichlorophosphate derivative of 85 can also be used 
directly.118  
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Scheme 24:  Watts and coworkers’ synthesis of CL using phosphorylating reagent 85. 
While P(V)-based methodologies are successful, they are accompanied by an increased 
risk of acyl migration due to the lower reactivity of P(V) reagents vs P(III) reagents, as well as 
other side reactions.119 This prompted Ahmad and coworkers to apply phosphoramidite 
chemistry to CL synthesis (Scheme 25).91, 120 They demonstrated that chlorophosphoramidite 
reagents with either a methyl or cyanoethyl protecting group undergo successful coupling of 
DAGs and benzyl-protected glycerol 92 in a CL synthesis. Subsequent phosphate deprotection, 
salt exchange, and hydrogenolysis delivered the desired CL diammonium salts in good yields. 
This method has been widely adopted for the assembly of symmetrically substituted CLs, 
including for cyclopropane-containing derivatives.92 
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Scheme 25: Ahmad and coworkers’ chlorophosphoramidite methods using either a methyl or cyanoethyl 
protecting group. 
While these approaches are effective, they do not permit the incorporation of 
differentially substituted phosphatidic acid units. The approach was refined by Holmes in order 
to prepare CLs that could be linked to a resin (Scheme 26).121 The key difference in this 
approach compared to previous methods is the use of the orthogonally protected glycerol 97, 
which allows the two phosphates to be incorporated sequentially. DAG 94 was selectively 
monocoupled with phosphoramidite 95 in 92% yield. The isolated intermediate P(III) species 97 
was then submitted to a second coupling with glycerol 96 followed by oxidation with 
m-chloroperoxybenzoic acid (m-CPBA), resulting in phosphate 98 in 74% yield. Selective 
cleavage of the PMB ether under oxidative conditions gave alcohol 99 in good yield. The final 
step in assembling the CL scaffold was a second phosphoramidite coupling and oxidation that 
proceeded in similar yields to the first. 
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Scheme 26: Holmes phosphoramidite method for installing distinct phosphatidic acid units in CL. The Bn 
and CBz protecting group were successfully cleaved as well but have not been shown for the sake of brevity. 
Miyoshi and coworkers expanded the method to allow for the incorporation of 
oxidation-prone acid chains by altering the protecting group scheme used on the central glycerol 
(Scheme 27).122 Bis-TBS-protected glycerol (S)-101 was used to prepare compound 102, which 
contains two linoleic acid residues. Selective deprotection of the primary TBS ether with Olah’s 
reagent provided alcohol 103 in 63% yield. The TBS ether on the central glycerol was ultimately 
cleaved using dilute aqueous HCl in THF and provided CL 84 in 71% yield over the final two 
deprotection steps. They also extended this work to diazirine-containing CL derivatives for use 
in a photoaffinity labeling study (Scheme 28).123 
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Scheme 27: Miyoshi's modification for incorporating polyunsaturated acyl chains. 
 
Scheme 28: Miyoshi and coworkers’ application of their methodology to the synthesis of a diazirine 
containing CL derivative. 
1.6 RESULTS AND DISCUSSION 
CL undergoes remodeling in which the fatty acid composition changes from a higher content of 
saturated fatty acids to primarily unsaturated fatty acids in mature CL. What is the underlying 
significance of this process and how is selectivity achieved? These changes are likely not driven 
by improved bioenergetic function, as mitochondria containing either remodeled or unremodeled 
CL are functionally equivalent.124 However, CL’s role as a source of oxidized polyunsaturated 
fatty acids39 is dependent upon the presence of polyunsaturated residues, which may provide a 
biological role for remodeling.  
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S. cerevisiae provides a convenient system for studying CL biosynthesis as all the 
enzymes are well characterized and the remodeling process only utilizes Cld1 and tafazzin for 
the deacylation and reacylation steps respectively. Since Cld1 begins the remodeling process, it 
is possible that it plays a large role in the observed fatty acid compositional changes of CL. 
Indeed, results by Leber and coworkers suggest that Cld1 selectively cleaves palmitic acid 
residues from CL, though their experiments were conducted using whole cells and did not 
provide direct evidence of this claim.71 A clearer understanding of Cld1 selectivity would 
provide a partial explanation for the observed fatty acid observed alterations. Commercial CL 
sources are sold mostly as uniformly tetra-acylated derivatives or mixtures isolated from various 
sources (bovine heart, E. coli, etc.), which prompted the synthesis of a targeted group of CLs to 
help improve the understanding of Cld1 selectivity. The method of sequential phosphate 
synthesis developed by Holmes and Miyoshi was selected as a starting point for the synthetic 
efforts due to the ability to incorporate different 1,2-DAGs. 
1.6.1 Synthesis of Cardiolipins 
As mentioned above, the synthetic strategy was closely based on prior work by Holmes and 
Miyoshi.121, 122 Glycidol 29 was chosen as the starting point as opposed to solketal to avoid the 
need for the selective acylation reactions, which normally require the use of a large excess of 
either the glycerol or fatty acid component. Nearly equimolar quantities of glycidol 29 and the 
desired fatty acid can be reacted with catalytic tributylamine, resulting in monoacylglycerol 109a 
in good yield (Scheme 29).125 Protection of the primary alcohol using TrCl followed by EDCI 
coupling with palmitic acid gave protected 1,2-diacylglycerol 45a in 69% yield. Subsequent 
attempts to cleave the Tr group without acyl migration were not successful (Table 3). Weakly 
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acidic conditions using either boric acid126 or PPTS failed to provide useful conversions (entries 
1 and 2). Stronger acids such as p-toluenesulfonic acid (p-TsOH) and hydrochloric acid101 both 
lead to partial acyl migration during the course of the reaction or purification, respectively 
(entries 3 and 4). Lewis acidic conditions using bismuth(III) chloride127 or standard 
hydrogenation conditions with Pd/C also gave similarly unsatisfactory results (entries 5 and 6).  
 
Scheme 29: Attempted synthesis of 1,2-DAG 46a from Tr protected intermediate 45a. *Migration occurs 
during purification. 
Table 3: Conditions used in attempted conversion of 45a to 46a. *Migration occurs during purification. 
 
Changing the protecting group to the more acid labile 4,4’-dimethoxytrityl (DMT) group 
was more successful (Scheme 30). Boric acid also failed to cleave the DMT group and the mixed 
solvent CHCl3:AcOH:H2O gave incomplete conversion (Table 4, entries 1 and 2). However, a 
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resin-bound sulfonic acid (Amberlite-IR120H) gave complete conversion to the desired 
1,2-DAG 46a in good yield without acyl migration (entry 3). This method was then further 
applied to the synthesis of two additional DAGs (Scheme 31).  
 
Scheme 30: Deprotection of DMT protected DAG 110a. All reactions were conducted at room temperature. 
Table 4: Screen of reaction conditions for the cleavage of DMT protecting group in 110a. 
 
 
Scheme 31: Synthesis of DAGs 46b-c. 
With the three requisite 1,2-diacylglycerol segments in hand, attention turned to the 
synthesis of the protected central glycerol of CL. This was accomplished through bis-TBS 
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protected alcohol 101 in 4 steps (Scheme 32). Beginning from solketal 30, protection of the 
alcohol with benzyl bromide gave intermediate 112 in 74% yield. Initially, hydrolysis of the 
isopropylidene was conducted using 2:1 AcOH:H2O and though acceptable yields could be 
obtained (~70% of the intermediate diol), the removal of excess AcOH was cumbersome. This 
method was ultimately supplanted by using aqueous HCl in 2:1 THF:H2O, which simplified both 
reaction setup and workup. Thus, the desired alcohol 111 could be obtained from 101 following 
hydrolysis of the isopropylidene, TBS protection of the intermediate diol, and hydrogenolysis of 
the benzyl ether in 73% yield over three steps. 
 
Scheme 32: Synthesis of bis-TBS protected alcohol 101. 
Synthesis of CLs 84a-c was accomplished using phosphoramidite chemistry (Scheme 
32). Compounds 46a-b were converted to a phosphoramidite using chlorophosphoramidite 40 
and coupled in the same pot to alcohol 101 using 4,5-dicyanoimidazole as the promoter.128 
Though 1H-tetrazole is a more commonly used promoter, 4,5-dicyanoimidazole has been found 
to be more active, is substantially less expensive, and less hazardous.129 Oxidation to the 
phosphate using tetrabutylammonium periodate (Bu4NIO4) gave 112a-b in good yields. Selective 
TBS deprotection has been reported in closely related systems using Olah’s reagent,122 but the 
use of camphorsulfonic acid (CSA) proved a more convenient and reproducible method that gave 
similar yields. With alcohols 113a-b in hand, the second phosphate was installed using 
phosphoramidite coupling, delivering protected CLs 114a-c.  
Deprotection of CLs was performed as a two-step sequence. Demethylation of 114a-c 
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directly in the next step. The TBS group was surprisingly resistant to cleavage under both acidic 
and fluoride-mediated conditions, with all conditions tested showing either partial ester cleavage 
or difficulties in exchanging undesired counterions (such as pyridinium from Olah’s reagent or 
tetrabutylammonium from TBAF). Treatment with HCl in 2:1 THF:H2O followed by quenching 
with aqueous ammonium hydroxide provided the cleanest product, and ester hydrolysis 
byproducts could be removed by preparative TLC prior to use in biological assays. 
 
Scheme 33: Synthesis of Cardiolipins 84a-c. See Table 5 for yields and R definitions of compounds 114a-c and 
84a-c. 
Table 5: R group definitions and yields of compounds 114a-c and 84a-c. 
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1.6.2 Circumventing Ester Hydrolysis 
In order to circumvent the undesired ester hydrolysis during the final desilylation, the more labile 
triethylsilyl (TES) group was used in place of the TBS. The TES group is cleaved ~300 times 
more rapidly under acid conditions than TBS,130 which should preclude any ester hydrolysis. 
Selective cleavage of a primary TES ether over a secondary TES ether is a known process, 
though with significantly fewer examples than the same transformation of TBS ethers.131 
However, there is very little known about the selective cleavage of vicinal 1o/2o TES ethers. In 
order to explore possible conditions for this transformation, 1,2-hexanediol was protected with 
TESCl and several different deprotection conditions were investigated (Scheme 34 and Table 6). 
2,4,6-Trimethylbenzoic acid and triphenylacetic acid were used as bulky proton sources and 
failed to provide any conversion even after extended reaction times (entries 1 and 2). A similar 
result was observed for the more acidic organophosphinic acid (entry 3). PPTS gave primarily 
recovered starting material, but also a significant amount of the desired monodeprotection (29%, 
entry 4). Lewis acids such as FeCl3,132 NaAuCl4,133 and Sc(OTf)3, gave either complex reaction 
mixtures or complete double deprotection (entries 5-7). Conditions reported by Phillips using 
catalytic fluoride ion under neutral conditions gave poor selectivity and resulted in primarily 
double deprotection (entry 8).134 Two different oxidative cleavages were attempted as well. 
Cerium(IV) nitrate adsorbed on SiO2135 again gave a complex mixture (entry 9). Finally, Swern 
oxidation conditions have been shown to selectively oxidize primary TES and TMS ethers to the 
corresponding aldehydes in closely related systems.136 However, these conditions resulted in an 
approximately 2:1 mixture of the desired aldehyde (cleavage of primary TES ether) to undesired 
ketone (cleavage of secondary TES ether, entry 10). 
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Scheme 34: Model system used for investigating selective TES group cleavage conditions. 
Table 6: Conditions screened for the selective deprotection of model bis-silyl ether 115. 
 
 Encouraged by the results obtained with PPTS, the synthesis of bis-TES-protected 
glycerol 118 was attempted in a similar manner to bis-TBS protected 101, this time beginning 
from commercially available (S)-solketal (Scheme 35). Benzyl protection, isopropylidene 
hydrolysis, and TES protection all proceeded in good yields. Surprisingly however, the 
hydrogenation to remove the benzyl group led to partial cleavage of a TES ether (presumably the 
primary ether). This is a known side reaction in some instances for relatively unhindered silyl 
C4H9
OTES
OTES
C4H9
OTES
OH
Reagent
solvent
+ Double deprotection
116115
Reagent Temperature (oC)
1
2
Entry
-20 to r.t
-20 to r.t117
mol%
5 to 18
5 to 18
R.S.M.
R.S.M.
2,4,6-
trimethylbenzoic acid
P
O OH
Ph
Ph
117
3
-20 to r.ttriphenylacetic acid 5 to 100 R.S.M.
5
6 -20 to 0NaAuCl4.2H2O 1 to 5 complex mixture
7
FeCl3 2 complex mixturer.t
Solvent
1:1 CH2Cl2:MeOH
1:1 CH2Cl2:MeOH
1:1 CH2Cl2:MeOH
THF:MeOH
MeOH
TBAF 24 double deprotectionr.t THF:buffer8
CAN/SiO2 24 complex mixturer.t 1:1 CH2Cl2:iPrOH9
Sc(OTf)3 30 0 CH2Cl2 double deprotection
10 Swern 400 -78 CH2Cl2 Low Selectivity*
* ~2:1 mixture of aldehyde and ketone
4 PPTS 10 -50 1:1 CH2Cl2:MeOH
Yield of 116
29%
 48 
groups such as trimethylsilyl (TMS) and TES, even when controlling for traces of acid in the 
catalyst that may be left over from commercial production (Scheme 36; residual acid can be 
quite different with different suppliers).137, 138 Prior work suggested that this undesired side 
reaction could be suppressed by using acetonitrile as the solvent.138 However, this also led to a 
complete shutdown of the desired hydrogenolysis of the benzyl group, perhaps due to the poor 
solubility of the starting material.  
 
Scheme 35: TES cleavage under hydrogenation conditions. 
 
Scheme 36: Known TES cleavage under hydrogenation conditions138 
In order to improve the selectivity of the final deprotection in the synthesis of bis-TES 
glycerol 118, the benzyl ether was replaced by a 3,4-dimethoxylbenzyl (DMB) ether, which was 
envisioned to allow for selective cleavage under oxidative conditions (Scheme 37). Protection of 
the alcohol in (S)-30 with freshly prepared 3,4-dimethoxybenzyl bromide followed by 
transacetalization gave the desired diol (R)-122 in 74% yield over two steps. TES protection 
followed by DMB ether cleavage with DDQ gave a substantially improved yield of 73% over 
two steps compared to similar efforts with the benzyl ether (note: a PMB ether can also be 
carried through this sequence but is more challenging to purify in the final step). Subsequent 
optimizations allowed this sequence to be performed with only a single purification in nearly 
identical yield (54% over 4 steps).  
1. NaH, THF, 0 oC
then BnBr to rt
 
2. HCl (aq.)
 74%, 2 steps 63
OH
OHBnO
O
OHO
1. TESCl, DMAP 
Imidazole, CH2Cl2
2. H2, Pd/C, EtOAc
118
OTES
OTESHO
(S)-30
+
Desilylation
Ph OTES
H2, Pd/C
EtOAc
Ph OTES Ph OH
120:121: ~2:1
119 120 121
+
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Scheme 37: Successful preparation of alcohol 118 utilizing the DMB ether protecting group. 
The alcohol 118 was then used in preparing phosphate 123 (Scheme 38). (S)-Solketal 30 
was benzyl protected with sodium hydride and benzyl bromide, followed by acidic 
isopropylidene cleavage yielding diol 63. The diol was subjected to EDCI coupling leading to 
protected dipalmitoylglycerol 64a in 91% yield. Subsequent hydrogenolysis of the benzyl group 
in a Parr hydrogenator (5 bar) with Pd/C catalyst provided diacylglycerol (S)-46a in near 
quantitative yields, with no purification required. 1,2-Diacylglycerols are known to be prone to 
isomerization,79, 139 and thus elevated pressures were used to minimize reaction times and reduce 
the risk of unwanted byproduct formation. One pot phosphate formation was accomplished using 
chlorophosphoramidite 40 followed by activation of the intermediate phosphoramidite with 
4,5-dicyanoimidazole and coupling to alcohol 118.  Finally, oxidation with Bu4NIO4 gave 
phosphate 123 in 59% yield.     
1. NaH, TBAI, DMBBr 
THF, 0 oC to r.t.
 
2. H2SO4 (cat.), MeOH
74%, 2 steps
O
OHO
(S)-30 (R)-122
OH
OHDMBO
1. TESCl, DMAP 
Imidazole, CH2Cl2
2 .DDQ, CH2Cl2:pH 7 buffer
73%, 2 steps 118
OTES
OTESHO
O
OHO
(S)-30
4 steps
54% 118
OTES
OTESHO
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Scheme 38: Synthesis of phosphate 123. 
Further optimization of the selective TES deprotection was then conducted on compound 
123. Incidentally, the only reported example uses reducing conditions with H2 and Pd/C (Scheme 
39).140 The reaction times reported were very short (<5 min) and in most cases, no selectivity 
between the TES ethers was observed. Thus it is likely that steric effect of the 
tert-butyldiphenylsilyl (TBDPS) ether in 124 plays a significant role in shielding the secondary 
TES ether. Based on the prior discussion about silyl group cleavage under these conditions and 
the varying quality of Pd/C, it was postulated that this method would be very difficult to 
reproduce. 
 
Scheme 39: The only selective deprotection of 1o/2o 1,2-bis-TES ethers found in the literature.  
Compound 123 was found to be less reactive than model substrate 115 (Scheme 40 and 
Table 7). This is likely due at least in part to the very low solubility of compound 123 in 1:1 
CH2Cl2:MeOH below –25°C. Performing the reaction at –10 °C provided a satisfactory yield 
(entry 1). Other acidic deprotection conditions were explored as well. Olah’s reagent, while 
providing slightly lower yields than PPTS, also proved difficult to reproduce and so was not 
1. NaH, THF, 0 oC
then BnBr to rt
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74% 63
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HO OBn
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91%
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O
R
O
R
O
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97%
1. 40,  DIPEA, CH2Cl2
2. 117, 4,5-Dicyanoimidazole
 then Bu4NIO4
   59%
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O O
O
R
O
R
O
P
OMe
O
O
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64a
R = C15H31
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R = C15H31
O OH
O
R
O
R
O
(S)-46a
R = C15H31
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TBDPSO
6
H2, Pd/C
MeOH
3 min
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OH
OTES
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investigated further (entry 2). Weaker acids such as acetic acid (AcOH) or 
hexafluoroisopropanol (HFIP) used in large excess failed to improve results (entries 3 and 4). 
The significantly stronger acid triphenylphosphine hydrobromide provided complete double 
deprotection within 30 min (entry 5). TBAF buffered with acetic acid resulted in nonselective 
deprotection (entry 5).  
 Given the lack of encouraging results with deprotection conditions other than PPTS, 
efforts were made to fine-tune this reaction. Reducing the temperature to –20 °C did not affect 
the overall yield, but improved the reliability with which the unreacted starting material could be 
recovered (entry 7). Changing the counterion from tosylate to trifluoroacetate greatly decreased 
the rate of the reaction but did not affect the overall yield (entry 8). Dimethylaniline 
hydrochloride is a slightly stronger acid (pKa 2.5 vs 3.4 in DMSO) and gave similar results to 
PPTS, but since it is not commercially available and is substantially more hygroscopic, was not 
used further (entry 9). Similarly, changing the alcoholic component of the solvent from methanol 
to isopropanol greatly decreased the reaction rate without improving the yield. Thus, the most 
reliable conditions were found to be 10 mol% PPTS in 1:1 CH2Cl2:MeOH at –20 °C and 
provided the desired deprotection product 126 in 43% yield (78% BRSM). 
 
Scheme 40: Conversion of 123 to 126.  
 
O
P
O OTES
O
OMe
OTES
123
R O P O OH
O
OMe
OTES
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O
OC15H31
O
C15H31
O Table 7
R
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Table 7: Optimization of selective TES ether cleavage conditions. 
 
A potential explanation for the inability to increase the yield of the desired product is 
shown in Scheme 41. It should be noted that in all cases with tractable product mixtures, some 
combination of unreacted starting material, monodeprotection, and double deprotection occurs 
cleanly. Reversible protonation of the silyl ethers likely occurs selectively at the less hindered 
primary position giving intermediate I1. Following cleavage of the Si–O bond, a second 
protonation can occur at the remaining silyl ether oxygen. It is possible that the neighboring 
alcohol oxygen can participate in stabilizing the protonated silyl ether in intermediate I2 and thus 
increase the rate at which the second TES is cleaved. 
Reagent Temperature (oC)
1
2
Entry
-10
-10TBAF
Yield of 126 (%)
0
low selectivity
3
0HF.Py 31
4
AcOH 33
5
6
Solvent
1:1 CH2Cl2:MeOH
THF:AcOH
THF
2:1:1 THF:AcOH:H2O
HFIP R.S.M.r.t CH2Cl2:HFIP:MeOH
PyTFA 40-20 1:1 CH2Cl2:MeOH
7
PPTS -10 1:1 CH2Cl2:MeOH 43
8
PPTS -20 1:1 CH2Cl2:MeOH 43
Ph3PHBr
r.t
9
PPTS r.t 1:1 CH2Cl2:iPrOH 2610
PhNMe2.HCl -20 1:1 CH2Cl2:MeOH 43
mol%
—
5
5
5
—
5
5
5
100
100
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Scheme 41: Proposed rational for the difficulties in increase the yield of the selective cleavage of TES ethers 
of 1,2-diols. 
Alcohol 126 was then carried through a second phosphoramidite coupling/oxidation 
sequence, yielding protected CL 128a in low yield (Scheme 42).  Subsequent demethylation with 
sodium iodide was carried out in acetone at reflux, as the higher temperature of 2-butanone was 
found to be unnecessary and reaction mixtures were generally cleaner. TES ether cleavage using 
H2SiF6141, 142 in THF gave the desired CL 129a in a modest yield of 39%. In prior work, THF 
gave significantly reduced reaction rates compared to MeCN, but this reaction was complete in 
30 min with no ester hydrolysis. 
O OSiEt3
OSiEt3
123
O O
O
I1
SiEt3
H
Et3Si
ROH
O OH
O
I2
Et3Si H
O OH
OH
127
N
H
OTs
N
H
OTs
O OH
O
126
Et3Si
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Scheme 42: Successful preparation of CL 129a without ester hydrolysis. 
1.6.3 Development of a Bioinspired Late Stage Acylation 
With the knowledge that the final deprotection could be achieved without ester hydrolysis, focus 
was shifted to designing a more streamlined synthesis of CL analogs. The two general 
approaches to CL synthesis (Scheme 43) both utilize 1,2-diacylglycerols that are prepared by 
early incorporation of the acyl residues, which makes them inconvenient for analog synthesis. A 
more streamlined approach was inspired by the biosynthesis of CL, in which the full CL is first 
synthesized, then exchange of fatty acid residues occurs as needed (Section 1.3). Methods for 
enzymatic deacylation of CL have been developed,143, 144 but they use unprotected CLs and 
generally do not provide high yields.  
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Scheme 43: Proposed method for incorporating fatty acids after CL backbone assembly. 
In practice, this strategy is equivalent to using a protecting group on one of the glycerol 
positions that can be cleaved under mild conditions orthogonal both to the TES ether and methyl 
phosphates (130, Scheme 43). Additionally, migration of the acyl group must be avoided and 
thus the reaction should be conducted under neutral conditions. Finally, the subsequent acylation 
reaction should be conducted using the crude material from the deprotection step to avoid any 
issues of acyl migration during purification. 
Initial inspiration was drawn from the 4-azidobutyryl esters developed by Kusumoto 
(Scheme 44).145 These can be cleaved under mild hydrogenation or Staudinger reduction 
conditions, were the azide is first reduced to the amine, followed by cyclization to release the 
desired alcohol. They have been applied in sensitive substrates previously146 and the lactam 
byproduct 135 was not expected to interfere with subsequent acylation. Additionally, two 
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variants were developed that have increasing degrees of conformational restriction and should 
allow for even more facile cleavage if needed.147, 148 
 
Scheme 44: Kusumoto's 4-azidobutryl ester protecting group. 
Protected glycerol synthesis began from (S)-solketal 30 (Scheme 45). TBPDS protection 
of the alcohol was selected due to its moderate acid stability (to survive isopropylidene cleavage) 
and orthogonal cleavage conditions to the azido-esters. Isopropylidine cleavage on related 
systems has been performed using FeCl3 adsorbed on SiO2149 or 90% acetic acid.150 FeCl3/SiO2 
gave poor conversion and it was undesirable to remove large quantities of acetic acid. An 
adaptation using citric acid was developed that not only uses significantly less acid (5 equiv. vs  
>1500 equiv.) but allows for a telescoped TBDPS protection/isopropylidene deprotection with a 
simplified purification (the prior synthesis uses a two flask approach that requires a solvent 
switch from DMF to 90% acetic acid with both chromatography and crystallization required for 
purification after the second step).  
The resulting diol 136 could then be converted to diesters 138a-c by sequential acylation 
reactions. Compound 138a was prepared by a selective acylation with 
N,N-dicyclohexylcarbodiimide (DCC) and acid 137 followed by acylation of the secondary 
alcohol with palmitic acid under EDCI coupling conditions in 49% over 2 steps. Compound 
138b was prepared in an unoptimized 12% yield by sequential acylation with acid chloride 139 
and palmitoyl chloride. Compound 138c was prepared using the same DCC coupling used in 
preparing 138a and the intermediate alcohol was isolated in an unoptimized 49% yield. 
R
O
O
N3
H2, Pd/C
or
PPh3
132
R
O
O
NH2
133
R
OH
HN
O
+
134
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Subsequent acylation with palmitoyl chloride gave the desired diester 138c in sufficient purity to 
use in test deprotection reaction (product contaminated with palmitic acid). 
 
Scheme 45: Synthesis of azide-esters 138a-c with varying degrees of conformational restriction. 
Cleavage of the azido-esters proved to be challenging (Scheme 46, Table 8). Attempted 
cleavage under Staudinger reduction conditions or hydrogenation with Pd/C successfully reduced 
the azide to the amine (138*), but subsequent cyclization and ester cleavage was incomplete in 
all cases. This is consistent with prior results that required elevated temperatures for ester 
cleavage.145, 146 Additionally, isomerization of the desired compound 141a to 141b occurred to 
varying degrees. Similar results for all azido-esters 138a-c were obtained and further efforts to 
improve this step were abandoned. 
O
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Scheme 46: Attempted cleavage of azido-esters 138a-c. 
Table 8: Attempted cleavage of azido-ester protecting groups. 138* is 138 containing an amine (i.e. azide 
reduction was always successful but ester cleavage was incomplete). 
 
Oxidation-labile benzyl ethers (PMB, DMB) also possess the requisite orthogonality for 
the synthesis of the protected fragment. One challenge associated with the use of these protecting 
groups is their selective installation on diol 136. Dibutyltin oxide has been used with great 
success in related selective alkylations and acylations in carbohydrate chemistry151, 152 and 
related 1,2-diols.153, 154 PMB protection of diol 136 proceeded with acceptable efficiency, but the 
corresponding DMB protection gave 22% yield, likely due to the lower stability of this ether 
(Scheme 34). In both cases, purification proved to be quite challenging and ultimately led to the 
redesign of the synthesis for these compounds (vide infra). EDCI coupling proceeded in 77% 
yield for both 142a and 142b giving protected glycerols 143a-b. Both the PMB and DMB ethers 
138a-c
Table 8O
OTBDPSO R
O
O
C15H31
O
OHTBDPSO
O
C15H31
OH
OTBDPSO
+
C15H31
O141a 141b
Solvent 138*:141a:141bEntry
1
2
3
2:1:1THF
i-PrOH
THF 1.3:1:1.9
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DPPE, H2O
1:1:1
Temp (oC)
r.t.-65
r.t
r.t
(CH2)3N3
(CH2)3N3
(CH2)3N3
R
4 i-PrOH 1.7:1.7:1H2, Pd/Cr.tC(CH3)2(CH2)2N3
5 THF 1:1.3:1PPh3, H2Or.tC(CH3)2(CH2)2N3
6 i-PrOH 2.8:1.1:1H2, AcOH, Pd/Cr.tC(CH3)2(CH2)2N3
7 THF 3.8:1:1.1PBu3, H2Or.t
N3
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can be cleaved using DDQ under buffered conditions without acyl migration. Likewise, TBAF 
buffered with acetic acid139 allows for orthogonal cleavage of the TBDPS groups. 
 
Scheme 47: Synthesis of protected glycerols 145a-b. 
Given that the DMB protected glycerol 145b ultimately proved to be the most useful 
(vide infra), the synthesis was optimized to allow for more efficient material throughput. The 
simplest solution was to use the opposite enantiomer used to prepare alcohol 142b and utilize 
reaction conditions already known to be effective for installing the DMB ether on solketal and 
selective isopropylidene cleavage (Scheme 48). Using (R)-30, this sequence proceeded in similar 
yield to the opposite enantiomer. Selective protection of the primary alcohol with TBDPSCl gave 
142b in 78% yield with complete selectivity. Finally, EDCI coupling gave the desired protected 
glycerol 143b in 88% yield, an improvement of 36% over the sequence compared to using the 
Bu2SnO method (49% from (R)-30 to 143b vs 13% for (S)-30 to 143b). 
 
Scheme 48: Alternative synthesis of 143b. 
Key CL precursor 146 was prepared through phosphoramidite coupling of phosphate 126 
and protected glycerol 145b as performed previously (Scheme 49, Table 9). Three different 
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oxidative cleavages of the DMB ether were attempted. CAN on SiO2135 gave approximately 50% 
conversion but also lead to the cleavage of the TES ether. Catalytic DDQ using manganese(III) 
acetate as the terminal oxidant155 gave only trace conversion. Using stoichiometric DDQ in a 
biphasic CH2Cl2:phosphate buffer system provided full conversion to the desired alcohol and 
was used directly in subsequent transformations. 
 
Scheme 49: Synthesis of DMB protected CL precursor 146 and optimization of DMB cleavage. 
Table 9: DMB cleavage conditions for the conversion of 146 to 147. 
 
The crude alcohol 147 was directly used in the installation of the final fatty acid residue 
(Scheme 50, Table 10).  DCC performed poorly and had the additional complication that the urea 
byproduct could not be separated from the desired compound (entry 1). T3P® gave a cleaner 
product but a similarly poor yield (entry 2). The commercially available palmitoyl chloride 
proceeded well in 66% yield (entry 3). An activated N-hydroxysuccinimide (NHS) ester with 
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catalytic DMAP was relatively unreactive proceeding with low conversion (entry 4). The mixed 
pivaloyl anhydride with catalytic DMAP was found to be equally effective to the acid chloride 
(entry 5), but contained a small amount of TES cleavage in the product (likely due to traces of 
HCl). Increasing the amount of triethylamine to 3 equiv. suppressed this side reaction. 
Ultimately, the mixed pivaloyl anhydrides were selected for further use, as they are generally 
less moisture sensitive than the corresponding acid chlorides. 
Scheme 50:Conversion of DMB-protected 146 to protected CL 128a. 
Table 10: Screening of reaction conditions for deprotection/acylation sequence. 
The bioinspired acylation sequence was then used to incorporate fatty acids of various 
degrees of unsaturation (Scheme 51). Stearic (C18, saturated) and oleic (C18, monounsaturated) 
acids can be installed in 58% and 63% yields respectively. The method is also successful for 
polyunsaturated fatty acids. Linoleic (C18, diunsaturated) and arachidonic (C20, 
tetraunsaturated) acid residues, which contain one and three easily oxidized bis-allylic positions 
respectively, can be installed in similar yields of 65% and 57%. 
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Scheme 51: Synthesis of CLs 129b-e.  
Given the importance of oxidized CLs in apoptosis,156, 157 efforts were made to 
demonstrate that oxygenated lipids could be incorporated as well. One of the simplest way to 
prepare an oxidized fatty acid is from a monounsaturated fatty acid through a Sharpless 
asymmetric dihydroxylation.158 The cis-fatty acids are known to give poor enantioselectivities, 
and thus the trans-18:1 elaidic acid was chosen as the starting point (Scheme 52, Table 11). The 
anthraquinone based ligand (DHQD)2AQN has been shown to provide superior results for 
isolated trans-alkenes compared to the more commonly used (DHQD)2PHAL.159 This was 
indeed found to be the case, but conversion was significantly lower (entries 1, 2). Increasing the 
ligand loading from 1 to 1.6 mol% of (DHQD)2PHAL allowed for a more satisfactory 93% yield 
and >95% ee (based on comparison of specific rotation to literature value) of 149 (entry 3). This 
also permitted the use of the commercially available AD-mix β with a small amount of 
additional ligand, which simplified reaction setup. Subsequent protection of the diol 149 with 
TESCl and mild ester hydrolysis conditions using potassium trimethylsilanoate (TMSOK) gave 
the desired compound 150 in 89% yield over two steps. 
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Scheme 52: Preparation of protected fatty acid diol 150. 
Table 11: Conditions screened for the dihydroxylation of 148-methyl ester. 
 
A similar direct conversion of a simple fatty acid to an epoxidized derivative proved 
more challenging (Scheme 53, Table 12). Direct Shi epoxidation of elaidic acid methyl ester 151 
was first attempted. Under standard reaction conditions using D-fructose derived catalyst Shi 
ketone with 1.4 equiv. of oxone, no reaction was observed. Performing the reaction at a slightly 
higher temperature had no effect (entry 2). It is well known that the Shi ketone decomposes via a 
Baeyer-Villiger oxidation if the pH is too low, which significantly hampers the epoxidation 
(Scheme 54, 153 to 154 and 155).160, 161 In the current experiments, the pH was measured 
between 7 and 8 following the addition of all reagents (entry 3), the same range that had led to 
rapid catalyst decomposition in prior studies. Adjustment of the pH to ~9 with K2CO3 followed 
by additional portions of both the catalyst and oxone also did not lead to any further conversion. 
A final attempt to promote epoxidation using superstoichiometric Shi ketone and a large excess 
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of oxone162 led to only 10% conversion to the desired epoxide (entry 4). One possible reason for 
the difficulties in promoting this reaction may be due to 151 forming micelles in the highly polar 
reaction medium. This would aggregate the alkenes away from the bulk solution in the center of 
the micelle, which could slow epoxidation enough to lead to either decomposition of the Shi 
ketone via the Baeyer-Villiger pathway or oxone decomposition preferentially.  
 
Scheme 53: Shi epoxidation of 151. 
Table 12: Attempted Shi epoxidation. DMM = dimethoxymethane buffer = 0.05 M Na2B4O7 in disodium 
ethylenediaminetetraacetic acid (4 x 10-4 M). 
 
 
O
O
C8H17
7
Shi ketone, Bu4NHSO4
Oxone, K2CO3
1:2:2
MeCN:DMM:Buffer
O
O
6
O
C8H17
151 152
O
O
O
O
O
O
Shi ketone =
Oxone 
(equiv.) Temp (
oC)Shi ketone (equiv.) Yield 152
0.3
0.3
1.4
1.4
-10
-5-r.t.
R.S.M.
R.S.M.
0.3 (x3)
2.0
2.1
3.8
-5
-5
R.S.M.
10%
Entry
1
2
3
4
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Scheme 54: Mechanism of Shi epoxidation. 
Since diol 149 is easily obtained, it was used to access the desired epoxide. The Moffatt 
reagent 161163 has been used to stereospecifically convert vicinal diols to epoxides via the 
intermediacy of vicinal chloro-acetates.163, 164 The chloro-acetates are generated through a unique 
mechanistic pathway (Scheme 55). Because the acid chloride of 161 is sterically hindered, it has 
been proposed that nucleophilic attack by one alcohol in the diol 160 occurs preferentially at the 
acetate carbonyl, followed by cyclization onto the acid chloride. Intermediate 163 can then eject 
a chloride ion. The resulting protonated dioxolanone 164 is poised to undergo ring opening to 
acetoxonium ion 165, which is subsequently attacked by the pendant alcohol. Following another 
proton transfer, loss of the α-hydroxy acid generates a second acetoxonium ion 167, which can 
undergo substitution at either carbon resulting in vicinal chloro-acetates 168a-b. These 
compounds can be converted to a single epoxide product upon cleavage of the acetates under 
basic conditions. 
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Scheme 55: Generation of vicinal chloro-acetates using the Moffatt reagent.  
This method proved to be highly effective, converting diol 149 to 1:1 mixture of vicinal 
chloro-acetates 169a-b in quantitative yield (Scheme 56). Initially, stepwise acetate 
cleavage/epoxide formation with NaOMe and subsequent ester hydrolysis with TMSOK gave the 
desired epoxy acid 171 in 35% yield over two steps. Ultimately, a one-pot epoxide formation and 
ester hydrolysis using TMSOK was found to be more effective and delivered the desired product 
in 93% yield in a single step.   
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Scheme 56: Preparation of epoxy acid 171. 
The oxidized fatty acids could then be incorporated into protected CLs using the 
bioinspired acylation method (Scheme 57) in comparable yields to the naturally occurring fatty 
acids. Protected diol derivative 146f could then be deprotected smoothly using the same 
demethylation/desilylation sequence used previously, giving 80% of the desired CL 147f. 
However, epoxide 146g undergoes partial epoxide hydrolysis during the final desilylation 
reaction, likely promoted by the acidic aqueous conditions (H2SiF6 is sold as a solution in water). 
 
Scheme 57: Incorporation of oxidized fatty acids using the developed method. 
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1.6.4 Biological Results 
One major conundrum in CL biosynthesis is how the acyl chain composition is controlled during 
the remodeling process. Two possible explanations are 1) fatty acid availability in donor GPLs 
and 2) enzymatic selectivity in either the hydrolysis and/or reacylation step(s). S. cerevisiae is 
well suited  for studying this process because it only utilizes a single CL remodeling pathway.165 
In studies performed by the Bayir, Greenberg, Hüttemann, and Kagan labs, supplementation of 
yeast cells with oleic or linoleic acid led to the majority of CL species being tetraacylated with 
the supplemented acid. This effect was not observed with longer chain polyunsaturated fatty 
acids arachidonic acid (C20, tetraunsaturated) and docosahexaenoic acid (C22, hexaunsaturated), 
suggesting that a mechanism exists to select for certain fatty acids and is not controlled by fatty 
acid availability alone. An increase in the oleic acid and linoleic acid content of donor GPLs PE 
and PC with corresponding decrease in C16 fatty acid content was also observed. LC/MS 
analysis of the lyso-PE /lyso-PC content of these experiments also suggested that PEs and PCs 
containing oleic or linoleic acid were preferentially utilized in reacylating CL.  
In order to assess the inherent selectivity of Cld1 for the hydrolysis of particular fatty 
acid residues, compounds 84a-c, as well as commercially obtained tetramyristoyl CL (TMCL, 
saturated C14), tetraoleoyl CL (TOCL, monounsaturated C18), and tetralinoleoyl-CLs (TLCL, 
diunsaturated C18) were each incubated with purified Cld1 from S. cerevisiae. Cld1 showed 
selectivity for hydrolyzing CLs containing C16 and C18 saturated fatty acids (84a, 84c, and 84b 
respectively, shown in pink and red, Figure 15) over shorter chain and C18 unsaturated fatty acid 
containing CLs (shown in blue) as judged by the appearance of monolyso-CL by HPLC-MS.74 
Additional in vitro experiments using isolated Cld1 and liposomes containing CLs isolated from 
cld1Δ cells (1:1 dioleoyl-PC:CL) also showed primarily the release of palmitic acid. These 
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studies demonstrate that enzymes involved in CL remodeling have a fundamental selectivity that 
is at least partially responsible for the observed trend towards unsaturation in CL biosynthesis. 
 
Figure 15: Cld1-catalyzed hydrolysis of various CLs. CL liposomes (1:1 CL:dioleoyl PC) were incubated with 
Cld1 in 50 mM HEPES buffer for 20 min at 37 °C. Analysis of mono-lyso-CL content was performed after 
lipid extraction by the Folchs method using LC-MS. *p < 0.05 vs mono-lyso TMCL, #p < 0.002 vs mono-lyso 
TOCL, $p < 0.005 vs mono-lyso TLCL (n = 4–10). Reprinted with permission from ACS Chem. Bio. 2017, 12, 
265-281. Copyright 2017 American Chemical Society. 
 
1.6.5 Conclusion 
CLs 84a-c were prepared as mixtures of diastereomers and enabled the testing of Cld1’s 
hydrolysis selectivity. This has begun to clarify the reason why CLs posses a different fatty acid 
composition following the remodeling process. During this work, it became clear that there were 
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no facile ways in which to incorporate precious or unstable fatty acids into the CL scaffold late 
in the synthesis. The biosynthetic remodeling of CL inspired a strategy that allows for the late 
stage incorporation of saturated, monounsaturated, oxidation-prone polyunsaturated, and 
unnatural fatty acids. This method eliminates 3 steps per analog led to the synthesis of 
enantiopure CLs 129a-f. While the method was only applied to CLs, it should be equally 
applicable to other major phospholipids classes as well.  
 
Figure 16: Structure of all CL analogs prepared. 
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2.0  EXPERIMENTAL SECTION 
2.1 GENERAL 
All air and moisture sensitive reactions were carried out under a nitrogen or argon atmosphere. 
All reactions carried out above room temperature were performed using an oil bath or aluminum 
bead bath set to the specified temperature and monitored with an external thermometer. 
Tetrahydrofuran (THF) and diethyl ether were distilled from sodium/benzophenone ketyl. 
Dichloromethane was distilled from CaH2. Diisopropylethylamine (DIPEA) and 
diisopropylamine were distilled from and stored over KOH. Deoxygenation was performed by 
bubbling nitrogen through the solvent for 10 minutes. All other reagents were used as received. 
Concentration following workups and chromatography was performed using a rotary evaporator 
connected to a PIAB Lab Vac H40. Traces of solvents were removed from products by high 
vacuum.  
Reactions were monitored by thin layer chromatography analysis (pre-coated silica gel 60 
F254 plates, 250 µm layer thickness) and visualized with a 254 nm UV light or by staining with 
a KMnO4 solution. Flash chromatography on SiO2 (Silicycle, 40-63 µm) was used for 
purification where indicated.  
Melting points were determined using a Laboratory Devices Mel-Temp II and are 
uncorrected. Infrared spectra were obtained from neat solids or oils on a Perkin Elmer ATR IR or 
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Smiths Detection IdentifyIR FT-IR spectrometer. High-resolution mass spectra were obtained on 
a Thermo Scientific Exactive Orbitrap mass spectrometer using electrospray ionization.  
1H NMR spectra were obtained on a Bruker Advance at 300 MHz, 400 MHz, or 500 
MHz in CDCl3 or CD3OD. Chemical shifts (δ) were reported in parts per million with the 
residual solvent peak used as an internal standard δ 1H / 13C (solvent): 7.26 / 77.00 (CDCl3); 3.31 
(CD3OD). 1H NMR spectra were obtained and are tabulated as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = 
multiplet, bs = broad singlet), number of protons, and coupling constant(s). 13C NMR spectra 
were recorded using a proton-decoupled pulse sequence run at 100 MHz or 125 MHz and are 
tabulated by observed peaks. 31P NMR spectra were recorded using a complete decoupled pulse 
sequence run at 202 MHz. 
2.2 EXPERIMENTAL PROCEDURES 
 
N,N-Diisopropylamidomethylchlorophosphite (40).166 To a solution of methyl 
phosphorodichloridite (10.06 g, 71.91 mmol, 1.0 equiv.) in Et2O (205 mL) at 0°C under nitrogen 
was added diisopropylamine (20.2 mL, 144 mmol, 2.0 equiv.) over 45 min. The reaction mixture 
was then stirred for 16 h at room temperature. The salt was filtered off under nitrogen, rinsed 
with Et2O (2x80 mL), and the solvent was distilled off under nitrogen. Purification by distillation 
under high vacuum gave N,N-diisopropylamidomethylchloro-phosphite (40, 12.78 g, 64.66 
mmol, 90%) as a clear colorless oil. This compound was stored diluted in CH2Cl2 (0.5-1.5 M) 
P NCl
OMe
 73 
at -20 °C under inert gas. 1H NMR (CDCl3, 500 MHz) δ 3.80-3.72 (m, 2 H), 3.60 (d, 3 H, J = 
14.0 Hz), 1.28-1.19 (m, 12 H); 31P NMR (CDCl3, 202 MHz) δ 184.0.  
 
General Procedure A: 1-O-Palmitoylglycerol (109a).125, 167 A solution of palmitic acid (4.99 g, 
19.5 mmol, 1.0 equiv.), 50% glycidol in CH2Cl2 (2.70 mL, 21.4 mmol, 1.1 equiv.) and 
tributylamine (0.090 mL, 0.37 mmol, 0.02 equiv.) was heated to 85 °C and stirred for 5 h. The 
crude product was recrystallized from i-Pr2O:Et2O (1:1) to yield 1-O-palmitoylglycerol (109a, 
4.57 g, 13.8 mmol, 71%) as a colorless solid: Mp 71.9-72.5 °C; 1H NMR (CDCl3, 300 MHz) δ 
4.22, 4.16 (ABX, 2 H, JAB = 11.7 Hz, JAX = 4.7 Hz, JBX = 6.1 Hz), 3.97-3.90 (m, 1 H), 3.70, 3.60 
(ABX, 2 H, JAB = 11.6 Hz, JAX = 3.8 Hz, JBX = 5.8 Hz), 2.35 (t, 2 H, J = 7.7 Hz), 1.66-1.58 (m, 2 
H), 1.29-1.25 (m, 24 H), 0.85 (t, 3 H, J = 6.8 Hz); 13C NMR (CDCl3, 100 MHz) δ 174.4, 70.3, 
65.2, 63.3, 34.1, 31.9, 29.7-29.6 (m), 29.4, 29.3, 29.1, 24.9, 22.7, 14.1. IR ν 3293, 2913, 2848, 
1728 cm-1. 
 
1-O-Stearoylglycerol (109b).168 Prepared according to General Procedure A using stearic acid 
(5.14 g, 17.2 mmol, 1.0 equiv.), 50% glycidol in dichloromethane (2.4 mL, 18.1 mmol, 1.05 
equiv.) and tributylamine (0.08 mL, 0.3 mmol, 0.02 equiv.). The crude product was 
recrystallized from i-Pr2O:Et2O (1:1) to yield 1-O-stearoylglycerol (109b, 4.36 g, 12.2 mmol, 
71%) as a colorless solid: 1H NMR (CDCl3, 300 MHz) δ 4.2, 4.15 (ABX, 2 H, JAB = 11.7 Hz, JAX 
= 4.6 Hz, JBX = 5.9 Hz), 3.96-3.90 (m, 1 H), 3.70, 3.61 (ABX, 2 H, JAB = 11.4 Hz, JAX = 3.8 Hz, 
O OH
OH
C15H31
O
O OH
OH
C17H35
O
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JBX = 6.1 Hz), 2.71 (bs, 2 H), 2.35 (t, 2 H, J = 7.7 Hz), 1.65-1.60 (m, 2 H), 1.28-1.25 (m, 28 H), 
0.88 (t, 3 H, J = 6.6 Hz). 
 
1,2-O-Dipalmitoyl-3-O-triylglycerol (45a).101 To a solution of 109a (2.09 g, 6.32 mmol, 1.0 
eq.) in pyridine (12 mL) was added TrCl (1.91 g, 6.85 mmol, 1.08 eq.) and DMAP (78 mg, 0.63 
mmol, 0.1 eq.). The reaction mixture was heated to 50 °C and stirred for 22 h. The reaction 
mixture was poured into water (50 mL) and extracted with CH2Cl2 (2x25 mL). The organic 
layers were rinsed with brine (25 mL), dried (MgSO4), and concentrated. A solution of this 
alcohol in CH2Cl2 (22 mL) was then added dropwise to a solution of EDCI (1.24 g, 6.40 mmol, 
1.1 eq.), palmitic acid (1.64 g, 6.40 mmol, 1.1 eq.) and DMAP (0.362 g, 2.94 mmol, 0.5 eq.) in 
CH2Cl2 (15 mL) that had been stirring for 15 min prior to addition of the alcohol. Stirring was 
continued for 4 h. The reaction mixture was diluted with CH2Cl2 (10 mL), rinsed with water (15 
mL), brine (15 mL), dried (MgSO4), and concentrated. Purification by filtration through SiO2 
(95:5 hexanes:ethyl acetate containing 1% Et3N) gave 1,2-O-dipalmitoyl-3-O-triylglycerol  (45a, 
3.81 g 4.00 mmol, 69%, 85% pure) as a colorless solid. 1H NMR (CDCl3, 300 MHz) δ 7.42 (d, 
2.0 H, J = 2 Hz), 7.43-7.41 (m, 6 H), 7.32-7.23 (m, 10 H), 5.27-5.22 (m, 1 H), 4.34, 4.24 (ABX, 
2 H, JAB = 11.9 Hz, JAX = 3.6 Hz, JBX = 6.3 Hz), 3.23 (dd, 2 H, J1 = 2.4 Hz, J2 = 4.8 Hz), 2.33 (t, 2 
H, J = 7.5 Hz), 2.22 (t, 2 H, J = 7.5 Hz), 1.65-1.54 (m, 4 H), 1.28-1.25 (m, 48 H), 0.91 (t, 3 H, J 
= 6.6 Hz). 
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General Procedure B: 1,2-O-Dipalmitoyl-3-O-dimethoxyltriylglycerol (110a). To a solution 
of 109a (4.57 g, 13.8 mmol, 1.0 equiv.) in 1:2 pyridine:CH2Cl2 (35 mL) at 0°C was added 
dimethoxyltrityl chloride (DMTCl) (4.82 g, 14.1 mmol, 1.0 equiv.) and DMAP (0.177 g, 1.43 
mmol, 0.1 equiv.). The orange solution was stirred at this temperature for 15 min., then warmed 
to room temperature and stirred for 13 h. The orange reaction mixture was quenched with water 
(30 mL) and extracted with CH2Cl2 (2x50 mL). The organic portion was rinsed with water (40 
mL), brine (40 mL), dried (MgSO4), and concentrated. The residue was then concentrated from 
PhMe (2x20 mL) and the resulting orange oil used without further purification. A solution of 
EDCI (2.93 g, 15.3 mmol, 1.1 equiv.), palmitic acid (3.91 g, 15.3 mmol, 1.1 equiv.) and DMAP 
(0.851 g, 6.90 mmol, 0.5 equiv.) in CH2Cl2 (60 mL) was allowed to stir at room temperature 
under nitrogen for 15 min. Then, the previously obtained oil from DMT protection (8.77 g, 13.9 
mmol 1.0 eq) in CH2Cl2 (30 mL) was added and stirring continued for 4 h. The reaction mixture 
was diluted with water (50 mL) and the layers separated. The organic layer was rinsed with 
water (50 mL), brine (50 mL), dried (MgSO4), and concentrated. Purification by filtration 
through SiO2 (9:1 CH2Cl2:hexanes) gave 1,2-O-dipalmitoyl-3-O-dimethoxyltriylglycerol 
(110a,7.94 g, 9.11 mmol, 66%) as a colorless solid. Acceptable purity can also be obtained by 
trituration with MeOH several times. Mp 64.5-66.0 °C; 1H NMR (CDCl3, 300 MHz) δ 7.42 (d, 
2.0 H, J = 2 Hz), 7.40-7.20 (m, 7 H), 6.82 (d, 4 H, J = 8.7 Hz), 5.28-5.22 (m, 1 H), 4.34, 4.24 
(ABX, 2 H, JAB = 11.7 Hz, JAX = 3.5 Hz, JBX = 6.7 Hz), 3.79 (s, 6 H), 3.22 (d, 2 H, J = 5.1 Hz), 
2.33 (t, 2 H, J = 7.5 Hz), 2.23 (t, 2 H, J = 7.5 Hz), 1.65-1.53 (m, 4 H), 1.28-1.25 (m, 48 H), 0.91 
(t, 3 H, J = 6.6 Hz); 13C NMR (CDCl3, 125 MHz) δ 173.4, 173.0, 158.5, 144.5, 135.7, 130.0, 
O ODMT
O
C15H31
O
C15H31
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128.1, 127.8, 126.8, 113.1, 86.0, 70.5, 62.9, 62.0, 55.1 34.4, 34.1, 31.9, 29.7-29.1 (m), 25.0, 
24.8, 22.7, 14.1; IR ν 2915, 2846, 1729 cm-1; HRMS (ESI+) m/z calculated C56H87O7 [M+H]+ 
871.6452; found 303.14 (DMT+). 
 
1,2-O-Distearoyl-3-O-dimethoxyltriylglycerol (110b). Prepared according to General 
Procedure B using 109b (4.36 g, 12.2 mmol, 1.0 equiv.), DMTCl (4.29 g, 12.5 mmol, 1.03 
equiv.) and DMAP (0.145 g, 1.18 mmol, 0.1 equiv.). For the second step, EDCI (2.57 g, 13.4 
mmol, 1.1 equiv.), stearic acid (4.01 g, 13.4 mmol, 1.1 equiv.) and DMAP (0.754 g, 6.11 mmol, 
0.5 equiv.) were used. Purification by trituration with MeOH gave 
1,2-O-distearoyl-3-O-dimethoxyltriylglycerol (110b, 6.68 g, 6.48 mmol, 53%) as a colorless 
solid. Mp 67-68.4 °C; 1H NMR (CDCl3, 300 MHz) δ 7.45 (d, 2 H, J = 7.2 Hz), 7.35-7.24 (m, 7 
H), 6.82 (d, 4 H, J = 8.7 Hz), 5.29-5.28 (m, 1 H), 4.34, 4.24 (ABX, 2 H, JAB = 11.7 Hz, JAX = 3.5 
Hz, JBX = 6.7 Hz), 3.82 (s, 6 H), 3.25 (d, 2 H, J = 3.3 Hz), 2.36 (t, 2 H, J = 7.5 Hz), 2.27 (t, 2 H, J 
= 7.5 Hz), 1.69-1.56 (m, 4 H), 1.29 (m, 54 H), 0.91 (t, 3 H, J = 6.6 Hz); 13C NMR (CDCl3, 125 
MHz) δ 173.4, 173.0, 158.5, 144.6, 135.8 (2C), 130.0 (2C), 128.1, 127.8, 126.8, 113.1, 113.0, 
86.1, 70.5, 62.9, 62.1, 55.2, 34.4, 34.1, 31.9, 31.8, 29.7-29.1 (m), 25.0, 24.9, 22.7, 14.1; IR ν 
2915, 2848, 1730 cm-1. 
 
1-O-Palmitoyl-2-O-palmitoleoyl-3-O-dimethoxyltriylglycerol (110c). Prepared according to 
General Procedure B using 109a (2.04 g, 6.17 mmol, 1.0 equiv.), DMTCl (2.15 g, 6.28 mmol, 
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1.0 equiv.), and DMAP (0.079 g, 0.64 mmol, 0.1 equiv.). For the second step, EDCI (228 mg, 
1.19 mmol, 1.1 equiv.), palmitoleic acid (309 mg, 1.19 mmol, 1.1 equiv.) and DMAP (64 mg, 
0.52 mmol, 0.47 equiv.) were used. Purification by chromatography on SiO2 (95:5 hexanes:ethyl 
acetate) gave 1-O-palmitoyl-2-O-palmitoleoyl-3-O-dimethoxyltriylglycerol (110c, 0.619 g, 0.712 
mmol, 65%) as a clear colorless oil. 1H NMR (CDCl3, 300 MHz) δ 7.43 (d, 2 H, J = 8.4 Hz), 
7.31-7.25 (m, 7 H), 6.82 (d, 4 H, J = 8.7 Hz), 5.40-5.30 (m, 2 H), 5.29-5.22 (m, 1 H), 4.35, 4.24 
(ABX, 2 H, JAB = 11.7 Hz, JAX = 3.5 Hz, JBX = 6.7 Hz), 3.79 (s, 6 H), 3.23-3.21 (m, 2 H), 2.33 (t, 
2 H, J = 7.5 Hz), 2.23 (t, 2 H, J = 7.7 Hz), 2.02-2.00 (m, 4 H), 1.67-1.53 (m, 4 H), 1.30-1.26 (m, 
40 H), 0.88 (t, 6 H, J = 6.8 Hz); 13C NMR (CDCl3, 125 MHz) δ 173.4, 173.0, 158.5, 144.6, 135.8 
(2C), 130.0 (2C), 128.1, 127.8, 126.8, 113.1, 113.0, 86.1, 70.5, 62.9, 62.0, 55.2, 34.4, 34.1, 31.9, 
31.8, 29.7-29.0 (m), 25.0, 27.2, 25.0, 24.9, 22.7, 22.6, 14.1 (2C); IR ν 2923, 2853, 2093, 1741, 
1250 cm-1. 
 
General Procedure C: 1,2-O-Dipalmitoylglycerol (46a).169 To a solution 110a (7.94 g, 9.11 
mmol, 1.0 equiv.) in 1:1 CHCl3:MeOH (90 mL) was added Amberlite IR-120H (4.0 g). The 
reaction mixture was stirred 2.5 h, then filtered through basic alumina (ethyl acetate). The 
resulting yellow oil was precipitated from 3:1 Et2O:hexanes and filtered giving 
1,2-O-dipalmitoylglycerol (46a, 3.75 g, 5.50 mmol, 60%, 90% pure) as a colorless solid. 1H 
NMR (CDCl3, 400 MHz) δ 5.08 (pent, 1 H, J = 5.0 Hz), 4.32, 4.24 (ABX, 2 H, JAB = 11.8 Hz, 
JAX = 4.5 Hz, JBX = 5.9 Hz), 3.74-3.73 (m, 2 H), 2.33 (apparent q, 4 H, J = 8.0 Hz), 1.65-1.58 (m, 
4 H), 1.28-1.25 (m, 48 H), 0.88 (t, 3 H, J = 6.6 Hz).  
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1,2-O-Distearoylglycerol (46b).169 Prepared according to General Procedure C using 110b (4.34 
g, 4.68 mmol, 1.0 equiv.) and Amberlite IR-120H (2.07 g).  Purification by trituration with 3:1 
Et2O:hexanes gave 1,2-O-distearoylglycerol (46b, 2.08 g, 3.39 mmol, 72%) as a colorless solid. 
1H NMR (CDCl3, 500 MHz) δ 5.08 (pent, 1 H, J = 5.0 Hz), 4.32, 4.25 (ABX, 2 H, JAB = 12.0 Hz, 
JAX = 4.5 Hz, JBX = 5.5 Hz), 3.79-3.72 (m, 2 H), 2.34 (t, 2 H, J = 7.7 Hz), 2.32 (t, 2 H, J = 7.5 
Hz), 2.00 (t, 1 H, J = 6.25 Hz), 1.64-1.54 (m, 4 H), 1.29-1.25 (m, 56 H), 0.88 (t, 3 H, J = 7.0 Hz). 
 
1-O-Palmitoyl-2-O-palmitoleoylglycerol (46c). Prepared according to General Procedure C 
using 110c (100 mg, 0.115 mmol, 1.0 equiv.) and Amberlite IR-120H (52 mg). Purification by 
chromatography on SiO2 (1:0 to 5:1 CH2Cl2:ethyl acetate) gave 
1-O-palmitoyl-2-O-palmitoleoylglycerol (46c, 64 mg, 0.113 mmol, 98%) as a light yellow oil. 
1H NMR (CDCl3, 300 MHz) δ 5.40-5.30 (m, 2 H), 5.10-5.05 (m, 1 H), 4.32, 4.25 (ABX, 2 H, JAB 
= 12.2 Hz, JAX = 4.4 Hz, JBX = 5.5 Hz), 3.78-3.70 (m, 2 H), 2.33 (apparent q, 4 H, J = 7.3 Hz), 
2.02-2.00, (m, 4 H), 1.64-1.54 (m, 4 H), 1.30-1.27 (m, 40 H), 0.88 (t, 6 H, J = 6.7 Hz); 13C NMR 
(CDCl3, 125 MHz) δ 173.8, 173.4, 130.0, 129.7 128.1, 72.1, 62.0, 61.6, 34.3, 34.1, 31.9, 31.8, 
29.7-29.0 (m), 27.2, 25.0, 24.9, 22.7, 22.6, 14.1; IR ν 3502, 2919, 2850, 2093, 1737, 1163 cm-1; 
HRMS (ESI+) m/z calculated for C35H67O5 [M+H]+ 567.4983, found 567.4960. 
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4-((Benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolane (111).169 A slurry of 60% NaH in mineral 
oil (360 mg, 9.00 mmol, 1.2 equiv.) in THF (10 mL) at 0 °C under nitrogen was added a solution 
of 2,2-dimethyl-1,3-dioxolane-4-methanol (1.0 mL, 7.8 mmol, 1.0 equiv.) in THF (5 mL). The 
reaction mixture was stirred for 30 min., then BnBr (0.98 mL, 1.4 mmol, 1.1 equiv.) was added 
in a drop wise fashion. The reaction mixture was warmed to room temperature and stirred for 2.5 
h. The reaction was quenched with water (8 mL), diluted with Et2O (20 mL), and the layers 
separated. The aqueous portion extracted with Et2O (25 mL) and the combined organic fractions 
were rinsed with, brine (10 mL), dried (MgSO4), and concentrated. Purification by 
chromatography on SiO2 (95:5 to 9:1 to 85:15 hexanes: ethyl acetate) gave 
4-((benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolane (111, 1.15 g, 5.17 mmol, 67%) as a clear 
colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.35-7.29 (m, 5 H), 4.60, 4.56 (ABq, 2 H, JAB = 12.0 
Hz), 4.31 (pent, 1 H, J = 6.0 Hz), 4.06 (dd, 1 H, J1 = 6.4 Hz, J2 = 8.0 Hz), 3.75 (dd, 1 H, J1 = 6.4 
Hz, J2 = 8.4 Hz), 3.56, 3.46 (ABX, 2 H, JAB = 9.8 Hz, JAX = 5.9 Hz, JBX = 5.7 Hz ), 1.42 (s, 3 H), 
1.37 (s, 3 H). 
 
2,3-O-Bis(tert-butyldimethylsilyl)glycerol (101).170 111 (1.15 g, 5.17 mmol, 1.0 equiv.) was 
dissolved in 2:1 THF:H2O (10 mL), 12 M HCl (2.1, 25 mmol, 4.9 equiv.) added, and the reaction 
mixture was stirred for 1 h. The reaction was poured into sat. NaHCO3 (30 mL) and extracted 
with Et2O (3x 25 mL). The organic portion was rinsed brine (25 mL), dried (MgSO4), and 
concentrated. The resulting yellow oil was dissolved in CH2Cl2 (8.7 mL) at 0 °C under nitrogen 
Et3N (1.4 mL, 9.9 mmol, 2.3 equiv.) and TBSOTf (2.2 mL, 9.5 mmol, 2.2 equiv.) added, and the 
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cloudy white reaction mixture was stirred for 3 h. The reaction mixture was quenched with H2O 
(8 mL) and diluted with CH2Cl2 (10 mL). The layers were separated and the organic portion 
rinsed with brine (8 mL), dried (MgSO4), and concentrated. Purification by chromatography on 
SiO2 (99:1 to 95:5 hexanes:ethyl acetate) gave 
1-O-benzyl-2,3-O-bis(tert-butyldimethylsilyl)glycerol (1.72, 4.31 mmol, 83% over 2 steps) as a 
clear colorless oil. 1H NMR (CDCl3, 500 MHz) δ 7.35-7.33 (m, 4 H), 7.28-7.26 (m, 1 H), 4.54 (s, 
2 H), 3.86 (pent, 1 H, J = 5.3 Hz ), 3.61 (dd, 1 H, J1 = 6 Hz, J2 = 10.0 Hz), 3.57-3.52 (m, 2 H), 
3.42 (dd, 1 H, J1 = 5.5 Hz, J2 = 10.0 Hz), 0.87 (s, 18 H), 0.070 (d, 6 H, J = 1.5 Hz), 0.042 (s, 6 
H).  
To a solution of the intermediate (1.62 g, 4.06 mmol, 1.0 equiv.) in ethyl acetate (20 mL) 
was added 10% Pd/C (0.161 g, 0.152 mmol, 0.037 equiv.). The mixture was submitted to 
hydrogenation on a Parr hydrogenator under H2 (5 atm) for 1 h. The mixtures were filtered 
through Celite (ethyl acetate) and concentrated giving 2,3-O-bis(tert-butyldimethylsilyl)glycerol 
(101, 1.15 g, 3.59 mmol, 88%) as a clear colorless oil that can be used without further 
purification. An analytically pure sample can be obtain by chromatography on SiO2 (95:5 to 9:1 
hexanes:ethyl acetate). 1H NMR (CDCl3, 300 MHz) δ 3.79-3.74 (m, 1 H), 3.69-3.53 (m, 4 H), 
2.10 (bs, 1 H), 0.89 (s, 18 H), 0.10-0.06 (m, 12 H).  
 
General Procedure D: 3-(((2,3-Bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy) 
phosphoryl)oxy)propane-1,2-diyl dipalmitate (112a). To a solution of 46a (1.73 g, 2.89 mmol, 
1.0 equiv.) and DIPEA (0.53 mL, 3.2 mmol, 1.1 equiv.) in CH2Cl2 (30 mL) under nitrogen was 
added 0.5 M 40 (6.0 mL, 3.0 mmol, 1.1 equiv.) and the reaction mixture was stirred for 1 h. To 
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this solution was added 101 (0.921 g, 2.87 mmol, 0.99 equiv.) and 4,5-dicyanoimidazole (0.700 
g, 5.80 mmol, 2 equiv.) in THF (4.9 mL) in a dropwise fashion. The reaction mixture was stirred 
for 1 h, cooled to 0 °C, Bu4NIO4 (1.46 g, 3.36 mmol, 1.2 equiv.) added, and stirring continued 
for 30 min. The reaction mixture was diluted with water (15 mL) and the layers separated. The 
combined organic layers were rinsed with sat. Na2S2O3 (15 mL), sat. NaHCO3 (15 mL), brine 
(15 mL), dried (MgSO4), and concentrated. The crude material was then filtered through a plug 
of SiO2 (1:1 hexanes:ethyl acetate) and concentrated. Purification by chromatography on SiO2 
(5:1 to 3:1 hexanes:ethyl acetate) gave 3-(((2,3-bis((tert-butyldimethylsilyl)oxy)propoxy) 
(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (112a, 1.42 g, 1.47 mmol, 51%) as a 
clear colorless oil. 1H NMR (CDCl3, 300 MHz) δ 5.22 (pent, 1 H, J = 4.8 Hz), 4.36-4.30 (m, 1 
H), 4.19-4.09 (m, 4 H), 3.97-3.83 (m, 2 H), 3.76 (d, 3 H, J = 11.1 Hz; diasteromers visible), 
3.56-3.54 (m, 2 H), 2.31 (q, 4 H, J = 7.10 Hz), 1.61-1.56 (m, 4 H), 1.28-1.25 (m, 48 H), 
0.88-0.85 (m, 24 H), 0.08 (s, 3 H), 0.07 (s, 3 H), 0.05 (s, 6 H); 13C NMR (CDCl3, 125 MHz) δ 
173.2, 172.7, 72.0 (d, 3JCP = 7.5 Hz), 69.4 (d, 3JCP = 7.5 Hz), 69.2-69.1 (m), 65.4-65.3 (m), 64.0, 
61.6, 55.4 (d, 2JCP = 6.3 Hz), 34.1, 34.0, 31.9, 31.6, 29.7-29.1 (m), 25.8, 25.7, 24.8, 22.7, 22.6, 
18.3, 18.1,14.1, -4.7, -4.8, -5.5 (2C); IR ν 2922, 2854, 1741, 1252, 835 cm-1, HRMS (ESI+) m/z 
calculated for C51H106O10PSi2 [M+H]+ 965.7057; found 965.7086. 
 
3-(((2,3-Bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-di
yl distearate (112b). Prepared according to General Procedure D using 46b (542 mg, 0.884 
mmol, 1.0 equiv.), DIPEA (0.16 mL, 0.98 mmol, 1.1 equiv.), and 0.5 M 40 (1.9 mL, 0.98 mmol, 
1.1 equiv.). For the second step, 101 (283 mg, 0.884 mmol, 1.1 equiv.) and 4,5-dicyanoimidazole 
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(213 mg, 1.77 mmol, 2.0 equiv.), and Bu4NIO4 (455 mg, 1.05 mmol, 1.2 equiv.) were used. 
Purification by chromatography on SiO2 (5:1 hexanes:ethyl acetate) gave 
3-(((2,3-bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl 
distearate (112b, 0.605 g, 0.592 mmol, 67%) as a waxy colorless solid. Mp = 31.0-31.9 °C; 1H 
NMR (CDCl3, 300 MHz) δ 5.24-5.20 (m, 1 H), 4.37-4.31 (m, 1 H), 4.22-4.09 (m, 4 H), 3.97-3.84 
(m, 2 H), 3.77 (d, 3 H, J =11.1 Hz; diastereomers visible), 3.59-3.49 (m, 2 H), 2.31 (apparent q, 4 
H, J = 7.0 Hz), 1.61-1.57 (m, 4 H), 1.28-1.25 (m, 56 H), 0.88-0.86 (m, 24 H), 0.09 (s, 3 H), 0.08 
(s, 3 H), 0.05 (s, 6 H); 13C NMR (CDCl3, 125 MHz) δ 173.2, 172.7, 72.0 (d, 3JCP = 8.8 Hz), 69.4 
(d, 3JCP = 7.5 Hz), 69.2-69.1 (m), 65.4-65.3 (m), 64.0, 61.7, 54.4 (d, 2JCP = 5.0 Hz), 34.2, 34.0, 
31.9, 29.7-29.1 (m), 25.9, 25.7, 24.8, 22.7, 22.6, 18.3, 18.1, 14.1, -4.7, -4.8, -5.4, -5.5; IR ν 2923, 
2852, 1743, 1252, 835 cm-1; HRMS (ESI+) m/z calculated for C55H114O10PSi2 [M+H]+
1021.7688, found 1021.7766. 
General Procedure E 3-(((2-((Tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy) 
phosphoryl)oxy) propane-1,2-diyl dipalmitate (113a). To a solution of 112a (800 mg, 0.829 
mmol, 1.0 equiv.) in 1:1 CH2Cl2:MeOH (8.3 mL) at 0 °C was added camphorsulfonic acid (195 
mg, 0.823 mmol, 1.0 equiv.). The reaction mixture was maintained between -5 and 5 °C and 
stirred for 5.5 h. The reaction mixture was filtered through a small plug of basic alumina (ethyl 
acetate) and concentrated. Purification by chromatography on SiO2 (3:1 to 1:1 hexanes:ethyl 
acetate) gave 3-(((2-((tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl) 
oxy)propane-1,2-diyl dipalmitate (113a, 435 mg, 0.511 mmol, 62%) as a white solid. Mp 
27.8-28.0 °C; 1H NMR (CDCl3, 400 MHz) δ 5.29-5.20 (m, 1 H), 4.33 (dd, 1 H, J1 = 4.4 Hz, J2 
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=12.0 Hz), 4.21-4.14 (m, 3 H), 4.06-4.01 (m, 2 H), 3.93-3.89 (m, 1 H), 3.80-3.76 (m, 3 H), 
3.67-3.50 (m, 2 H), 2.35-2.31 (m, 5 H), 1.62-1.60 (m, 4 H), 1.28-1.25 (m, 48 H), 0.90-0.86 (m, 
15 H), 0.11 (s, 6 H); 13C NMR (CDCl3, 100 MHz) δ 173.2, 172.8 (diastereomers visible), 71.1 
(d, 3JCP = 7.0 Hz), 69.4-69.3 (m), 67.7 (m), 65.6-65.5 (m), 63.0, 61.6, 54.6 (m), 34.1, 34.0, 31.9, 
29.7-29.1 (m), 25.7, 24.8, 22.7, 18.0, 14.1, -4.8, -4.9; IR ν 2922, 2854, 1741, 1252, 835 cm-1; 
HRMS (ESI+) m/z calculated for C45H92O10PSi [M+H]+ 851.6192, found 851.6180. 
 
3-(((2-((Tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl)oxy)propane
-1,2-diyl distearate (113b). Prepared according to General Procedure E using 112b (961 mg, 
0.941 mmol, 1.0 equiv.) and CSA (221 mg, 0.932 mmol, 0.99 equiv.). Purification by 
chromatography on SiO2 (4:1 to 1:1 hexanes:ethyl acetate) gave 
3-(((2-((tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl)oxy)propane-1,2-
diyl distearate  (113b, 470 mg, 0.518 mmol, 55%) as a waxy colorless solid. Mp = 41.2-41.7 °C; 
1H NMR (CDCl3, 300 MHz) δ 5.25-5.22 (m, 1 H), 4.34 (dd, 1 H, J1 = 4.2 Hz, J2 = 12.0 Hz), 
4.19-4.11 (m, 3 H), 4.05-4.02 (m, 2 H), 3.95-3.90 (m, 1 H), 3.78 (d, 3 H, J  = 11.4 Hz; 
diastereomers visible), 3.67-3.60 (m, 2 H), 2.36-2.29 (m, 5 H), 1.62-1.58 (m, 4 H), 1.28-1.25 (m, 
56 H), 0.90-0.86 (m, 15 H), 0.11 (s, 6 H); 13C NMR (CDCl3, 125 MHz) δ 173.3, 172.8, 71.1 (d, 
3JCP = 7.1 Hz), 69.4 (m), 67.7 (m), 65.6 (m), 63.0, 61.6, 54.6 (m), 34.2, 34.0, 31.9, 29.7-29.1 (m), 
25.7, 24.8, 22.7, 18.0, 14.1, -4.7, -4.9; IR ν 3535, 2921, 2850, 1739, 733 cm-1; HRMS (ESI+) m/z 
calculated for C49H100O10PSi [M+H]+ 907.6818, found 907.6785. 
 
O O
O
C17H35
O
C17H35
O
P
OMe
O
O
OH
OTBS
 84 
 
General Procedure F: 3-(((3-(((2,3-(Palmitoyloxy)propoxy)(methoxy) 
phosphoryl)oxy)-2-((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propan
e-1,2-diyldipalmitate (114a). To a solution of 113a (322 mg, 0.378 mmol, 1.0 equiv.) in CH2Cl2 
(3.7 mL) at 0 °C under nitrogen was added DIPEA (0.069 mL, 0.42 mmol, 1.1 equiv.) and 0.5 M 
40 in CH2Cl2 (0.83 mL, 0.42 mmol, 1.1 equiv.). The reaction mixture was warmed to room 
temperature and stirred for 1.5 h. To this solution was added 46a (364 mg, 0.416 mmol, 1.1 
equiv.) and 4,5-dicyanoimidazole (90 mg, 0.76 mmol, 2.0 equiv.) in THF (1.5 mL) in a dropwise 
fashion. The reaction mixture was stirred for 2 h, cooled to 0 °C, Bu4NIO4 (186 mg, 0.429 mmol, 
1.1 equiv.) added, and stirring continued 40 min. The reaction mixture was diluted with water (3 
mL) and CH2Cl2 (5 mL) and the layers separated. The combined organic layers were rinsed with 
sat. Na2S2O3 (3 mL), brine (3 mL), dried (MgSO4), and concentrated. The crude product was 
filtered through a plug of SiO2 (1:1 hexanes:ethyl acetate) and concentrated. Purification by 
chromatography on SiO2 (3:1 to 2:1 to 1:1 hexanes:ethyl acetate) gave 
3-(((3-(((2,3-(palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tert-butyldimethylsilyl)oxy)
propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (114a, 381 mg, 0.255 mmol, 
67%) as a colorless solid. Mp 36.5-37.5 °C; 1H NMR (CDCl3, 400 MHz) δ 5.25-5.22 (m, 2 H), 
4.36-4.31 (m, 2 H), 4.22-4.12 (m, 6 H), 4.05-3.97 (m, 5 H), 3.78 (d, 6 H, J = 14.0 Hz; 
diastereomers visible), 2.32 (apparent q, 8 H, J = 8.0 Hz), 1.61-1.57 (m, 8 H), 1.28-1.25 (m, 96 
H), 0.89-0.86 (m, 21 H), 0.11 (s, 6 H); 13C NMR (CDCl3, 125 MHz) δ 173.1, 172.7, 69.8 (m), 
69.4 (d, 3JCP = 6.3 Hz), 67.8 (d, 3JCP = 6.3 Hz), 65.7 (m), 61.6, 54.6 (d, 2JCP = 6.3 Hz), 34.2, 
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34.0, 31.9, 29.7-29.1 (m), 25.6, 24.9, 22.7, 18.0, 14.1, -4.9; IR ν 2913, 2848, 1737, 1465, 913, 
744 cm-1; HRMS (ESI+) m/z calculated for C81H161O17P2Si [M+H]+ 1496.0973, found 1496.0903. 
 
General Procedure G: 3-(((3-(((2,3-(Stearoyloxy)propoxy)(methoxy) 
phosphoryl)oxy)-2-((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propan
e-1,2-diyl distearate (114b). To a solution of 46b (356 mg, 0.570 mmol, 1.0 equiv.) and DIPEA 
(0.10 mL, 0.63 mmol, 1.1 equiv.) under nitrogen was added 0.5 M 44 (1.2 mL, 0.63 mmol, 1.1 
equiv.) in CH2Cl2 and the reaction mixture stirred for 1 h. To this solution was added a solution 
of 113b (470 mg, 0.518 mmol, 1.0 equiv.) and 4,5-dicyanoimidazole (125 mg, 1.04 mmol, 2.0 
equiv.) in THF (1.5 mL) in a dropwise fashion The reaction mixture was stirred for 3 h, cooled to 
0 °C, Bu4NIO4 (173 mg, 0.399 mmol, 1.2 equiv.) added, and stir 45 min. The reaction mixture 
was diluted with water (2 mL) and CH2Cl2 (5 mL) and the layers separated. The combined 
organic layers were rinsed with sat. Na2S2O3 (2x3 mL), sat. NaHCO3 (3 mL), brine (3 mL), dried 
(MgSO4), and concentrated. The crude product was filtered through a plug of SiO2 (1:1 
hexanes:ethyl acetate) and concentrated. To aide in separation of starting alcohols from the 
desired product, this material was dissolved in CH2Cl2 (4 mL) and TBSCl (43 mg, 0.29 mmol 0.5 
equiv.), imidazole (21 mg, 0.31 0.6 equiv.) and DMAP (3 mg, 0.024 mmol 0.04 equiv.) added. 
The mixture was stirred for 4.5 h. The reaction was quenched with water (4 mL) and diluted with 
CH2Cl2 (4 mL). The layers were separated, and the organic layer rinsed with brine (4 mL), dried 
(MgSO4), and concentrated. Purification by chromatography on SiO2 (5:1 to 3:1 to 1:1 
hexanes:ethyl acetate) gave 3-(((3-(((2,3-(stearoyloxy)propoxy)(methoxy) 
phosphoryl)oxy)-2-((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,
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2-diyl distearate (114b, 335 mg, 0.208 mmol, 40%) as a waxy colorless solid. Mp = 48.1-48.2 
°C; 1H NMR (CDCl3, 300 MHz) δ 5.25-5.22 (m, 2 H), 4.36-4.30 (m, 2 H), 4.29-4.04 (m, 11 H), 
3.78 (d, 6 H, J = 11.4 Hz; diastereomers visible), 2.32 (apparent q, 8 H, J = 7.2 Hz), 1.61-1.57 
(m, 8 H), 1.25 (m, 112 H), 0.89-0.86 (m, 21 H), 0.11 (s, 6 H); 13C NMR (CDCl3, 125 MHz) δ 
173.2, 172.8, 69.7 (m), 69.4 (m), 67.9 (m), 65.6 (m), 61.6, 54.6 (d, 2JCP = 5.9 Hz), 34.2, 34.0, 
31.9, 29.7-29.1 (m), 25.6, 24.8, 22.7, 18.0, 14.1, -4.9; IR ν 2918, 2851, 1741, 1043 cm-1; HRMS 
(ESI+) m/z calculated for C89H177O17P2Si [M+H]+ 1608. 2225, found 1608.2190. 
 
3-(((3-(((2-Palmitoleoyloxy-3-(palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tert-but
yldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (127c). 
Prepared according to General Procedure G using 46c (156 mg, 0.275 mmol, 1.0 equiv.) and 
DIPEA (0.050 mL, 0.30 mmol, 1.1 equiv.) under nitrogen was added 0.5 M 40 (0.60 mL, 0.30 
mmol, 1.1 equiv.). For the second step, 113a (212 mg, 0.249 mmol, 1.0 equiv.), 
4,5-dicyanoimidazole (60 mg, 0.50 mmol, 2.0 equiv.), and Bu4NIO4 (128 mg, 0.30 mmol, 1.2 
equiv.) were used. For the third step, TBSCl (19 mg, 0.5 equiv.), imidazole (17 mg, 1 equiv.) and 
DMAP (3 mg, 0.1 equiv.) were used. Purification by chromatography on SiO2 (5:1 to 3:1 to 1:1 
hexanes:ethyl acetate) gave 3-(((3-(((2-palmitoleoyloxy-3-(palmitoyloxy)propoxy)(methoxy) 
phosphoryl)oxy)-2-((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,
2-diyl dipalmitate (114c, 145 mg, 0.0970 mmol, 39%) as a clear colorless oil. 1H NMR (CDCl3, 
300 MHz) δ 5.39-5.33 (m, 2 H), 5.25-5.22 (m, 2 H), 4.36-4.32 (m, 2 H), 4.23-4.12 (m, 6 H), 
4.05-4.00 (m, 5 H), 3.78 (d, 6 H, J = 11.4 Hz; diastereomers visible), 2.32 (apparent q, 8 H, J = 
7.2 Hz), 2.02-2.00 (m, 4 H), 1.61-1.54 (m, 8 H), 1.30-1.26 (m, 88 H), 0.89-0.86 (m, 21 H), 0.11 
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(s, 6 H); 13C NMR (CDCl3, 125 MHz) δ 173.2, 172.8, 130.0, 129.7, 69.7 (m), 69.4 (d, 3JCP = 6.5 
Hz), 67.8 (d, 3JCP = 5.5 Hz), 65.6 (m), 61.6, 54.6 (d, 2JCP = 6.0 Hz), 34.1, 34.0, 31.8, 29.7-29.0 
(m), 25.6, 24.8, 22.7, 22.6 18.0, 14.1, -4.9; IR ν 2919, 2850, 1741, 1465, 1034 cm-1; HRMS 
(ESI+) m/z calculated for C81H159O17P2Si [M+H]+ 1494.0816, found 1494.0825. 
 
General Procedure H: Tertrapalmitoylcardiolipin diammonium salt (84a). To a solution of 
114a in 2-butanone (0.8 mL) was added NaI (24 mg, 0.16 mmol, 4.0 equiv.). The solution was 
heated at reflux for 13.5 h and concentrated. The resulting crude waxy yellow solid was 
dissolved in 0.1:2:1 1 M HCl:THF:H2O (1 mL) and the resulting yellow solution stirred for 12 h. 
The orange-brown reaction mixture was quenched with 30% NH4OH (2 mL), the resulting white 
slurry extracted with CHCl3 (3x5 mL), and concentrated. The resulting faint yellow solid was 
triturated with Et2O giving the tertrapalmitoylcardiolipin diammonium salt (84a, 40 mg, 0.029 
mmol, 73%) as a colorless solid containing 5-7% (ESI-MS-) monolysocardiolipin impurity that 
can be removed by thin layer chromatography. 1H NMR (CDCl3, 400 MHz) δ 7.46 (bs, 8 H), 
5.21(bs, 2 H), 4.37 (m, 2 H), 4.17-4.13 (m, 2 H), 3.91 (bs, 9 H), 2.29 (apparent q, 8 H, J = 8.5 
Hz), 1.58 (m, 8 H), 1.28-1.25 (m, 98 H), 0.87 (t, 12 H, J = 6.8 Hz); HRMS (ESI-) m/z calculated 
for C73H141O17P2 [M-H]- 1351.9639, found 1351.9648.  
 
Tertastearoylcardiolipin diammonium salt (84b). Prepared according to General Procedure H 
using 114b. Purification by precipitation from hot THF gave the tertastearoylcardiolipin 
diammonium salt (84b, 53 mg, 0.035 mmol, 38%) as a colorless powder containing 5-7% 
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(ESI-MS-) monolysocardiolipin impurity that can be removed by thin layer chromatography. 1H 
NMR (CDCl3, 400 MHz) δ 7.44 (bs, 8 H), 5.21 (bs, 2 H), 4.37-4.35 (m, 2 H), 4.17-4.13 (m, 2 H), 
3.92 (bs, 9 H), 2.30 (apparent q, 8 H, J = 8.3 Hz), 1.59-1.58 (m, 8 H), 1.28-1.25 (m, 112 H), 0.88 
(t, 12 H, J = 6.8 Hz); MS (ESI-) m/z calculated for C81H156O17P2 [M-2H]2- 731.5, found 731.8.  
 
Tripalmitoyl-monopalmitoleoylcardiolipin diammonium salt (84c). Prepared according to 
General Procedure H using 114c. Purification by trituration with Et2O gave 
tripalmitoyl-monopalmitoleoylcardiolipin diammonium salt (84c, 83 mg, 0.060 mmol, 70%) as a 
colorless powder containing 5-7% (ESI-MS-) monolysocardiolipin impurity that can be removed 
by thin layer chromatography. 1H NMR (CDCl3, 400 MHz) δ 7.44 (bs, 8 H), 5.35-5.32 (m, 2 H), 
5.21 (bs, 2 H), 4.39-4.35 (m, 2 H), 4.17-4.13 (m, 2 H), 3.84 (bs, 9 H), 2.30 (apparent q, 8 H, J = 
8.1 Hz), 2.01-1.99 (m, 4 H), 1.66-1.58 (m, 8 H), 1.28-1.25 (m, 106 H), 0.88 (t, 12 H, J = 6.4 Hz); 
MS (ESI-) m/z calculated for C73H138O17P2 [M-2H]2- 674.5, found 674.7. 
 
5-Butyl-3,3,8,8-tetraethyl-4,7-dioxa-3,8-disiladecane (115). To a solution of 1,2-hexanediol 
(0.200 mL, 1.56 mmol, 1.0 equiv.) in CH2Cl2 (4.4 mL) at 0 °C under nitrogen was added 
imidazole (244 mg, mmol, 2.2 equiv.), and TESCl (0.543 mL, 3.20 mmol, 2.1 equiv.). The 
cloudy white slurry was warmed to room temperature and stirred for 21.5 h. The reaction 
mixture was diluted with CH2Cl2 (8 mL), rinsed with water (4 mL), brine (4 mL), dried 
(Na2SO4), and concentrated. Purification by chromatography on SiO2 (98:2 hexanes:ethyl 
acetate) gave 5-butyl-3,3,8,8-tetraethyl-4,7-dioxa-3,8-disiladecane (115, 384 mg, 1.11 mmol, 
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67%, 95% pure by 1H NMR) as a clear, colorless oil. 1H NMR (CDCl3, 500 MHz) δ 3.66 (pent, 1 
H, J = 6.0 Hz ), 3.52, 3.42 (ABX, 2 H, JAB = 9.8 Hz, JAX = 5.6 Hz, JBX = 6.4 Hz), 1.60-1.53 (m, 1 
H), 1.40-1.28 (m, 5 H), 0.97-0.91 (m, 21 H), 0.63-0.57 (m, 12 H); 13C NMR (CDCl3, 125 MHz) 
δ 73.3, 67.2, 31.4, 27.4, 22.9, 14.0, 6.9, 6.8, 6.7, 6.5, 5.1, 4.3; IR ν 2954, 2876, 1109, 1003, 723 
cm-1; HRMS (ESI+) m/z calculated for C18H43O2Si2 [M+H]+  347.2796, found 347.2811. 
 
(R)-3-O-Benzylglycerol (63). 169 To a slurry of NaH (1.24 g, 31.0 mmol, 1.8 equiv.) and BnBr 
(2.1 mL, 17.5 mmol, 1.0 equiv.) in THF (57 mL) at 0 °C under nitrogen was added 
(S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (2.2 mL, 17.3 mmol, 1.0 equiv.) in a dropwise 
fashion. The reaction mixture stirred for 15 min then warmed to room temperature for 18 h. 5 M 
HCl (17 mL, 85 mmol, 5 equiv.) was added and stirring continued for 0.5 h. The reaction was 
quenched with sat. NaHCO3 (90 mL), and the mixture extracted with MTBE (3x65 mL). The 
combined organic fractions were rinsed with sat. NaHCO3 (50 mL), brine (50 mL), dried 
(MgSO4), and concentrated. Purification by chromatography on SiO2 (1:1 to 1:2 to 1:3 
hexanes:ethyl acetate) gave (R)-3-O-benzylglycerol (63, 2.30 g, 12.6 mmol, 73%) as a clear 
yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.38-7.29 (m, 5 H), 4.56 (s, 2 H), 3.90 (bs, 1 H), 
3.73-3.71 (m, 1 H), 3.66-3.63 (m, 1 H), 3.59, 3.56 (ABX, 2 H, JAB = 9.5 Hz, JAX = 3.8 Hz, JBX = 
6.1 Hz), 2.60 (bs, 1 H), 2.08 (bs, 1 H). 
 
(S)-2,3-O-Bis(triethylsilyl)glycerol (118). To a suspension of NaH (2.92 g, 122 mmol, 1.5 
equiv.) in THF (225 mL) at 0°C under nitrogen was added 3,4-dimethoxybenzyl bromide (crude, 
quantitative yield assumed, 1.1 equiv; transferred using 50 mL THF), TBAI (1.50 g, 4.06 mmol, 
0.05 eq.), and (S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (7.00 mL, 55.5 mmol, 1.00 equiv.; 
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OHBnO
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dropwise). The white suspension was warmed to room temperature and stirred for 18 h. The 
mixture was diluted with water (120 mL), extracted with Et2O (3x200 mL). The combined 
organic portions were rinsed with brine (120 mL), dried (Na2SO4), and concentrated.  
The resulting dark orange-brown oil was dissolved in MeOH (500 mL), 2% H2SO4 (aq., 
4.5 mL, mmol, 0.02 equiv.) was added, and the resulting solution stirred for 18 h. The reaction 
mixture was quenched by adding solid KHCO3 (1 g) and stirring for 15 min. The MeOH was 
removed under reduced pressure, the residue taken up in PhMe (200 mL) and rinsed with water 
(100 mL). The aqueous portion was extracted with ethyl acetate (2x200 mL) and the combined 
organic layers rinsed with brine (150 mL), dried (Na2SO4) and concentrated.  
The dark orange oil was placed under nitrogen, dissolved in CH2Cl2 (160 mL), cooled to 
0 °C, and DMAP (0.698 g, 5.66 mmol, 0.1 equiv.), imidazole (8.42 g, 124 mmol, 2.2 equiv.), and 
TESCl (19.5 mL, 115 mmol, 2.1 equiv.) added. The cloudy pale yellow slurry was warmed to 
room temperature and stirred for 14.5 h. The reaction mixture was rinsed with water (200 mL) 
and the aqueous layer extracted with CH2Cl2 (200 mL). The combined organic layers were rinsed 
with brine (200 mL) and dried (Na2SO4). The solution of the crude product was diluted to a 10:1 
CH2Cl2:pH 7 0.1 M sodium phosphate buffer solution (560 mL total) and cooled to 0 °C. DDQ 
(14.13 g, 61.64 mmol, 1.1 equiv.) was added and the mixture immediately turns dark green. The 
reaction mixture was warmed to room temperature and stirred for 35 min. The precipitate was 
filtered off and the filtrate rinsed with water (100 mL), sat. NaHCO3 (3x100 mL), and brine (100 
mL). The organic layer was decolorized with carbon, dried (Na2SO4), and concentrated. The 
resulting purple-brown oil was diluted with hexanes, the dark purple-brown precipitate filtered 
off, and the filtrated concentrated. Further purification was performed by filtration through SiO2 
(97:3 to 93:7 hexanes:ethyl acetate), resulting in (S)-2,3-O-bis(triethylsilyl)glycerol (118, 14.87 
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g, 44.06 mmol, 54% over 4 steps) as a clear pale yellow oil. [α]D21 = -19.3 (c = 1.0, CHCl3); 1H 
NMR (CDCl3, 400 MHz) δ 3.81-3.76 (m, 1 H), 3.68-3.57 (m, 4 H), 2.21 (dd, 1 H, J1 = 4.8 Hz, J2 
= 7.6 Hz), 0.96 (t, 9 H, J = 8.0 Hz), 0.96 (t, 9 H, J = 7.8 Hz), 0.61 (pent, 12 H, J = 7.6 Hz); 13C 
NMR (CDCl3, 125 MHz) δ 72.3, 65.0, 64.7, 6.7 (2C), 4.8, 4.2; IR ν 3463, 2954, 2877, 723 cm-1; 
HRMS (ESI+) m/z calculated for C15H37O3Si2 [M+H]+ 321.2281, found 343.2094 [M+Na]. 
  
(S)-1,2-O-Dipamitoyl-3-O-benzylglycerol (64a).107 To a solution of 63 (1.44 g, 7.90 mmol 1.0 
equiv.), DMAP (0.098 g, 0.79 mmol, 0.1 equiv.), EDCI (3.54 g, 17.5 mmol, 2.2 equiv.) in 
CH2Cl2 (52 mL) under nitrogen was added palmitic acid (4.71 g, 17.5 mmol, 2.2 equiv.). The 
reaction mixture was stirred for 14 h and the reaction mixture rinsed with water (30 mL), brine 
(30 mL), dried (MgSO4) and concentrated. Purification by chromatography on SiO2 (97:3 to 95:5 
to 93:7 hexanes:ethyl acetate) gave (S)-1,2-O-dipamitoyl-3-O-benzylglycerol (64, 4.72 g, 7.16 
mmol, 91%) as a colorless solid. 1H NMR (CDCl3, 500 MHz) δ 7.36-7.29 (m, 5 H), 5.26-5.22 
(m, 1 H), 4.56, 4.52 (ABq, 2 H, JAB = 12.3 Hz), 4.34, (dd, 2 H, J1 = 3.5 Hz, J2 = 12.0 Hz), 4.18, 
(dd, 2 H, J1 = 6.5 Hz, J2 = 12.0 Hz), 3.60, 3.58 (ABX, 2 H, JAB = 10.5 Hz, JAX = 1.6 Hz, JBX = 1.4 
Hz), 2.32 (t, 2 H, J = 7.5 Hz), 2.27 (t, 2 H, J = 7.5 Hz), 1.63-1.57 (m, 4 H), 1.30-1.25 (m, 48 H), 
0.88 (t, 6 H, J = 7.0 Hz). 
 
(S)-1,2-O-Dipalmitoylglycerol ((S)-46a).107 To three batches of 64a (2.52 g, 3.82 mmol, 1.00 
equiv.) in THF (19 mL) was added 10% Pd/C (0.082 g, 0.23 mmol, 0.02 equiv.) to each batch. 
The mixtures were submitted to hydrogenation on a Parr hydrogenator under H2 (5 bar) for 3.5 h. 
O OBn
O
C15H31
O
C15H31
O
O OH
O
C15H31
O
C15H31
O
 92 
The combined reaction mixtures were filtered through Celite (CHCl3) and concentrated giving 
(S)-1,2-O-dipalmitoylglycerol ((S)-46a, 6.52 g, 11.48 mmol, quant.) as a colorless solid that was 
used without further purification. 1H NMR (CDCl3, 400 MHz) δ 5.08 (apparent pent, 1 H, J = 5.2 
Hz), 4.32, 4.24 (ABX, 2 H, JAB = 11.6 Hz, JAX = 7.4 Hz, JBX = 2.6 Hz), 3.73-3.55 (m, 2 H), 2.33 
(q, 4 H, J = 8.0 Hz), 1.99 (bs, 1 H), 1.64-1.60 (m, 4 H), 1.28-1.25 (m, 48 H), 0.88 (t, 6 H, J = 6.6 
Hz). 
 
(2R)-3-((((R)-2,3-Bis((triethylsilyl)oxy)propoxy)(methoxy)phosphoryl) oxy)propane-1,2-diyl 
dipalmitate (123). Performed according to general procedure D using (S)-46a (732 mg, 1.29 
mmol, 1.0 equiv.), and DIPEA (0.25 mL, 1.4 mmol, 1.1 equiv.), and 0.5 M 40 (2.8 mL, 1.4 
mmol, 1.1 equiv.).  For the second step, 118 (458 mg, 1.43 mmol, 1.1 equiv.), 
4,5-dicyanoimidazole (307 mg, 2.57 mmol, 2.0 equiv.), and Bu4NIO4 (618 mg, 1.43 mmol, 1.1 
equiv.) were used. The crude material was then filtered through a plug of SiO2 (1:1 hexanes:ethyl 
acetate) and concentrated. Purification by chromatography on SiO2 (7:1 to 6:1 to 5:1 
hexanes:ethyl acetate) gave (2R)-3-((((R)-2,3-bis((triethylsilyl)oxy)propoxy)(methoxy) 
phosphoryl)oxy) propane-1,2-diyl dipalmitate (123, 737 mg, 0.763 mmol, 59%; mixture of 
diastereomers at phosphorus) as a clear colorless oil. 1H NMR (CDCl3, 500 MHz) δ 5.23 (pent, 1 
H, J = 5.0 Hz), 4.36-4.32 (m, 1 H), 4.24-4.11 (m, 4 H), 3.98-3.93 (m, 1 H), 3.86 (apparent pent., 
1 H, J = 5.3 Hz), 3.77 (d, 3JHP = 11.0 Hz, diastereomers), 3.58-3.53 (m, 2 H), 2.33 (t, 2 H, J = 7.8 
Hz), 2.30 (t, 2 H, J = 7.8 Hz), 1.63-1.59 (m, 4 H), 1.28-1.25 (m, 48 H), 0.96 (t, 9 H, J = 8.0 Hz), 
0.95 (t, 9 H, J = 7.8 Hz), 0.88 (t, 6 H, J = 7.0 Hz), 0.62 (q, 6 H, J = 8.0 Hz), 0.59 (q, 6 H, J = 8.0 
Hz); 13C NMR (CDCl3, 125 MHz) δ 173.2, 172.8 (2C), 71.8 (d, 3JCP = 8.1 Hz), 69.4 (d, 3JCP = 
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7.9 Hz), 69.1 (t, 2JCP = 4.9 Hz), 65.3 (t, 2JCP = 6.4 Hz), 63.7, 61.6 (d, 3JCP = 4.3 Hz), 54.4 (d, 2JCP 
= 5.8 Hz), 34.1, 34.0, 31.9, 29.7-29.1 (m), 24.8, 22.7, 14.1, 6.7 (2C), 4.8, 4.3; IR ν 2919, 
2850.1741,1034 cm-1; HRMS (ESI+) m/z calculated for C51H106O10PSi2 [M+H]+ 965.7057, found 
965.7031. 
 
(2R)-3-((((R)-3-Hydroxy-2-((triethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1
,2-diyl dipalmitate (126). To a solution of 123 (2.25 g, 2.33 mmol, 1.0 equiv.) in 1:1 
CH2Cl2:MeOH (23 mL) at -20 °C was added PPTS (0.029 g, 0.11 mmol, 0.05 equiv.) in CH2Cl2 
(0.8 mL). The reaction mixture was maintained between -25 and -20 °C and stirred for 2.5 h. The 
reaction mixture was quenched by adding Et3N (0.065 mL), warmed to room temperature, and 
concentrated. Purification by chromatography on SiO2 (3:1 to 1:1 hexanes:ethyl acetate) gave 
(2R)-3-((((R)-3-Hydroxy-2-((triethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-di
yl dipalmitate (126, 0.853 g, 1.00 mmol, 43%; mixture of diastereomers at phosphorus) as a 
waxy colorless solid. 0.780 g of 123 was also recovered (35% recovery). Mp = 27.1-28.4 °C; 1H 
NMR (CDCl3, 400 MHz) δ 5.26-5.21 (m, 1 H), 4.33 (dd, 1 H, J1 = 4.4 Hz, J2 = 12.0 Hz), 
4.23-4.13 (m, 3 H), 4.08-4.03 (m, 2 H), 3.93-3.90 (m, 1 H), 3.79 (d, 3JHP = 11.2 Hz, 
diastereomers visible), 3.65, 3.61 (ABX, 2 H, JAB = 11.4 Hz, JAX = 4.9 Hz, JBX = 3.9 Hz), 2.32 (q, 
2 H, J = 8.0 Hz), 2.35-2.29 (bs, 1 H), 1.62-1.57 (m, 4 H), 1.28-1.25 (m, 48 H), 0.97 (t, 9 H, J = 
8.0 Hz), 0.88 (t, 6 H, J = 6.8 Hz), 0.63 (q, 6 H, J = 8.0 Hz); 13C NMR (CDCl3, 125 MHz) δ 
173.3, 172.9 (2C), 70.9 (d, 3JCP = 7.5 Hz), 69.3 (d, 3JCP = 10.0 Hz), 67.6 (t, 2JCP = 5.0 Hz), 65.6 
(t, 2JCP = 5.6 Hz), 63.0 (d, 4JCP = 2.5 Hz), 61.6, 54.6-6 (t, 2JCP = 5.6 Hz), 34.1, 34.0, 31.9, 
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29.7-29.1 (m), 24.8, 22.7, 14.1, 6.7, 4.7. IR ν 2919, 2850, 1741, 1034 cm-1; HRMS (ESI+) m/z 
calculated for C49H100O10PSi [M+H]+ 851.6197, found 851.6193. 
 
3-(((3-(((2,3-(Palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((triethylsilyl)oxy)propox
y)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (128a). Prepared according to 
general procedure G using 126 (130 mg, 0.153 mmol, 1.0 equiv.), DIPEA (0.03 mL, 0.2 mmol, 
1.1 equiv.), and 0.5 M 40 in CH2Cl2 (0.34 mL, 0.17 mmol, 1.1 equiv.). For the second step, 
(S)-46a (102 mg, 0.167 mmol, 1.1 equiv.), 4,5-dicyanoimidazole (37 mg, 0.31 mmol, 2.0 equiv.) 
in THF (0.60 mL), and Bu4NIO4 (74 mg, 0.17 mmol, 1.1 equiv.) were used. Purification by 
chromatography on SiO2 (3:1 to 2:1 to 1:1 hexanes:ethyl acetate) gave 
3-(((3-(((2,3-(palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((triethylsilyl)oxy)propoxy)(
methoxy) phosphoryl)oxy)propane-1,2-diyl dipalmitate (128a, 40 mg, 0.027 mmol, 17%) as a 
colorless solid. Mp = 37.3-38.1 °C; 1H NMR (CDCl3, 400 MHz) δ 5.26-5.20 (m, 2 H), 4.35-4.31 
(m, 2 H), 4.24-4.11 (m, 6 H), 4.09-4.00 (m, 5 H), 3.78 (d, 3JHP = 11.2 Hz, diasteromers visible), 
2.32 (q, 8 H, J = 8.0 Hz), 1.61-1.58 (m, 8 H), 1.30-1.25 (m, 96 H), 0.96 (t, 9 H, J = 8.0 Hz), 0.88 
(t, 12 H, J = 6.8 Hz), 0.63 (q, 6 H, J = 8.0 Hz); 13C NMR (CDCl3, 125 MHz) δ 173.2, 172.8, 
69.4 (d, 3JCP = 8.8 Hz), 67.8 (m), 65.6 (m), 61.6, 54.7 (d, 3JCP = 5.0 Hz), 34.1, 34.0, 31.9, 
29.7-29.1 (m), 24.8, 22.7, 14.1, 6.6, 4.7; IR ν 2916, 2850, 1739, 1036 cm-1. HRMS (ESI+) m/z 
calculated for C81H161O17P2Si [M+H]+ 1496.0978, found 1518.0823 [M+Na]+. 
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General Procedure I: Tetrapalmitoylcardiolipin disodium salt (129a). To a solution of 128a 
(39 mg, 0.026 mmol, 1.0 equiv.) in acetone (0.52 mL) was added NaI (12 mg, 0.080 mmol, 3.0 
equiv.) and the solution heated to reflux for 10 h. Following concentration, the resulting white 
solid was dissolved in CH2Cl2 (10 mL) and rinsed with sat. brine:H2O (1:1, 3 mL). The organic 
layer was concentrated. The resulting light yellow solid dissolved in THF (0.52 mL) was added 
H2SiF6 (20% wt. in H2O, 1 drop) and the yellow reaction mixture stirred for 0.5 h. The reaction 
mixture was quenched with sat. NaHCO3 (3 mL) and extracted with CHCl3 (2x5 mL). The 
combined organic layers were rinsed with brine (3 mL), dried (Na2SO4) and concentrated. The 
crude orange-yellow solid was triturated with Et2O, dissolved in hot THF (0.1 mL) and allowed 
to cool to room temperature. The resulting precipitate was filtered, rinsed with Et2O, and dried 
giving tetrapalmitoylcardiolipin disodium salt (129a, 14 mg, 0.010 mmol, 39%) as a faintly 
brown solid. 1H NMR (CDCl3, 500 MHz) δ 5.2 (bs, 2 H), 4.41-4.48 (m, 2 H), 4.18 (m, 2 H), 3.90 
(bs, 9 H), 2.30-2.28 (m, 8 H), 1.63-1.58 (m, 8H), 1.25 (m, 96 H), 0.88 (t, 12 H, J = 7.0 Hz); MS 
(ESI-) m/z calculated for C73H140O17P2 [M-2H]2-  675.5, found 676.2. 
 
(R)-3-O-(tert-Butyldiphenylsilyl)glycerol (136).150 To a solution of 
(S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (2.0 mL, 15.6 mmol, 1.0 equiv.) in THF (35 mL) 
0 °C under nitrogen was added was added imidazole (1.18 g, 17.3 mmol, 1.1 equiv.), DMAP 
(0.189 g, 1.53 mmol, 0.1 equiv.) and TBDPSCl (4.50 mL, 17.3 mmol, 1.1 equiv.). The resulting 
white slurry was stirred for 17 h. The reaction mixture was diluted with water (10 mL), citric 
acid monohydrate (15.18 g, 78.22 mmol, 5.0 equiv.) added, and the cloudy white emulsion 
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heated to 65 °C for 1.25 h (clears when temperature reaches 60 °C). The reaction mixture was 
poured into sat. NaHCO3 (100 mL) and extracted with methyl t-butyl ether (3x50 mL). The 
organic portion was rinsed sat. NaHCO3 (50 mL), brine (50 mL), dried (MgSO4), and 
concentrated. Recrystallization from 95:5 hexanes:ethyl acetate (20 mL) at -20 °C gave 
(R)-3-O-(tert-butyldiphenylsilyl) glycerol (136, 3.77 g, 11.4 mmol, 73%) as a colorless solid. 1H 
NMR (CDCl3, 400 MHz) δ 7.67-7.65 (m, 4 H), 7.45-7.38 (m, 6 H), 3.83-3.79 (m, 1 H),  
3.76-3.62 (m, 4 H), 2.56 (d, 1 H, J = 4.8 Hz), 1.95 (bs, 1 H), 1.07 (s, 9 H). 
 
(R)-1-O-(4-Azidobutanoyl)-3-O-(tert-butyldiphenylsilyl)-2-O-palmitoylglycerol (138a). To a 
solution of 136 (68 mg, 0.0.21 mmol, 1.0 equiv.), 4-azidobutyric acid (29 mg, 0.22 mmol, 1.1 
equiv.), and DMAP (1 mg, 0.01 mmo, 0.05 eq.) in CH2Cl2 (1.3 mL) at 0 °C under nitrogen was 
added DCC (88 mg, 0.36 mmol, 1.9 eq. in CH2Cl2 (0.17 mL) in a dropwise fashion over 2 min. 
The reaction mixture was then stirred for 2 h at 0 °C, then allowed to warm to room temperature 
for an additional 21 h. The reaction mixture filtered through Celite (CH2Cl2) and concentrated. 
Purification by chromatography on SiO2 (7:1 to 5:1 hexanes:ethyl acetate) gave 
(R)-3-O-(tert-butyldiphenylsilyl)-1-O-(4-azidobutanoyl)glycerol (56 mg, 0.13 mmol, 62% yield) 
as a clear colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.66-7.64 (m, 4 H), 7.45-7.34 (m, 6 H), 
4.20, 4.18 (ABX, 2 H, JAB = 9.6 Hz, JAX = 2.6 Hz, JBX = 3.8 Hz), 3.94 (sextet, 1 H, J = 5.6 Hz), 
3.72, 3.67 (ABX, 2 H, JAB = 10.4 Hz, JAX = 4.7 Hz, JBX = 5.7 Hz), 3.34 (t, 2 H, J = 6.6 Hz), 2.51 
(d, 1 H, J = 5.6 Hz), 2.40 (t, 2 H, J = 7.2 Hz), 1.88 (pent, 2 H, J = 7.2 Hz), 1.07 (s, 9 H); 13C 
NMR (CDCl3, 125 MHz) δ 172.7, 135.5, 132.8, 129.9, 127.8, 70.0, 65.3, 64.4, 50.5, 31.0, 26.8, 
24.2, 19.2; IR ν 3463, 2932, 2098, 1737cm-1. 
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  To a solution of the intermediate alcohol (56 mg, 0.13 mmol, 1.0 eq.), EDCI (37 mg, 0.19 
mmol, 1.5 eq.), and DMAP (2 mg, 0.02 mmo, 0.1 eq.) in CH2Cl2 (0.84 mL) under nitrogen was 
added palmitic acid (37 mg, 0.14 mmol, 1.1 eq.). The reaction mixture was then stirred for 2 d. 
The reaction mixture was diluted with MTBE (8 mL), and rinsed with 1 N NaHSO4 (3 mL), 
water (3 mL), and brine (3 mL). The organic portion was dried (MgSO4) and concentrated. 
Purification by filtration through a plug of SiO2 (9:1 hexanes:ethyl acetate) gave 
(R)-3-O-(tert-butyldiphenylsilyl)-2-O-palmitoyl-1-O-(4-azidobutanoyl)glycerol (138a, 68 mg, 
0.10 mmol, 79%) as a clear colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.66-7.64 (m, 4 H), 
7.45-7.34 (m, 6 H), 5.20-5.15 (m, 1 H), 4.43, 4.23 (ABX, 2 H, JAB = 11.8 Hz, JAX = 3.7 Hz, JBX = 
6.3 Hz), 3.78, 3.75 (ABX, 2 H, JAB = 10.6 Hz, JAX = 4.8 Hz, JBX = 4.8 Hz), 3.33 (t, 2 H, J = 6.8 
Hz), 2.38 (t, 2 H, J = 7.2 Hz), 2.34-2.20 (m, 2 H), 1.87 (pent, 2 H, J = 6.8 Hz), 1.61-1.54 (m, 2 
H), 1.30-1.25 (m, 24 H), 1.05 (s, 9 H), 0.88 (t, 3 H, J = 6.8 Hz). 
 
(R)-1-O-(4-Azido-2,2-dimethylbutanoyl)-3-O-(tert-butyldiphenylsilyl)-2-O-palmitoylglycerol 
(138b). To a solution of 136 (481 mg, 1.46 mmol, 1.0 eq.) in 1:1 pyridine:CH2Cl2 (4.8 mL) at 0 
°C under nitrogen was added 4-azido-2,2-dimethylbutanoyl chloride148 (crude product, 
quantitative yield assumed, 1.0 equiv.) in CH2Cl2 (0.5 mL) in a dropwise fashion. The reaction 
mixture was then stirred for 3 h. The reaction mixture was quenched with water, diluted with 
CH2Cl2 (5 mL), and the layers separated. The organic layer was rinsed with 1 M NaHSO4 (2x3 
mL), brine (3 mL), dried (MgSO4), and concentrated. Significant pyridine remains, so the oil was 
taken up in CH2Cl2 (10 mL), rinsed with 1 M, HCl (2x3 mL), brine (3 mL), dried (MgSO4), and 
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concentrated. Purification by chromatography on SiO2 (9:1 to 85:15 to 1:1 hexanes:ethyl acetate) 
gave (R)-3-O-(tert-butyldiphenylsilyl)-1-O-(4-azido-2,2-dimethylbutanoyl)glycerol (182 mg, 
0.329 mmol, 23%, 85% pure, hydrolyzed acid chloride as impurity) as a clear colorless oil. 1H 
NMR (CDCl3, 400 MHz) δ 7.66-7.64 (m, 4 H), 7.46-7.40 (m, 2 H), 7.38-7.35 (m, 4 H), 4.20 (d, 2 
H, J = 4.4 Hz), 3.95 (m, 1 H), 3.71, 3.66 (ABX, 2 H, JAB = 8.4 Hz, JAX = 3.6 Hz, JBX = 4.8 Hz), 
3.26 (t, 2 H, J = 6.0 Hz), 2.54 (d, 1 H, J = 3.2 Hz), 1.82 (t, 2 H, J = 6.0 Hz), 1.18 (s, 6 H), 1.07 (s, 
9 H). 
To a solution of the intermediate alcohol (182 mg, 0.323 mmol, 1.0 equiv.), DMAP (4 
mg, 0.03 mmol, 0.1 equiv.), and pyridine (0.05 mL, 0.7 mmol, 2 equiv.) in CH2Cl2 (2.1 mL) 
under nitrogen at 0 °C was added palmitoyl chloride (0.14 mL, 4.6 mmol, 1.4 equiv.) in a 
dropwise fashion. The reaction mixture was then stirred for 16.5 h at room temperature. The 
reaction mixture was diluted with CH2Cl2 (5 mL) and quenched with 1 N HCl (4 mL). The layers 
were separated and the organic portion rinsed with sat. NaHCO3 (4 mL), brine (4 mL), dried 
(MgSO4) and concentrated. Removal of impurities attempted by rinsing with MeOH, but was 
unsuccessful (286 mg isolated). Major byproduct appears to be methyl palmitate. A portion of 
the unpurified material was used in a separate reaction without further purification (105 mg). The 
remaining portion (181 mg) was purified by chromatography on SiO2 (98:2 to (95:5 
hexanes:ethyl acetate) giving 129 mg of 138b. 1H NMR (CDCl3, 400 MHz) δ 7.66-7.63 (m, 4 H), 
7.45-7.37 (m, 6 H), 5.20-5.18 (m, 1 H), 4.42, 4.22 (ABX, 2 H, JAB = 11.8 Hz, JAX = 3.8 Hz, JBX = 
6.2 Hz), 3.78, 3.75 (ABX, 2 H, JAB = 10.6 Hz, JAX = 4.8 Hz, JBX = 4.8 Hz), 3.24 (t, 2 H, J = 7.6 
Hz), 2.27-2.24 (m, 2 H), 1.81 (t, 2 H, J = 7.6 Hz), 1.61-1.54 (m, 2 H), 1.30-1.25 (m, 24 H),1.17 
(s, 6 H), 1.05 (s, 9 H), 0.88 (t, 3 H, J = 6.8 Hz). 
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(R)-1-O-(2-(Azidomethyl)benzoyl)-3-O-(tert-butyldiphenylsilyl)-2-O-palmitoylglycerol 
(138c). To a solution of 136 (72 mg, 0.22 mmol, 1.0 equiv.), 2-(azidomethyl)benzoic acid171 (43 
mg, 0.0.24 mmol, 1.1 equiv.), and DMAP (2 mg, 0.02 mmo, 0.07 equiv.) in CH2Cl2 (1.3 mL) at 
0 °C under nitrogen was added DCC (86 mg, 0.38 mmol, 1.7 equiv. in CH2Cl2 (0.3 mL) in a 
dropwise fashion over 6 min. The reaction mixture was then stirred for 2 h at 0 °C, then allowed 
to warm to room temperature for an additional 21 h. The reaction mixture filtered through Celite 
(CH2Cl2) and concentrated. Purification by chromatography on SiO2 (7:1 to 5:1 hexanes:ethyl 
acetate) gave (R)-1-O-(2-(azidomethyl)benzoyl)-3-O-(tert-butyldiphenylsilyl)glycerol (53 mg, 
0.11 mmol, 50% yield) as a clear colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.96-7.94 (m, 2 H), 
7.66-7.65 (m, 4 H), 7.55-7.53 (m, 1 H), 7.48-7.33 (m, 7 H), 4.43 (d, 2 H, J = 5.2 Hz), 4.39 (s, 2 
H), 4.13-4.06 (m, 1 H), 3.82, 3.78 (ABX, 2 H, JAB = 10.4 Hz, JAX = 4.7 Hz, JBX = 5.3 Hz), 2.58 
(d, 1 H, J = 5.6 Hz), 1.82 (t, 2 H, J = 6.0 Hz), 1.08 (s, 9 H). 
To a solution of the intermediate alcohol (336 mg, impure), DMAP (8 mg, 0.07 mmol, 
0.1 equiv.) and pyridine (0.11 mL, 0.1.4 mmol, 2 equiv.) in CH2Cl2 (4.6 mL) under nitrogen at 0 
°C was added palmitoyl chloride (0.30 mL, 0.96 mmol, 1.4 equiv.) in a dropwise fashion. The 
reaction mixture was then stirred for 16 h at room temperature. The reaction mixture was diluted 
with CH2Cl2 (5 mL) and quenched with 1 N HCl (4 mL). The layers were separated and the 
organic portion rinsed with sat. NaHCO3 (2x4 mL), brine (4 mL), dried (MgSO4) and 
concentrated. Purification by chromatography on SiO2 (95:5 hexanes:ethyl acetate) gave the 
desire product 138c containing significant quantities of palmitic acid impurity (66% pure). This 
compound was used without further purification.  
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(R)-1-O-(tert-butyldiphenylsilyl)-3-O-(4-methoxylbenzyl)glycerol (142a). 136 (1.06 g, 3.21 
mmol, 1.0 equiv.) and Bu2SnO (1.06 g, 4.17 mmol, 1.3 equiv.) were suspended in PhMe (14 mL) 
under nitrogen and heated to reflux with azeotropic removal of water for 21 h. The solution was 
cooled to room temperature, TBAI (0.079 g, 0.32 mmol, 0.1 equiv.) and a solution of freshly 
prepared PMBBr172 in PhMe (1 mL). The reaction mixture was returned to reflux for 5.5 h, 
diluted with methyl t-butyl ether (20 mL), rinsed with water (2x10 mL), brine (10 mL), dried 
(MgSO4), and concentrated. Purification by chromatography on SiO2 (6:1 to 4:1 hexanes:ethyl 
acetate gave (R)-1-O-(tert-butyldiphenylsilyl)-3-O-(4-methoxylbenzyl)glycerol (142a, 556 mg, 
1.23 mmol) as a clear, colorless oil. The a second column was performed on a substantial mixed 
fraction (5:1 to 4:1 hexanes:ethyl acetate) giving an additional 231 mg. Combined yield 49%, 
90% pure by 1H NMR. 1H NMR (CDCl3, 400 MHz) δ 7.66-7.64 (m, 4 H), 7.45-7.35 (m, 6 H), 
7.24-7.21 (m, 2 H), 6.88-6.85 (m, 2 H), 3.94-3.87 (m, 1 H), 3.80 (s, 3 H), 3.71 (d, 2 H, J = 5.6 
Hz), 3.56, 3.53 (ABX, 2 H, JAB = 9.6 Hz, JAX = 4.7 Hz, JBX = 6.1 Hz), 2.49 (d, 1 H, J = 5.2 Hz), 
1.05 (s, 9 H); 13C NMR (CDCl3, 125 MHz) δ 159.2, 135.4, 133.2, 130.1, 129.8, 129.3, 127.7, 
113.8, 73.1, 70.8, 70.7, 64.8, 55.3, 26.8, 19.3; IR ν 3457, 2931, 2857, 1112, 702 cm-1; HRMS 
(ESI+) m/z calculated for C27H35O4Si [M+H]+ 451.2305, found 473.2124 [M+Na]+. 
 
(R)-1-O-(tert-butyldiphenylsilyl)-2-O-palmitoyl-3-O-(4-methoxylbenzyl)glycerol (143a). To 
a solution of 142a (785 mg, 1.74 mmol, 1.0 equiv.), EDCI (415 mg, 2.14 mmol, 1.2 equiv.), and 
DMAP (65 mg, 0.53 mmol , 0.3 equiv.) in CH2Cl2 (11 mL) under nitrogen was added palmitic 
acid (584 mg, 2.16 mmol, 1.2 equiv.). The reaction mixture was then stirred for 21 h. The 
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reaction mixture was diluted with CH2Cl2 (5 mL), and rinsed with water (5 mL), brine (5mL), 
dried (MgSO4) and concentrated. Purification by chromatography on SiO2 (1:0 to 98:2 to 96:4 
hexanes:ethyl acetate) gave 
(R)-1-O-(tert-butyldiphenylsilyl)-2-O-palmitoyl-3-O-(4-methoxylbenzyl) glycerol (143a, 926 
mg, 1.34 mmol, 77%) as a clear colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.66-7.63 (m, 4 H), 
7.44-7.34 (m, 6 H), 7.22-7.20 (m, 2 H), 6.86-6.84 (m, 2 H), 5.15 (pent, 1 H, J = 5.2 Hz), 4.46, 
4.44 (ABq, 2 H, JAB = 11.6 Hz), 3.80-3.79 (m, 5 H), 3.65, 3.62 (ABX, 2 H, JAB = 10.4 Hz, JAX = 
3.5 Hz, JBX = 4.5 Hz), 2.34-2.22 (m, 2 H), 1.60-1.55 (m, 2 H), 1.30-1.25 (m, 24 H), 1.02 (s, 9 H), 
0.88 (t, 3 H, J = 6.8 Hz). 13C NMR (CDCl3, 125 MHz) δ 173.3, 159.2, 135.6, 135.5 133.4, 133.3, 
130.1, 129.7, 129.2, 127.7 (2C), 113.8, 72.8, 72.7, 68.1, 62.6, 55.3, 34.5, 31.9, 29.7-29.2 (m), 
26.7, 25.0, 22.7, 19.2, 14.1; IR ν 2923, 2854, 1737,1112, 701 cm-1; HRMS (ESI+) m/z calculated 
for C43H65O5Si [M+H]+ 689.4601, found 711.4421 [M+Na]+. 
 
(S)- 2-O-palmitoyl-3-O-(4-methoxylbenzyl)glycerol (145a). To a solution of 143a (72 mg, 0.10 
mmol, 1.0 equiv.) in THF (0.9 mL) was added 1 M AcOH in THF (0.14 mL, 0.14 mmol, 1.4 
equiv.) followed by 1 M TBAF in THF (0.11 mL, 0.11 mmol, 1.1 equiv.). The solution was 
stirred for 4.5 h. The reaction mixture was quenched with pH 7 phosphate buffer (3 mL) and 
extracted with methyl t-butyl ether (10 mL). The organic layer was rinsed with pH 7 phosphate 
buffer (3 mL), brine (3 mL), dried (Na2SO4), and concentrated. 72 mg isolated and used without 
further purification. 
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(S)-3-O-(3,4-dimethoxybenzyl)glycerol ((S)-12).173 To as suspension of NaH (0.770 g, 32.1 
mmol, 2.0 equiv.), TBAI (0.196 g, 0.792 mmol, 0.05 eq.), and freshly prepare 
3,4-dimethoxybenzyl bromide174 (crude, quantitative yield assumed, 1.1 equiv; transferred using 
5 mL THF) in THF (50 mL) at 0°C under nitrogen was added 
(R)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (2.00 mL, 15.8 mmol, 1.00 equiv.) in a dropwise 
fashion over 5 min. The white suspension was warmed to room temperature and stirred for 15 h. 
The reaction mixture was quenched with water (50 mL), extracted with Et2O (3x70 mL). The 
combined organic portions were rinsed with brine (50 mL), dried (Na2SO4), and concentrated. 
The resulting orange oil was dissolved in MeOH (105 mL), 2% H2SO4 was added (aq., 0.88 mL, 
0.32 mmol, 0.02 equiv.), and the resulting solution stirred for 22 h. The reaction mixture was 
quenched by adding solid KHCO3 (0.300 g) and stirring for 5 min. MgSO4 was added, and about 
2/3 of the MeOH removed under reduced pressure. The resulting slurry was filtered through 
Celite (ethyl acetate) and concentrated. Purification by chromatography on SiO2 (1:3 
hexanes:ethyl acetate to 97:3 ethyl acetate:MeOH) gave (S)-3-O-(3,4-dimethoxybenzyl)glycerol 
((S)-122, 2.89 g, 11.93 mmol, 76%) as a clear pale yellow oil. 1H NMR (CDCl3, 500 MHz) δ 
6.87-6.84 (m, 3 H), 4.50 (s, 2 H), 3.89-3.88 (m, 7 H), 3.73-3.71 (m, 1 H), 3.66-3.64 (m, 1 H), 
3.59-3.52 (m, 2 H), 2.52 (d, 1 H, J = 2.0 Hz), 2.01 (bs, 1 H). 
 
(R)-1-O-(tert-Butyldiphenylsilyl)-3-O-(3,4-dimethoxylbenzyl)glycerol (142b). To a solution of 
(S)-122 (9.64 g, 39.8 mmol, 1.0 equiv.) and imidazole (3.52 g, 51.7 mmol, 1.3 equiv.) at 0°C 
under nitrogen in CH2Cl2 (133 mL) was added TBDPSCl (10.3 mL, 40.0 mmol, 1.0 equiv.) in a 
dropwise fashion over 20 min. The reaction mixture was allowed to warm to room temperature 
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and stirred for 21 h. The reaction mixture was diluted with CH2Cl2 (100 mL), rinsed with water 
(100 mL), 0.5 M HCl (100 mL), brine (100 mL), dried (Na2SO4), and concentrated. Purification 
by chromatography on SiO2 (3:1 to 2:1 hexanes:ethyl acetate) gave 
(R)-1-O-(tert-butyldiphenylsilyl)-3-O-(3,4-dimethoxylbenzyl) glycerol (142b, 14.8 g, 30.7 
mmol, 68%; 90% pure by 1H NMR, contains ethyl acetate) as a clear, faintly yellow oil. 1H NMR 
(CDCl3, 400 MHz) δ 7.66-7.64 (m, 4 H), 7.45-7.35 (m, 6 H), 6.85-6.80 (m, 3 H), 4.47 (s, 1 H), 
3.93-3.91 (m, 1 H), 3.87 (s, 3 H), 3.84 (s, 3 H), 3.73-3.71 (m, 2 H), 3.56, 3.53 (ABX, 2 H, JAB = 
9.8 Hz, JAX = 4.6 Hz, JBX = 5.8 Hz), 2.48 (d, 1 H, J = 5.2 Hz), 1.05 (s, 9 H). 
 
(R)-1-O-(tert-Butyldiphenylsilyl)-2-O-palmitoyl-3-O-(3,4-dimethoxylbenzyl)glycerol (143b). 
To a solution of 142b (2.66 g, 5.53 mmol, 1.0 equiv.), EDCI (1.34 g, 6.64 mmol, 1.2 equiv.), 
DMAP (0.210 g, 1.70 mmol, 0.31 equiv.) in CH2Cl2 under nitrogen was added palmitic acid 
(1.78 g, 6.59 mmol, 1.2 equiv.). The reaction mixture was stirred for 6 h, diluted with CH2Cl2 (10 
mL), rinsed with water (20 mL), brine (20 mL), dried (MgSO4) and concentrated. Purification by 
chromatography on SiO2 (9:1 to 5:1 hexanes:ethyl acetate) 
(R)-1-O-(tert-butyldiphenylsilyl)-2-O-palmitoyl-3-O-(3,4-dimethoxylbenzyl) glycerol (143b, 
3.49 g, 4.85 mmol, 88%) as a clear colorless oil. [α]D21 =  +4.6 (c = 1.0, CHCl3); 1H NMR 
(CDCl3, 125 MHz) δ 7.66-7.63 (m, 4 H), 7.43-7.40 (m, 2 H), 7.38-7.34 (m, 4 H), 6.84-6.79 (m, 3 
H), 5.17 (pent, 1 H, J = 5.0 Hz), 4.47, 4.44 (ABq, 2 H, JAB = 11.8 Hz), 3.87 (s, 3 H), 3.84-3.78 
(m, 5 H), 3.66, 3.63 (ABX, 2 H, JAB = 10.8 Hz, JAX = 4.8 Hz, JBX = 6.2 Hz), 2.34-2.24 (m, 2 H), 
1.60-1.55 (m, 2 H), 1.30-1.25 (m, 24 H), 1.03 (s, 9 H), 0.88 (t, 3 H, J = 7.0 Hz); 13C NMR 
(CDCl3, 500 MHz) δ 173.3, 149.0, 148.6, 135.6, 135.5, 133.3 (2 C), 130.6, 129.7, 127.7 (2 C), 
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120.2, 111.0, 110.9 73.1, 72.7, 68.2, 62.7, 55.9, 55.8, 34.5, 31.9, 29.7-29.2 (m), 26.7, 25.0, 22.7, 
19.2, 14.1; IR ν 2924, 2854, 1737,1112, 701 cm-1; HRMS (ESI+) m/z calculated for C44H66O6Si 
[M+H]+ 719.4707; found 741.4514 [M+Na]+. 
 
(S)-2-O-palmitoyl-3-O-(3,4-dimethoxylbenzyl)glycerol (145b). To a solution of 143b (5.29 g, 
7.36 mmol, 1.0 equiv.) in THF (49 mL) was added AcOH (0.51 mL, 8.8 mmol, 1.2 equiv.) 
followed by 1.0 M TBAF in THF (8.1 mL, 8.1 mmol, 1.1 equiv.). The solution was stirred for 
3.75 h. The reaction mixture was quenched with 0.1 M pH 7 sodium phosphate buffer (40 mL), 
and extracted with Et2O (2x80 mL). The organic layer was rinsed with pH 7 phosphate buffer 
(40 mL), brine (40 mL), dried (Na2SO4), and concentrated. Purification by recrystallization from 
9:1 hexanes:Et2O (30 mL) gave (S)-2-O-palmitoyl-3-O-(3,4-dimethoxylbenzyl)glycerol (145b, 
2.97 g, 5.93 mmol, 81%, 96% pure by 1H NMR) as colorless crystals. [α]D21 = -3.7 (c = 1.0, 
CHCl3). Mp = 56.9-59.0 °C; 1H NMR (CDCl3, 500 MHz) δ 6.87-6.82 (m, 3 H), 5.05 (app. pent, 
1 H, J = 5.0 Hz), 4.51, 4.47 (ABq, 2 H, JAB = 11.8 Hz), 3.89 (s, 3 H), 3.88 (s, 3 H), 3.83-3.70 (m, 
2 H), 3.66, 3.63 (ABX, 2 H, JAB = 11.0 Hz, JAX = 5.9 Hz, JBX = 6.1 Hz), 2.35 (t, 2 H, J = 7.5 Hz), 
2.02 (t, 1 H, J = 6.3 Hz), 1.64-1.60 (m, 2 H), 1.29-1.25 (m, 24 H), 0.88 (t, 3 H, J = 6.8 Hz); 13C 
NMR (CDCl3, 125 MHz) δ 173.7, 149.1, 148.8, 130.2, 120.3, 111.0, 110.9, 73.4, 72.9, 68.8, 
62.8, 55.9 (2C), 34.4, 31.9, 29.7-29.1 (m), 22.7, 14.1; IR ν 3548, 2917, 2849, 1729 cm-1; HRMS 
(ESI+) m/z calculated for C28H49O6 [M+H]+ 481.3529, found 503.3347 [M+Na]+.’ 
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(2R)-3-((methoxy(3-((methoxy((R)-3-((3,4-dimethoxybenzyl)oxy)-2-(palmitoyloxy)propoxy)
phosphoryl)oxy)-2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate 
(146). Prepared according to General Procedure G using 126 (1.22 g, 1.43 mmol, 1.0 equiv.), 
DIPEA (0.36 mL, 1.6 mmol, 1.1 equiv.), and 1.0 M 40 in CH2Cl2 (1.57 mL, 1.57 mmol, 1.1 
equiv.). For the second step, 145b (0.756 g, 1.57 mmol, 1.1 equiv.), 4,5-dicyanoimidazole (0.258 
g, 2.16 mmol, 1.5 equiv.), Bu4NIO4 (0.708 g, 1.60 mmol, 1.1 equiv.) were used. Purification by 
chromatography on SiO2 (2:1 to 1:1 2:3 hexanes:ethyl acetate) gave 
(2R)-3-((methoxy(3-((methoxy((R)-3-((3,4-dimethoxybenzyl)oxy)-2-(palmitoyloxy)propoxy)pho
sphoryl)oxy)-2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (146, 
0.662 g, 0.470 mmol, 33%; mixture of diastereomers at phosphorus) as a clear colorless oil. 1H 
NMR (CDCl3, 400 MHz) δ 6.86-6.83 (m, 3 H), 5.23-5.20 (m, 2 H), 4.50-4.43 (m, 2 H), 4.35-4.31 
(m, 1 H), 4.27-4.10 (m, 5 H), 4.05-3.96 (m, 5 H), 3.89 (s, 3 H), 3.88 (s, 3 H), 3.79-3.74 (m, 6 H), 
3.60-3.58 (m, 2 H), 2.31 (apparent q, 6 H, J = 8.0 Hz), 1.65-1.55 (m, 6 H), 1.28-1.25 (m, 72 H), 
0.96 (t, 9 H, J = 8.0 Hz), 0.88 (t, 9 H, J = 6.6 Hz), 0.62 (q, 6 H, J = 8.0 Hz); 13C NMR (CDCl3, 
125 MHz) δ 173.2, 173.0, 172.8, 149.1, 148.8, 130.2, 120.3, 111.0, 110.9, 73.3 (d, 3JCP = 2.5 
Hz), 70.5 (d, 3JCP = 7.5 Hz), 69.5-69.3 (m), 67.8-67.5 (m), 66.2-66.0 (m), 65.6-65.5 (m), 61.6, 
55.9, 55.8, 54.5-54.4 (m), 34.2, 34.1, 34.0, 31.9, 31.5, 29.7-29.1 (m), 24.9 (2C), 22.7, 14.1, 6.6, 
4.7; IR ν 2917, 2850, 2122, 1743, 1028 cm-1. HRMS (ESI+) m/z calculated for C74H141O18P2Si 
[M+H]+ 1407.9362; found 1429.9199 [M+Na]+. 
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General Procedure J: Pivaloyl anhydride formation: To a solution of fatty acid (1.0 equiv.) and 
Et3N (1.2 equiv.) in CH2Cl2 (0.2 M) under nitrogen was added pivaloyl chloride (1.0 equiv.) and 
the reaction mixture stirred for 1.5-3.0 h. The resulting solution of fatty acid anhydride was used 
directly. 
DMB cleavage of 146: To a biphasic mixture of 146 (1.00 equiv.) in 10:1 CH2Cl2:pH 7 
phosphate buffer (0.1 M) was added DDQ (1.2 equiv.). The reaction mixture immediately turns 
dark green and was stirred for 2.5 h. The reaction mixture was diluted with CH2Cl2 (7 mL) and 
rinsed with water (3 mL), sat. NaHCO3 (3x3 mL), brine (3 mL), dried (Na2SO4), and 
concentrated. The resulting crude alcohol (a brown oil) was used without further purification. 
Acylation: To the solution of the mixed pivaloyl-fatty acid anhydride (1.2 equiv.) under 
nitrogen was added Et3N (3.0 equiv.), crude alcohol from DMB cleavage reaction of 146 
(transferred as a 0.9 M solution in CH2Cl2,) and DMAP (0.2 equiv.) and the resulting pale brown 
reaction mixture stirred for 18-20 h. The reaction mixture was diluted with CH2Cl2 (7 mL), 
rinsed with water (3 mL), brine (3 mL), dried (Na2SO4), and concentrated. Purification was 
performed as specified. 
 
3-(((3-(((2,3-(Palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((triethylsilyl)oxy)propox
y)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (128a). Prepared according to 
general procedure J. Purification by chromatography on SiO2 (2:1 to 3:2 to 1:1 hexanes:ethyl 
acetate) gave 3-(((3-(((2,3-(palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2((triethylsilyl) 
oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (128a, 74 mg, 0.049 mmol, 
63%) as a waxy colorless solid. Characterization data were identical to those reported above. 
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(2R)-3-((Methoxy(3-((methoxy((R)-3-((stearoyloxy)-2-(palmitoyloxy)propoxy)phosphoryl)o
xy)-2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (128b). 
Prepared according to general procedure J. Purification by chromatography on SiO2 (3:1 to 2:1 to 
3:2 to 1:1 hexanes:ethyl acetate) gave  
(2R)-3-((methoxy(3-((methoxy((R)-3-((stearoyloxy)-2-(palmitoyloxy)propoxy)phosphoryl)oxy)-
2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)propane -1,2-diyl dipalmitate (128b, 71 mg, 0.047 
mmol, 63%) as a waxy colorless solid. Mp = 38.6-39.2 °C. 1H NMR (CDCl3, 400 MHz) δ 
5.26-5.20 (m, 2 H), 4.35-4.31 (m, 2 H), 4.24-4.10 (m, 6 H), 4.08-3.99 (m, 5 H), 3.78 (d, 3JHP = 
11.6 Hz, diastereomers), 2.32 (q, 8 H, J = 8.0 Hz), 1.61-1.58 (m, 8 H), 1.30-1.25 (m, 100 H), 
0.96 (t, 9 H, J = 8.0 Hz), 0.88 (t, 12 H, J = 6.8 Hz), 0.63 (q, 6 H, J = 7.9 Hz); 13C NMR (CDCl3, 
125 MHz) δ 173.2, 172.8, 69.4-69.3 (m), 67.8 (m), 65.6 (m), 61.6, 54.6 (d, 3JCP = 6.3 Hz), 34.1, 
34.0, 31.9, 29.7-29.1 (m), 24.8, 22.7, 14.1, 6.6, 4.7; IR ν 2916, 2850, 1739, 1036 cm-1; HRMS 
(ESI+) m/z calculated for C83H164O17P2Si [M+H]+ 1524.1291; found 1546.1132 [M+Na]+. 
 
(2R)-3-((Methoxy(3-((methoxy((R)-3-((oleyloxy)-2-(palmitoyloxy)propoxy)phosphoryl)oxy)-
2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (128c). Prepared 
according to general procedure J. Purification by chromatography on SiO2 (3:1 to 2:1 to 3:2 to 
1:1 hexanes: ethyl acetate) gave 
(2R)-3-((methoxy(3-((methoxy((R)-3-((oleyloxy)-2-(palmitoyloxy)propoxy)phosphoryl)oxy)-2-(
(triethylsilyl)oxy)propoxy)phosphoryl)oxy) propane-1,2-diyl dipalmitate (128c, 72 mg, 0.047 
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mmol, 64%) as a clear colorless oil. 1H NMR (CDCl3, 500 MHz) δ 5.36-5.31 (m, 2 H), 5.25-5.20 
(m, 2 H), 4.36-4.32 (m, 2 H), 4.25- 4.13 (m, 6 H), 4.06-3.95 (m, 5 H), 3.78 (d, 3JHP = 11.0 Hz, 
diastereomers visible), 2.33 (t, 4 H, J = 7.8 Hz), 2.31 (t, 4 H, J = 7.5 Hz) 2.03-1.99 (m, 4 H), 
1.63-1.59 (m, 8 H), 1.30-1.25 (m, 94 H), 0.96 (t, 9 H, J = 8.0 Hz), 0.88 (t, 12 H, J = 6.8 Hz), 0.63 
(q, 6 H, J = 8.0 Hz); 13C NMR (CDCl3, 125 MHz) δ 173.2, 172.8, 130.2, 130.0, 129.7, 69.4-69.3 
(m), 67.8 (m), 65.6 (m), 61.6, 54.6 (d, 3JCP = 6.3 Hz), 34.1, 34.0 (2C), 31.9 (2C), 29.8-29.1 (m), 
27.2 (2C), 24.8, 22.7, 14.1, 6.6, 4.7; IR ν 2922, 2853, 1743, 1035 cm-1; HRMS (ESI+) m/z 
calculated for C83H163O17P2Si [M+H]+ 1522.1135, found 1522.1135, 1544.0970 [M+Na]+. 
 
(2R)-3-((Methoxy(3-((methoxy((R)-3-((linoleyloxy)-2-(palmitoyloxy)propoxy)phosphoryl)ox
y)-2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (128d). 
Prepared according to general procedure J using degassed CH2Cl2 and shielding from light 
during the reaction. Purification by chromatography on SiO2 (3:1 to 2:1 to 3:2 hexanes: ethyl 
acetate) gave (2R)-3-((methoxy(3-((methoxy((R)-3-((linoleyloxy)-2-(palmitoyloxy) 
propoxy)phosphoryl)oxy)-2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)propane-1,2-diyl 
dipalmitate (128d, 76 mg, 0.050 mmol, 65%) as a clear colorless oil. 1H NMR (CDCl3, 400 
MHz) δ 5.39-5.25 (m, 4 H), 5.24-5.22 (m, 2 H), 4.35-4.31 (m, 2 H), 4.23-4.12 (m, 6 H), 
4.06-3.99 (m, 5 H), 3.78 (d, 3JHP = 11.6 Hz, diastereomers visible), 2.77 (t, 2 H, J = 6.4 Hz), 2.32 
(q, 8 H, J = 8.0 Hz), 2.05 (q, 2 H, J = 6.8 Hz), 1.62-1.59 (m, 18 H), 1.39-1.25 (m, 86 H), 0.96 (t, 
9 H, J = 7.8 Hz), 0.90-0.86 (m, 12 H), 0.63 (q, 6 H, J = 8.0 Hz); 13C NMR (CDCl3, 125 MHz) δ 
173.2 (2C), 172.8, 130.2, 130.0, 128.1, 127.9, 69.4-69.3 (m), 67.8 (m), 65.6 (m), 61.6, 54.6 (d, 
3JCP = 6.3 Hz), 34.1, 34.0 (2C), 31.9, 31.5, 29.7-29.1 (m), 27.2, 25.6, 24.8, 22.7, 22.6 14.1 (2C), 
O O
O
C15H31
O
C15H31
O
P
OMe
O
O
O
OTES
P
O
O
OMe
O
O
C17H31
O
O
C15H31
 109 
6.6, 4.7; IR ν 2922, 2853, 1743, 1036 cm-1; HRMS (ESI+) m/z calculated for C83H161O17P2Si 
[M+H]+ 1520.09783, found 1542.0802 [M+Na]+. 
 
(2R)-3-((Methoxy(3-((methoxy((R)-3-((arachidonoyloxy)-2-(palmitoyloxy)propoxy)phospho
ryl)oxy)-2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (128e). 
Prepared according to general procedure J using degassed CH2Cl2 and shielding from light 
during the reaction. The following modifications were used for the workup and purification: 
butylated hydroxytoluene (BHT, 2 mg; to prevent oxidation during workup) was added, the 
reaction mixture was diluted with CH2Cl2 (7 mL), rinsed with water (3 mL), brine (3 mL), dried 
(Na2SO4), and concentrated. Purification by chromatography on SiO2 (4:1 to 3:1 to 2:1 to 1:1 
hexanes:ethyl acetate; 1 mg BHT added before concentrating fractions) gave 
(2R)-3-((methoxy(3-((methoxy((R)-3-((arachidonoyloxy)-2-(palmitoyloxy)propoxy)phosphorylo
xy)-2-((triethylsilyl)oxy) propoxy)phosphoryl) oxy)propane-1,2-diyl dipalmitate (128e, 52 mg, 
0.029 mmol, 57%; mixture of diastereomers at phosphorus) as a clear colorless oil. Product 
contains ~2% BHT as a stabilizer. 1H NMR (CDCl3, 500 MHz) δ 5.38-5.32 (m, 8 H), 5.25-5.22 
(m, 2 H), 4.35-4.32 (m, 2 H), 4.23-4.13 (m, 6 H), 4.06-3.98 (m, 5 H), 3.78 (d, 3JHP = 11.0 Hz, 
diastereomers visible), 2.84-2.80 (m, 6 H), 2.34-2.30 (m, 8 H), 2.11 (q, 2 H, J = 7.0 Hz), 2.05 (q, 
2 H, J = 7.2 Hz), 1.70 (pent, 2 H, J = 7.5 Hz), 1.63-1.60 (m, 8 H), 1.39-1.25 (m, 78 H), 0.96 (t, 9 
H, J = 8.0 Hz), 0.90-0.87 (m, 12 H), 0.63 (q, 6 H, J = 8.0 Hz); 13C NMR (CDCl3, 125 MHz) δ 
173.1, 172.9, 172.7, 130.5, 129.0, 128.8, 128.6, 128.3, 128.1, 127.9, 127.6, 69.6-69.5 (m), 67.9 
(m), 65.6 (m), 61.8-61.7 (m), 54.5 (d, 3JCP = 6.3 Hz), 34.2, 34.0, 33.4, 31.9, 31.5, 30.4, 29.7-29.1 
(m), 27.2, 26.5, 25.7, 24.9, 24.7, 22.7, 22.6 (2C), 14.1, 6.6, 4.8; IR ν 2922, 2853, 1742, 1036 
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cm-1; HRMS (ESI+) m/z calculated for C85H161O17P2Si [M+H]+ 1544.0978, found 1544.1090 
[M+Na]+. 
 
Tripalmitoyl-monostearoyl cardiolipin disodium salt (129b). Prepared according to General 
Procedure I using 129b (53 mg, 0.035 mmol, 1.0 equiv.) and NaI (15 mg, 0.053 mmol, 2.9 
equiv.). For the second step, H2SiF6 (0.05 mL, 0.09 mmol, 2 equiv.) was used. Trituration with 
Et2O gave tripalmitoyl-monostearoyl cardiolipin disodium salt (129b, 42 mg, 0.029 mmol, 86%) 
as a colorless solid. [α]D20 = +5.1 (c = 0.54, CHCl3); 1H NMR (CD3OD, 500 MHz) δ 5.26-5.22 
(m, 2 H), 4.47 (dd, 2 H, J1 = 3.0, J2 = 12.0 Hz), 4.20 (dd, 2 H, J1 = 6.5, J2 = 12.0 Hz), 4.02-3.89 
(m, 9 H), 2.36-2.30 (m, 8 H), 1.62-1.59 (m, 8 H), 1.33-1.29 (m, 100 H), 0.90 (t, 12 H, J = 6.8 
Hz); HRMS (ESI-) m/z calculated for C75H144O17P2 [M]2- 688.4940, found 689.4955. 
 
Tripalmitoyl-monooleoyl cardiolipin disodium salt (129c). Prepared according to General 
Procedure I using NaI (19 mg, 0.13 mmol, 3.0 equiv.). For the second step H2SiF6 (0.05 mL, 
0.08 mmol, 2 equiv.) was used. The residue was purified by dissolving in hot 1:3 hexanes:Et2O 
and allowed to precipitate in the -20°C freezer overnight. The precipitate was collected by 
vacuum filtration and gave tripalmitoyl-monooleoyl cardiolipin disodium salt (129c, 40 mg, 
0.028 mmol, 68%) as a colorless solid. [α]D20 = +2.7 (c = 0.43, CHCl3); 1H NMR (CD3OD, 500 
MHz) δ 5.38-5.31 (m, 2 H), 5.26-5.22 (m, 2 H), 4.47 (dd, 2 H, J1 = 2.5, J2 = 12.0 Hz), 4.20 (dd, 2 
H, J1 = 7.0, J2 = 12.0 Hz), 4.01 (t, 4 h, J = 5.5 Hz), 3.95-3.89 (m, 5 H), 2.36-2.30 (m, 8 H), 
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2.04-2.02 (m, 4 H), 1.62-1.59 (m, 8 H), 1.33-1.29 (m, 94 H), 0.90 (t, 12 H, J = 9.0 Hz); HRMS 
(ESI-) m/z calculated for C75H142O17P2 [M]2- 688.4861, found 688.4885. 
 
Tripalmitoyl-monolinoleoyl cardiolipin disodium salt (129d). Prepared using a modified 
version of General Procedure I: To a solution of NaI (21 mg, 0.14 mmol, 3.3 equiv.) in a 
nitrogen-flushed reflux apparatus was added a solution of 128d (65 mg, 0.043 mmol, 1.0 equiv.) 
in degassed acetone (0.43 mL), followed by an additional portion of degassed acetone (0.43 mL, 
used to rinse the vial that starting material came from). The pale yellow solution was shielded 
from light and heated to reflux for 14.5 h. The acetone was removed under reduced pressure and 
the resulting pale yellow solid dissolved in CH2Cl2 (10 mL). The organic portion was rinsed with 
sat. brine:H2O (1:1, 3 mL), dried (Na2SO4), concentrated. The resulting pale yellow solid was 
dissolved in degassed THF (0.78 mL) under nitrogen, H2SiF6 (0.06 mL, 0.1 mmol, 2 equiv.) 
added, and the reaction mixture stirred for 0.5 h shielded from light. The reaction mixture was 
quenched with sat. NaHCO3 (3 mL), and extracted with CHCl3 (2x7 mL). The combined organic 
layers were rinsed with brine (3 mL), dried (Na2SO4) and concentrated. Purification by 
precipitation from hot 3:1 Et2O:hexanes and further cooling to -20°C gave 
tripalmitoyl-monolinoleoyl cardiolipin disodium salt (129d, 53 mg, 0.037 mmol, 87%) as a 
colorless solid. 1H NMR (CD3OD, 400 MHz) δ 5.36-5.30 (m, 4 H), 5.25-5.28 (m, 2 H), 4.47 (dd, 
2 H, J1 = 2.8, J2 = 12.0 Hz), 4.20 (dd, 2 H, J1 = 6.8, J2 = 12.0 Hz), 4.01 (t, 4 H, J = 5.4 Hz), 
3.95-3.88 (m, 5 H), 2.78 (t, 2 H, J = 6.2 Hz), 2.35 (t, 4 H, J = 7.4 Hz), 2.32 (t, 4 H, J = 7.6 Hz), 
2.07 (q, 4 H, J = 6.5 Hz), 1.61-1.59 (m, 8 H), 1.37-1.29 (m, 86 H), 0.93-0.89 (m, 12 H); HRMS 
(ESI-) m/z calculated for C75H140O17P2 [M]2- 687.4783; found 687.4800. 
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Tripalmitoyl-monoarachidoyl cardiolipin disodium salt (129e). Performed using a modified 
version of General Procedure I: To NaI (18 mg, 0.12 mmol, 3.1 equiv.) in a nitrogen flushed 
reflux apparatus was added a solution of 128e (60 mg, 0.39 mmol, 1.0 equiv.) in degassed 
acetone (0.4 mL), followed by an additional portion of degassed acetone (0.38 mL, used to rinse 
the vial that starting material came from). The pale yellow solution was shielded from light and 
heated to relax for 13.5 h. The acetone was removed under reduced pressure and the resulting 
pale yellow solid dissolved in CH2Cl2 (7 mL). The organic portion was rinsed with 20% Na2S2O3 
(3 mL), brine (3 mL), dried (Na2SO4), and concentrated. The residue was dissolved in degassed 
THF (0.78 mL) under nitrogen, H2SiF6 (0.05 mL, 0.08 mmol, 2 equiv.) added, and the reaction 
mixture stirred for 0.5 h shielded from light. The reaction mixture was quenched with sat. 
NaHCO3 (3 mL) and extracted with CHCl3 (2x7 mL). The combined organic layers were rinsed 
with brine (3 mL), dried (Na2SO4) and concentrated giving tripalmitoyl-monoarachidoyl 
cardiolipin disodium salt (129e, 44 mg, 0.030 mmol, 78%) as a pale yellow solid. [α]D20 = +2.5 
(c = 0.52, CHCl3); 1H NMR (CD3OD, 500 MHz) δ 5.39-5.30 (m, 8 H), 5.24 (bs, 2 H), 4.46 (d, 2 
H, J = 11.5 Hz), 4.20 (dd, 2 H, J1 = 6.5 Hz, J2 = 11.5 Hz), 4.01-4.00 (m, 4 H), 3.94-3.91 (m, 5 
H), 2.86-2.83 (m, 6 H), 2.36-2.30 (m, 8 H), 2.13-2.06 (m, 4 H), 1.69-1.60 (m, 8 H), 1.37-1.29 (m, 
78 H), 0.91-0.89 (m, 12 H); HRMS (ESI-) m/z calculated for C77H140O17P2 [M]2- 699.4783; found 
699.4788. 
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 Methyl (9R,10R)-9,10-dihydroxyoctadecanoate (149).158 Elaidic acid (0.510 g, 1.72 mmol, 1.0 
equiv.) was dissolved MeOH (5.7 mL) and one drop of conc. H2SO4 added. The solution was 
then heated to reflux for 9.25 h. The reaction mixture was neutralized with sat. NaHCO3 and the 
MeOH removed under reduced pressure. Water (3 mL) was added and the mixture extracted with 
Et2O (15 mL). The organic layer was then rinsed with sat. NaHCO3 (3 mL), brine (3 mL), dried 
(Na2SO4), and concentrated giving methyl elaidate (0.507 g, 1.71 mmol, quant.) as a clear oil.  
AD-mix β (1.40 g), additional (DHQD)2PHAL (0.005 g, 0.006 mmol, 0.006 equiv.) and 
methane sulfonamide (0.098 g, 1.0 mmol, 1.0 equiv.) were dissolved in (4 mL) and H2O (5 mL) 
at room temperature (takes about 10 min). The orange biphasic mixture was cooled to 0 °C, a 
portion of the methyl elaidate (0.296 g, 0.998 mmol, 1.0 equiv. in 0.5 mL; flask rinsed with 0.5 
mL t-BuOH) added, and the mixture stirred for 21 h at this temperature. The now yellow reaction 
mixture was quenched with Na2SO3 (1.40 g) and allowed to warm to room temperature. The 
mixture was extracted with Et2O (3x20 mL), and the combined organic layers rinsed with 2 M 
NaOH (15 mL), brine (15 mL), dried (Na2SO4), and concentrated. The crude mixture was filtered 
through a plug of SiO2 (4:1 to 1:1 hexanes:ethyl acetate) giving methyl 
(9R,10R)-9,10-dihydroxyoctadecanoate (149, 0.307 g, 0.929 mmol, 93%, >95% ee) as a 
colorless solid. [α]D21 = +22.1 (c = 1.0, MeOH; lit. +22.5); 1H NMR (CDCl3, 300 MHz) δ 3.67 (s, 
3 H), 3.40 (bs, 2 H), 2.30 (t, 2 H, J = 7.5 Hz), 1.98 (d, 1 H, J = 4.2 Hz), 1.94 (d, 1 H, J = 4.5 Hz), 
1.64-1.59 (m, 2 H), 1.47-1.28 (m, 24 H), 0.88 (t, 3 H, J = 6.8 Hz). 
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(9R,10R)-9,10-bis((Triethylsilyl)oxy)octadecanoic acid (150). To a yellow solution of 149 
(0.400 g, 1.21 mmol, 1.0 equiv.) in CH2Cl2 (3.5 mL) at 0 °C under nitrogen was added DMAP 
(0.015 g, 0.12 mmol, 0.1 equiv.), imidazole (0.181 g, 2.66 mmol, 2.2 equiv.), and TESCl (0.43 
mL, 2.53 mmol, 2.1 equiv.). The cloudy, pale yellow slurry was warmed to room temperature 
and stirred for 18.5 h. The reaction mixture was diluted with CH2Cl2 (10 mL), rinsed with water 
(4 mL), brine (10 mL), dried (Na2SO4), and concentrated. Purification by filtration through SiO2 
(97:3 hexanes:ethyl acetate) gave a pale yellow oil. This oil was dissolved in THF (6.3 mL), 
TMSOK (297 mg, 2.08 mmol, 2.1 equiv.) added, and the reaction was stirred 4 h. The reaction 
was quenched with 0.5 M citric acid (1 mL) and stirred for 5 min. The mixture was diluted with 
water (3 mL) and the resulting mixture was extracted with Et2O (2x10 mL). The combined 
organic fractions were rinsed with brine (3 mL), dried (Na2SO4), and concentrated. Purification 
by chromatography on SiO2 (9:1 to 6:1 to 4:1 to 2:1 hexanes:ethyl acetate) gave 
(9R,10R)-9,10-bis((triethylsilyl) oxy)octadecanoic acid (150, 464 mg, 0.854 mmol, 89%) as a 
clear pale yellow oil. [α]D20 = +33.1 (c =1.0, CHCl3); 1H NMR (CDCl3, 300 MHz) δ 3.53 (d, 2 
H, J = 7.5 Hz), 2.35 (t, 2 H, J = 7.5 Hz), 1.65-1.58 (m, 4 H), 1.50-1.40 (m, 2 H), 1.31-1.18 (m, 
20 H), 0.96, (t, 18 H, J = 8.0 Hz), 0.88 (t, 3 H, J = 6.8 Hz), 0.58, (q, 12 H, J = 8.0 Hz); 13C NMR 
(CDCl3, 125 MHz) δ 179.0, 75.7, 33.9, 31.9, 30.2-29.2 (m), 26.7 (2C), 24.7, 22.7, 14.1, 6.9, 5.2. 
IR ν 2952, 2923, 2876, 2855, 2847, 1710, 722 cm-1; HRMS (ESI-) m/z calculated for 
C30H64O4Si2 [M-H]- 543.4259; found 543.4262. 
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1-Chloro-2-methyl-1-oxopropan-2-yl acetate (161).163 2-Hydroxyisobutyric acid (4.05 g, 38.1 
mmol, 1.0 equiv.) was cooled in an ice bath and acetyl chloride (7.1 mL, 98 mmol, 2.6 equiv.) 
was added dropwise. When gas evolution has ceased (~10 min), the mixture was heated to reflux 
for 2 h. Excess acetyl chloride was removed by distillation. To the resulting oil was added SOCl2 
(2.60mL, 34.6 mmol, 0.91 equiv) and the mixture heated to reflux for 2 h. The crude oil was then 
distilled under high vacuum (~4 mm Hg) giving 1-chloro-2-methyl-1-oxopropan-2-yl acetate 
(161, 3.85 g, 23.4 mmol, 61%, b.p. = 50 °C) as a clear, colorless oil. 1H NMR (CDCl3, 500 MHz) 
δ 2.09 (s, 3 H). 1.60 (s, 3 H); 13C NMR (CDCl3, 125 MHz) δ 174.8, 169.8, 83.0, 23.9, 20.7. 
 
(9R,10S)-9-Acetoxy-10-chlorooctadecanoic acid methyl ester (169a); 
(9R,10S)-10-acetoxy-9-chlorooctadecanoic acid methyl ester (169b). To a suspension of 149 
(116 mg, 0.351 mmol, 1.0 equiv.) in Et2O (0.45 mL) was added 161 (124 mg, 0.753 mmol, 2.1 
equiv.) in Et2O (0.45 mL) a dropwise fashion. The resulting clear solution was then stirred for 21 
h. The reaction mixture was diluted with Et2O (10 mL), rinsed with sat. NaHCO3 (3x3 mL), 
brine (3 mL), dried (Na2SO4), and concentrated. Purification by filtration through SiO2 (4:1 
hexanes:ethyl acetate) gave (9R,10S)-9-acetoxy-10-chlorooctadecanoic methyl ester  and 
(9R,10S)-10-acetoxy-9-chlorooctadecanoic acid methyl ester (169a+169b, 137 mg, 0.350 mmol, 
quant.) as a clear colorless oil. Product is a ~1:1 mixture and was used without further 
purification. 1H NMR (CDCl3, 500 MHz) δ 4.99-4.96 (m, 1 H), 3.99-3.96 (s, 1 H), 3.67 (s, 3 H), 
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2.30 (t, 2 H, J = 7.5 Hz; both isomers visible), 2.09 (s, 3 H), 1.74-1.60 (m, 6 H), 1.31-1.26 (m, 20 
H), 0.89-0.87 (m, 3 H). 
 
8-((2R,3R)-3-Octyloxiran-2-yl)octanoic acid (171). To solution of 169a and 169b (135 mg, 
0.345 mmol, 1.0 equiv., 1:1 mixture) in THF (3.5 mL) under nitrogen was added TMSOK (197 
mg, 1.38 mmol, 4.0 equiv.) and the reaction mixture was stirred for 9 h. The reaction was 
quenched with 0.5 M citric acid (3 mL) and stirred for 5 min. The mixture was extracted with 
Et2O (3x8 mL). The combined organic fractions were rinsed with brine (6 mL), dried (Na2SO4), 
and concentrated. Purification by chromatography on SiO2 (3:1 to 2:1 hexanes ethyl acetate) 
gave 8-((2R,3R)-3-octyloxiran-2-yl)octanoic acid (171, 92 mg, 0.31 mmol, 89%) as a colorless 
solid. [α]54620 = +24 (c = 0.245, MeOH); Mp = 54.0-54.4 °C; 1H NMR (CDCl3, 500 MHz) δ 2.65 
(t, 2 H, J = 5.0 Hz), 2.35 (t, 2 H, J = 7.5 Hz), 1.65-1.27 (m, 24 H), 0.89-0.86 (t, 3 H, J = 7 Hz); 
13C NMR (CDCl3, 125 MHz) δ 177.7, 58.9 (2 C), 33.6, 32.1 (2 C), 31.8, 29.5-28.9 (m), 26.0, 
24.7, 22.6, 14.1; IR ν 3058, 2918, 2847, 1709, 1689, 878 cm-1; HRMS (ESI-) m/z calculated for 
C18H33O3 [M-H]- 297.2430; found 297.24233. 
 
(2R)-3-((methoxy(3-((methoxy((R)-3-((14-((9R,10R)-9,10-bis((triethylsilyl)oxy)octadecanoyl)
oxy)-2-(palmitoyloxy)propoxy)phosphoryl)oxy)-2-((triethylsilyl)oxy)propoxy)phosphoryl)o
xy)propane-1,2-diyl dipalmitate (128f). Prepared according to general procedure J. Purification 
by chromatography on SiO2 (2:1 to 3:2 hexanes: ethyl acetate) gave 
(2R)-3-((methoxy(3-((methoxy((R)-3-((14-((9R,10R)-9,10-bis((triethylsilyl)oxy)octadecanoyl)ox
O
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y)-2-(palmitoyloxy)propoxy)phosphoryl)oxy)-2-((triethylsilyl)oxy)propoxy)phosphoryl)oxy)pro
pane-1,2-diyl dipalmitate (128f, 77 mg, 0.043 mmol, 63%; mixture of diastereomers at 
phosphorus) as a clear, colorless oil. 1H NMR (CDCl3, 400 MHz) δ 5.25-5.23 (m, 2 H), 4.36-4.31 
(m, 2 H), 4.25-4.10 (m, 6 H), 4.05-3.97 (m, 5 H), 3.93 (t, 2 H, J = 6.5 Hz), 3.78 (d, 3JHP = 11.2 
Hz, diastereomers), 3.59 (apparent d, 2 H, J = 7.20 Hz), 2.32 (q, 8 H, J = 8.1 Hz), 1.1.61-1.58 
(m, 10 H), 1.50-1.40 (m, 2 H), 1.46-1.25 (m, 96 H), 0.96 (t, 9 H, J = 7.8 Hz), 0.95 (t, 18 H, J = 
7.8 Hz), 0.88 (t, 9 H, J = 6.8 Hz), 0.69-0.61 (m, 18 H); 13C NMR (CDCl3, 125 MHz) δ 173.2, 
172.8, 75.7 (2C), 69.4 (m), 68.2, 67.8 (m), 65.6 (m), 61.7, 54.6 (d, 3JCP = 6.3 Hz), 34.1, 34.0, 
31.9 (2C), 30.2, 29.9-29.1 (m), 26.8, 26.7, 24.9, 22.7, 14.1, 6.9, 6.6, 5.2, 4.7; IR ν 2922, 2853, 
1743, 1016, 741 cm-1; HRMS (ESI+) m/z calculated for C95H196O19P2Si3 [M+H]+ 1787.3153; 
found 1807.2811 [M+Na]+. 
  
(2R)-3-((((2S)-3-((((R)-2-palmitoyloxy-3-((9-((2R,3R)-3-heptyloxiran-2-yl)nonanoyl)oxy)pro
poxy)(methoxy)phosphoryl)oxy)-2-((triethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)pr
opane-1,2-diyl dipalmitate (128g). Prepared according to general procedure J. Purification by 
chromatography on SiO2 (prerinsed with 1% Et3N in 2:1 hexanes ethyl acetate; eluted with 3:1 to 
2:1 to 1:1 hexanes:ethyl acetate) gave 
(2R)-3-((((2S)-3-((((R)-2-palmitoyloxy-3-((9-((2R,3R)-3-heptyloxiran-2-yl)nonanoyl)oxy)propox
y)(methoxy)phosphoryl)oxy)-2-((triethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1
,2-diyl dipalmitate (128g, 64 mg, 0.041 mmol, 51%; mixture of diastereomers at phosphorus) as 
a waxy, colorless solid. Mp = 31.4-32.0 °C; 1H NMR (CDCl3, 400 MHz) δ 5.25-5.23 (m, 2 H), 
4.36-4.31 (m, 2 H), 4.25-4.12 (m, 6 H), 4.05-3.94 (m, 5 H), 3.78 (d, 3JHP = 11.2 Hz, 
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diastereomers), 2.64 (t, 2 H, J = 4.8 Hz), 2.32 (apparent q, 8 H, J = 8.0 Hz), 2.01-1.98 (m, 4 H), 
1.61-1.54 (m, 6 H), 1.50-1.43 (m, 6 H), 1.28-1.25 (m, 92), 0.96 (t, 9 H, J = 7.8 Hz), 0.88 (t, 9 H, 
J = 6.6 Hz), 0.63 (m, 6 H, J = 7.9 Hz); 13C NMR (CDCl3, 125 MHz) δ 173.2, 173.1, 172.7, 75.7, 
69.5-69.4 (m), 67.8 (m), 65.6 (m), 61.7, 58.8 (2 C), 54.5 (d, 3JCP = 6.3 Hz), 34.1, 34.0 (2 C), 31.2 
(2 C), 32.0, 31.0, 29.7-29.0 (m), 26.1, 26.0, 24.8 (2 C), 22.7, 22.6, 14.1 (2 C), 6.6, 4.7; IR ν 
2918, 2850, 1739, 1035, 722 cm-1; HRMS (ESI+) m/z calculated for C85H161O18P2Si [M+H]+ 
1560.0927, found 1560.0913. 
 
Tripalmitoyl-mono(9R,10R)-9,10-dihydroxyoctadecanoyl cardiolipin disodium salt (129f). 
Prepared according to General Procedure I using 128f (75 mg, 0.042 mmol, 1.0 equiv.) and NaI 
(19 mg, 0.13 mmol, 3.0 equiv.). For the second step, was used. The resulting crude solid was 
triturated with Et2O giving tripalmitoyl-monostearoyl diol cardiolipin disodium salt (129g, 49 
mg, 0.034 mmol, 80%) as a colorless solid. [α]D20 = +6.0 (c = 0.46, MeOH); 1H NMR (CD3OD, 
500 MHz) δ 5.26-5.22 (m, 2 H), 4.47-4.41 (m, 2 H), 4.20 (dd, 2 H, J1 = 6.5, J2 = 12.0 Hz), 4.01 
(t, 4 H, J = 5.3 Hz), 3.94-3.89 (m, 5 H), 3.37 (d, 2 H, J = 7.5 Hz), 2.36-2.31 (m, 8 H), 1.62-1.59 
(m, 8 H), 1.50 (m, 4 H), 1.49-1.29 (m, 94 H), 0.90 (t, 12 H, J = 6.5 Hz); 13C NMR (CD3OD, 125 
MHz) δ 174.9, 174.6, 75.3, 72.1 (m), 71.6 (m), 67.8 (m), 64.8 (m), 63.8 (m), 35.2, 35.0, 34.1, 
33.1, 30.9-30.3 (m), 27.1, 27.0, 26.0 (2C), 23.7, 14.4; HRMS (ESI-) m/z calculated for 
C75H144O19P2 [M]2- 705.4889, found 705.4883. 
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